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Abstract
Hepatitis C virus (HCV) infects an estimated 170 million people and is
responsible for considerable morbidity and mortality worldwide. Successful
resolution of infection is achieved naturally in approximately 30% of infected
individuals and correlates with a strong T cell response. Furthermore, treatment
with interferon (IFN)a achieves sustained virologic response in approximately
50% of chronically infected individuals. Conventional dendritic cells (cDCs), as
the most potent antigen presenting cells, and plasmacytoid DCs (pDCs), as the
principal IFNa/|3 producing cells, serve as potential targets for both immune

evasion and therapeutic strategies. In order to evaluate the effects of HCV on DC
function, we compared phenotypic and functional characteristics of DCs from
chronically infected patients to DCs from healthy donors. Our results suggest
that despite non-specific decreases in total numbers, DC phenotypic and
functional integrity is maintained. Consequently, we propose that other factors
associated with HCV immunity may act on DCs to regulate pathogenesis and
immunity. In light of the important roles of IFNa/p and CD4+ T cells in the
clinical response to HCV, we focused on the interplay of these factors with DCs
during CD8+ T cell priming. Using a human in vitro cross-presentation system,
we found that IFNa/p acts on immature DCs (iDCs) to inhibit CD8+ T cell
activation by cross-presentation. Further analysis revealed that ST ATI-

dependent inhibition of CD40-induced IL-12 w a s responsible for this block. In
contrast, a switch from STAT1 to STAT4 signaling enabled an immune enhancing
effect of IFNa/p on mature DCs (mDCs) that potentiated CD8+ T cell activation.
In order to evaluate this latter effect in vivo, we monitored the ability of pDC
IFNa/p production to substitute for CD4+ T cells in CD8+ T cell priming. The
results revealed that pDC activation overcomes the need for CD4 'help' in
priming CD8+ T cell responses in an IFNa/p receptor-dependent manner.
Importantly, IFNa/p produced by non-pDCs did not provide similar priming
signals. These results provide support for HCV immunotherapy trials and offer
a unique mechanism to account for the dual effects of IFNa/p in pathogenesis
and immunity.
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C h a p t e r 1: D e f i n i n g a role for D C s in H C V

pathogenesis

1.1 Introduction
Hepatitis C virus (HCV) infects an estimated 170 million people worldwide and,

as a leading cause of cirrhosis and liver disease, is associated with considerabl

morbidity and mortality. In order to develop vaccine strategies to reduce disease
burden, a comprehensive understanding of the components of effective HCV
immunity is needed. Two important discoveries have been critical in this regard.
First, extensive characterization of the immune response to HCV infection
revealed that strong cell-mediated immunity correlates with resolution of
infection. Second, interferon-alpha (IFNa) is a highly effective treatment for

chronic HCV infection. In light of these findings, I have focused on the role tha
two important dendritic cell (DC) subsets play in these
phenomena—conventional DCs (cDCs) as potent stimulators of the adaptive
immune response and plasmacytoid DCs (pDCs) as the main producers of IFNa.
Moreover, I will discuss the mechanisms of IFNa/p production and signaling
involved in its effects on adaptive immunity. A better understanding of the role
of DCs in orchestrating effective HCV immunity will provide insight into the
pathogenesis of and therapeutic strategies for HCV.

1.2. H C V Immunology
The immune system evolved to protect multicellular organisms from invading
pathogens. Like any good security system, the immune system has surveillance

and effector divisions to deal with these intruders; but, it is not just search a
destroy. The immune systems must also strive to 'do no harm' to the host.
Kilting the pathogen at the expense of the host would not be evolutionarily
advantageous. Similarly, invading pathogens have evolved in keeping with
these rules; they maintain a vested interest in host survival to allow for
replication and transmission. As such, they have evolved intricate mechanisms
of immune evasion in order to maintain their survival. These mechanisms of
evasion may either be direct antagonism of the immune response or
immunologic jujitsu (using the host response for its own benefit). An
understanding of these mechanisms offers insight into the important aspects for
pathogen survival, key targets for therapeutic intervention, and fundamental
mechanisms of the host immune response.
It is with these goals that I have considered the over-riding question of
hepatitis C virus (HCV) immunology: Why do some people naturally clear HCV

infection and some people progress to chronic infection? In order to address the

question fully, I focus not only on the host's ability to respond, but also on t
virus' ability to evade.

Pathogenesis and public health impact of HCV
Current estimates suggest that 3% of the world's population (approximately 170
million people) is infected with HCV1. Although HCV less commonly causes
acute hepatitis (10-40% of infections), more than 70% of infected persons

progress to chronic infection2 (Fig. 1.1). Chronic H C V is a major cause of chronic
liver disease and hepatocellular carcinoma (HCC). According to the World
Health Report of 2004, liver cirrhosis and HCC accounted for 1.4 million deaths,
20% of which are likely attributable to HCV infection3. In addition, HCV
infection is linked to numerous co-mordibities (e.g. type II cyroglobulinemia)
and is a leading cause of liver transplant in the USA and Europe.
The development of identification tools for hepatitis A and hepatitis B
over 30 years ago allowed for the identification of non-A, non-B hepatitis
transmissible by infected blood and blood products4. The causative agent was
identified as HCV in 1989 by expression cloning of cDNAs from the serum of an
infected patient5. Until effective screening measures where implemented in July
1992, infection was commonly passed through blood transfusions, hemodialysis,
and organ transplantation2. Furthermore, the use of contaminated needles for
vaccination campaigns from the 60's-70's are thought to have been responsible
for high rates of exposures in some areas6. Worldwide public health initiatives
to screen the blood supply for HCV and to provide clean medical supplies

significantly reduced the incidence of HCV infection. According to the Center for
Disease Control, the incidence of HCV infection dropped from 240,000/year in
the 1980s to 30,000 in 20037. Today, the highest incidence of HCV is among
intravenous drug users. Shared risk factors with HIV make co-infection quite
common. In fact, 50-90% of HIV infected injection drug users are co-infected and
show more rapid progression to liver disease 8.

> 3 0 years: female, y o u n g age at infection

1
Normal

Acute

Chronic

H C C risk

Liver

Infection

Infection

is 1 - 4 %

Develops

per year

in 7 0 %

< 2 0 years: alcohol use,
H I V coinfection

Figure 1.1 H C V Pathogenesis. Following exposure, acute H C V
infection ensues. Although previous estimates underestimated the
percentage of resolvers, chronic infection develops in the majority of
infections and cirrhosis develops in 2 0 % of those chronically infected.
Progression to cirrhosis is usually slower in females and those
infected at younger age. Progression to cirrhosis is generally
accelerated in those with concomitant alcohol use or H I V coinfection. In patients with H C V cirrhosis, the risk of developing
hepatocellular carcinoma ( H C C ) is 1-4% per year (adapted from
Lauer and Walker, N E J M , 2001).

H C V — T h e stealth virus

HCV is often termed the stealth virus for its ability to establish chronic infec
without efficient detection and clearance by the immune system. In addition,
this name also describes its penchant for evading experimental systems that
would allow for the characterization of its structure, function, and interaction

with its host. Notably, HCV research has been limited by inefficient cell culture
systems and the lack of a small animal model.
Despite these limitations, considerable details of genome structure and
protein function have been elucidated. cDNA cloning of the HCV genome
revealed a single-stranded RNA with positive polarity eventually determined to

be 9.6kb and placed into the Flaviviridae family due to sequence similarity5. In
lieu of a 5'-cap structure, the 5'-non coding region (NCR) of HCV has been
shown to have IRES activity9 and binds directly to ribosomal 40S subunit and
translational initiation factor eIF3 10 enabling translation from entering RNA.
ten HCV proteins are translated as a single polyprotein and processed by autocatalytic cleavage or proteolytic cleavage (Fig. 1.2).
The amino-terminal section of the polyprotein contains the structural
proteins (Core, El, and E2) followed by a small integral membrane protein p7
which may function as an ion channel. Core protein is a highly conserved basic

protein existing in 19- and 21-kd forms. Similar to other structural core protein
HCV core protein promotes virion formation by binding viral RNA and
associating with membranes at the cytoplasmic surface of the ER11. Envelope
glycoproteins El and E2 likely play an important role in mediating viral entry.
Biochemical data suggests that E2 binds to CD81, a tetraspanin expressed on
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Figure 1.2. H C V structure a n d function. T h e H C V g e n o m e is
represented schematically with all 10 proteins indicated. T h e 5' N C R
of H C V has a n internal ribosomal entry site w h i c h drives translation
of the H C V polyprotein. T h e polyprotein is cleaved as indicated in
the figure. T h e putative functions of the proteins in the H C V life
cycle are indicated.

various cell types including hepatocytes and B cells12. However, the lack of an
infectious cell culture system prevented the functional evaluation of E2 and
CD81 in veritable infection. The development of HCV pseudoparticles (HCVpp)
with HCV E1/E2 glycoproteins on the surface of a replication deficient HIV
particle enabled the functional assessment of this association and confirmed the
importance of E2 interaction with CD81 to mediate infection13"15. More recently,
the development of an infectious HCV cell culture (HCVcc) system further

validated the importance of E2, as well as CD81, in mediating viral entry16~18. E
may also play a role in entry. Sequence similarity of El residues 264-290 with
fusion peptides from related virus glycoproteins suggest that El may play an
analogous role in mediating entry 19.
The remainder of the genome encodes the non-structural (NS) proteins
(NS2, NS3, NS4A, NS4B, NS5A, NS5B) that play a crucial role in viral processing
and replication. NS3 is a 70kd protein with a serine protease domain and an
NTPase/helicase domain. NS3 is required for infectivity in vivo and acts with
NS4A co-factor to cleave NS3-4A, NS4A-4B, and NS4B-5A. NS5A-5B cleavage
does not require NS4A co-factor activity20. The role of NS3 helicase activity in

viral replication is not clear; however, mutations disrupting helicase function a
not infectious 21. Adaptive mutations in NS4B, NS5A, and NS5B strongly
enhance replication, suggesting that these proteins are important in the HCV
replication machinery22. NS5A is a membrane associated zinc metalloprotein
protein that exists in different phosphorylation states (56- and 58-kd). Zinc
coordination is required for NS5A function in the HCV replication complex23,24,
but its exact function remains unclear. Finally, NS5B is the RNA-dependent
RNA polymerase (RdRP) responsible for viral replication. Mutation of the

highly conserved G D D motif ablates in vivo infectivity21. The high error rate of
the RdRP enables escape mutations and quasispecies to develop within the
infected individual25.

Understanding effective HCV immunity
Although the lack of a small animal model for HCV precludes extensive probing
of host immunity, an important human model exists for the study of effective
HCV immunity—natural resolvers. Recent estimates suggest that nearly 30% of
those exposed to HCV clear the infection naturally and extensive work has been
done to characterize the nature of the immune response to HCV in humans.
Current results suggest that CD4+ and CD8+ T cells play an important role in
controlling acute infection, but significant data also exist for the involvement
other cells. Moreover, chimpanzees also succumb to HCV infection. Studies
with these animals have enabled extensive probing of the immune cells involved
in protective immunity.
The role for B cells in HCV immunity is complex. The high prevalence of
mixed cryoglobulinemia and lymphoma in chronic HCV has directed several
groups to investigate the role for HCV in driving B cell abnormalities26. One
study suggested a direct link between these abnormalities and HCV infection
showing that 7 out of 7 patients with splenic lymphoma with villous
lymphocytes in the setting of chronic HCV went into remission following
treatment of their HCV with IFNa therapy27. E2 binding of CD81, a component
of the B cell co-receptor complex, provided a possible mechanism for HCV
antigen driving B cell abnormalities12; however, despite accumulation of naive B

cells in the peripheral blood of H C V patients, antigenic stimulation does not
seem to be responsible for B cell activation and differentiation28.
Neutralizing antibodies play an important role in protective immunity to
many viral infections;29 however, the importance of antibodies in HCV immunity
is not clear. HCV-specific antibodies usually appear 7-8 weeks after infection

and there is evidence to suggest that they may neutralize infection both in vitro

and in vivo 31. The putative target of some of these neutralizing antibodies is t
N-terminal region of E2 which contains a hypervariable region (HVR1)30.
Sequence changes in the HVR-1 of E2 that occurred simulataneously with
antibody seroconversion suggest that antibody drives viral mutations. However,
early studies in chimpanzees and humans suggest that antibody seroconversion
does not protect against re-infection32,33. Furthermore, resolution may occur in

the absence of antibody seroconversion34,35. Specific qualitative properties of B
cell function and antibody specificity may be important parameters for
conferring protection in vivo. A more extensive evaluation of neutralizing
antibodies with the recently developed HCVcc system may offer new insight into
their importance.
Natural Killer (NK) cells may play an important role in mediating
effective innate immunity in HCV infection. When activated by virally infected

cells, NK cells release IFNy and cytolytic granules. In vitro studies suggest tha
E2 engagement of CD81 on NK cells may modulate cytokine production and NK

cell effector function36. A recent study aimed at identifying genetic susceptibil
to chronic HCV infection showed that patients with a specific NK inhibitory
receptor (KIR2DL3) and HLA haplotype (HLA-C) were more likely to clear
infection37. The inability of HLA-C to interact with KIR2DL3 may lower the

threshold for N K cell activation. O n e caveat of this study is that the correlation
only held for patients infected from "low dose" exposures.
Considerable effort has been made to understand the role of HCV-specific

T cells in viral clearance. Specifically, CD8+ T cells are crucial in host defens
against viral infection. CD8+ 'killer' T cells or cytotoxic T lymphocytes (CTLs)
recognize infected cells in an antigen specific manner by T cell receptor
engagement of foreign peptides bound to MHC class I (MHCI) molecules on the
cell surface of the infected cell. Thus engaged, the cytotoxic effect can be
achieved by release of apoptosis inducing granzymes or pore forming peforins as
well as a membrane-bound apoptosis-inducing ligand called Fas. In addition,
CTLs can also produce IFNy which can inhibit viral replication, induce MHCI
upregulation, and activate macrophage effector functions38. Consequently, both
the cytolytic and noncytolytic functions of CTLs are important in controlling
viral infection39.
Early work showed that CD8+ T cell immune responses are important
prognostic indicators in acute infections40 (Fig. 1.3). Similarly, protective
immunity in chimpanzees correlates with HCV-specific cellular immunity, not
antibody response M. Numerous studies have offered correlative support for the
role of T cell immunity in HCV clearance41. Direct evaluation of the role for
CD8+ T cells by in vivo depletion resulted in prolonged viremia offering proof
that CD8+ T cells play a crucial role in mediating resolution42. However, CD8+ T

cell responses are also seen in chronic infection and do not always correlate wit

clinical outcome43. As such, differences in CTL effector function in the tissue m
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Figure 1.3. T cell immunity plays a key role in the outcome of H C V
infection. Liver injury is observed weeks to months following initial
viremia as evidenced by the rise in transaminase levels. A. Although
T cell responses are variable during progression to chronic infection,
both the C D 8 + and C D 4 + T cell responses are generally blunted. B.
In contrast, robust C D 8 + and C D 4 + T cell responses correlate with
viral resolution and normal transminase (adapted from B o w e n and
Walker, 2005 Nature).
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account for their variable efficacy in viral clearance. Several reports have
suggested impaired cytokine secretion and cytotoxic function in vitro44,45;
however, the function of CD8+ T cells in situ is not known. Further, differences
in the differentiation of HCV specific memory T cells may account for limited
effector functions46.
Several studies suggest that CD4+ T cells are an important determinant
for effective CD8+ T cell immunity to HCV. In vivo depletion of CD4+ T cells in a
chimpanzee that had previously resolved infection prevented effective CD8+ T
cell immunity in a subsequent infection and allowed escape mutations to
develop47. Although the elimination of CD4+ T cells is not possible in humans,
studies in HIV/HCV co-infected patients offer similar data suggesting that the
diversity of the CD4 response is an important determinant for the magnitude
and breadth of the CD8+ T cell response to HCV48. A unique instance in which

two patients infected from a single source resulted in different clinical outcome
also suggests that CD4+ T cell diversity is important in supporting CD8+ T cell
responses during acute infection49. Finally, development of regulatory T (Treg)
cells, CD4+/CD25+ T cells that inhibit T cell activation50, may also modulate

HCV specific T cell function51, but the antigen specificity of Treg cell activity
unclear.
The strong evidence suggesting the importance of cell-mediated immunity
in an effective HCV immune response has raised many questions concerning the
components involved in generating this response. In order to explore these
questions, I have focused on two aspects of HCV immunity: the role of dendritic
cells (DCs) and the effect of IFNa/p. First, we will consider the DC as a pivotal
player in the priming of a T cell response.
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1.3. Dendritic Cells
The 'sentinels' of the immune system
The initiation of an immune response is a complex process. The invading
antigens and the lymphocytes that respond to their assault have long been
appreciated as crucial components of the host/pathogen interaction. However,
the spatial separation between the antigen in the site of infection or tumor and
the lymphocytes in the lymph nodes creates the need for a messenger
system—the antigen presenting cell (APC). Although not appreciated as such
originally, these APCs were first visualized in the skin by Paul Langerhans in
1868. DCs are considered the most potent APCs and exist throughout the skin,

mucousal surfaces, and peripheral tissue52. They can efficiently stimulate both B
and T lymphocytes. Importantly, DCs are required for priming naive T
lymphocytes 52. The existence of a DC 'sentinel' system offers the immune system

the ability to receive information of potential dangers in a centralized lymph ar
where it can subsequently identify and prime antigen specific effectors.

Maturation alters DC phenotype, function, and location

Two distinct differentiation states of DCs have been described that facilitate th

ability to act as 'sentinels' of the immune system (Fig. 1.4). In tissue, DCs are
present in what has been termed the 'immature' state. Immature DCs (iDCs) are
characterized by their primary role—antigen capture53. iDCs utilize four main
pathways to capture antigen: phagocytosis (via receptors including avP5,
phosphatidylserine receptor, and CD36), micropinocytosis, macropinocytosis,
and receptor mediated endocytosis (via receptors including MMR, DEC-205,
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Figure 1.4. D C s are the 'sentinels' of the i m m u n e system. D C s
serve as the messenger between the site of infection and the priming
of the adaptive i m m u n e response in the lymph node. Immature D C s
(iDCs) in the periphery are uniquely suited to capture antigen. In
response to maturation stimuli, D C s migrate through the afferent
lymph to the lymph node where they can present antigen to T cells in
secondary lymphoid organs. Mature D C s ( m D C s ) are aptly suited
for priming T cells with high levels of surface M H C and costimulatory molecule expression.
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FcRy and FcRe). iDCs are characterized immunohistochemically by their lack of
macrophage markers such as CDM, absence of the mature DC marker CD83 and
low surface expression of co-stimulatory molecules and MHC II (consistent with
their primary role being antigen capture). Upon exposure to inflammatory
cytokines (e.g.TNFa, IL-lp) or microbial stimuli (e.g. LPS, SAC, dsRNA), DCs
undergo a programmed phenotypic and functional change termed 'maturation'

that reflects the shift in their role from antigen capture to antigen processing

presentation. As DCs mature, they differentiate into stellate, non-adherent cells
thus providing increased surface area for T cell engagement. These mature DCs
(mDCs) are characterized by the surface expression of CD83 as well as high
levels of co-stimulatory molecules and MHC II reflecting their potent antigen

presentation capacity52. Functional activity of mDCs can be evaluated in vitro by

assaying their ability to prime allogeneic T lymphocytes54. DCs are 100-1000 fold
more potent allostimulators than bulk leukocytes. No one molecule has been
identified to explain the potency of mDCs; upregulation of MHCII (10-100-fold),
co-stimulatory molecules (e.g. CD80 and CD86), and cytokine production (e.g.
IL-12)55'56 all may play a role.
Coincident with these maturation changes, DCs upregulate CCR7 to
facilitate migration from the tissue to the lymph node57. Physiologically, this
migration puts mDCs in proximity of both naive and central memory T cells. As
such, the location and unique phenotypic profile puts the mDC in the right place

with all the tools for initiating a T cell response, be it activation or toleranc
Accordingly, I focus in depth in chapter 2 on the maturation profiles of DCs
during chronic HCV and the role they may play in HCV immunity.
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D C s specialize in antigen capture and presentation
The central feature of the DC 'sentinel' system is the endowment with a unique

ability to capture, process, and present antigen for an effective immune response
The ability of iDCs to capture antigen is not unique—in fact, macrophages
phagocytose more efficiently than DCs. However, while macrophages
phagocytose and subsequently degrade antigen, DCs sequester antigen in
MHCII-rich compartments (MIICs). These MIICs convert from late-endosomal to
non-lysosomal compartments upon maturation, enabling MHCII-peptide
complex discharge to the surface58. A recent report suggests that low levels of

lysosomal proteases allow DCs to sequester and process antigen, thus facilitating
antigen presentation59.
DCs also have specialized machinery for MHCI presentation. In contrast
to MHCII presentation, MHCI presentation is classically restricted to
endogenously expressed antigens processed by the proteasome and loaded onto
MHCI in the ER. This classical model however fails to account for the generation
of CD8+ T cell responses to tissue-restricted antigen (e.g. tumor antigen or
antigen from viruses that do not infect APCs). Early work by Michael Bevan
challenged the classical model for MHCI antigen presentation by showing that
exogenous antigen can be used to generate epitopes for CD8+ T cell priming60.
This mechanism was termed cross-priming due to the crossing of the canonical
boundaries of MHCI antigen presentation. This pathway plays an important role
in generating CD8+ T cell responses to tissue-restricted antigen61"63. Notably,
DCs have a unique capacity to cross-present antigen on MHCI in order to prime

a CTL response64. In addition to apoptotic cells, antigen from viral particles as
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well as i m m u n e complexes m a y be cross-presented to engage antigen-specific
CD8+ T cells65.
The mechanism by which HCV is presented to the immune system by

APCs is not clear. In the following chapters, I review and evaluate the ability o
HCV to directly infect APCs. Furthermore, in chapter 4,1 detail the development
of an in vivo system to evaluate cross-presentation of full length HCV.

Immunologic ouctomes of antigen presentation
Following antigen processing and presentation, DCs engage and activate T cells.
Initial models suggested that T cell activation requires two signals: 'signal 1'
(MHC-peptide complex) to engage antigen specific T cells and 'signal 2' (costimulation) to enable T cell activation. Co-stimulatory molecules CD80 and
CD86 are uniquely expressed on APCs and provide 'signal 2' via CD28
engagement on T cells. However, more recent data argues that the generation of

effective CTLs requires 'signal 3' or 'help,' provided either by "danger" signals
or in an antigen specific fashion by CD4+ T helper cells67 (Fig. 1.5). Although
immune response to several infectious agents were traditionally characterized as
helper-independent, recent studies suggest that CD4+ T cell help is an absolute
requirement for the generation of CD8+ T cell memory68,69. In vivo models of
cross-priming (via i.v. injection of irradiated OVA-loaded P2 microglobulin-/-

spleen cells) require CD4+ T cell 'help' to generate antigen-specific CTLs70. The
requirement for CD4+ T cell 'help' for cross-priming CTLs suggests two potential
scenarios: (1) A three-
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Figure 1.5. D C s mediate activation and tolerance of C D 8 + T cells.
Antigen presentation by m D C s can result in distinct immunologic
outcomes: activation or tolerance. In the absence of C D 4 help or
other danger signals, cross-presentation of antigen to C D 8 + T cells
leads to tolerance via division and death. Production of T G F - P by
D C s following phagocytosis of apoptotic cells or IL-10 production by
T
m a y skew towards tolerance. In contrast, in the presence of
'help' provide by C D 4 0 L ligation from C D 4 T cells, LPS engagement
of TLR4, or d s R N A engagement of TLR3, D C s are licensed to prime
C D 8 + T cells. IL-12 and IL-6 from the D C as well as IL-2 produce by
C D 4 helper cell are important cytokines for priming the C D 8 + T cell
response.
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cell interaction (DC, C D 4 + and C D 8 + T cell) in the lymph node suggesting a role
for short-range signals (e.g. IL-2) or (2) a 'licensed' DC which may serve as a
"temporal bridge between a CD4+ T-helper and a T-killer."71 This latter
hypothesis implies that CD4+ T cells impart a 'license' to DCs that enables them
to activate CTLs. CD40L is expressed on the surface of activated CD4+ T helper
cells and its engagement of CD40 on the DC is sufficient to generate effective
CTLs, supporting the second model72"74. Although CD40 stimulation is known to
lead to the upregulation of co-stimulatory molecules and the secretion of
cytokines (including TNFa, IL-ip, and IL-12)75, the signaling pathway in DCs
responsible for this functional switch remains unclear. Other TNF superfamily
members in addition to CD40L may also activate DCs to produce 'signal 3.'62
There is strong evidence to suggest that IL-12 produced by the DC may be an
important component of 'signal 3' in allowing full activation of naive CD8 T
cells76.
In addition to playing a central role in priming a T cell response, DCs can

also induce antigen specific T cell tolerance77. Although most self-reactive T ce
are deleted during development in the thymus in a process called central

tolerance, peripheral tolerance is thought to be responsible for inactivating T c
reactive to developmentally expressed and tissue-restricted antigens. The
induction of T cell anergy, deletion, and cytokine skewing are all mechanisms of
functional tolerance. All three mechanisms require engagement of T cell with
MHC-peptide complex. Due to the suggestion that naive T cells do not

circulate78, peripheral CD8+ T cell tolerance to tissue restricted antigens depen
on a cross-presenting APC to deliver antigen to the lymph node79. In vitro
studies have identified the DC as the crucial APC required for CD8+ T cell
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tolerance to cross-presented antigen62; this finding is supported by the recent in
vivo work of others80.
Some reports suggest that the maturation state of the DC controls the

immunologic outcome of the T cell response81. In other words, in the steady state
iDCs capture antigens and silence T cell responses either by deleting them or

expanding Treg cells. However, this poses two problems regarding T cell tolerance
by DCs in vivo. First, as mentioned above, since naive T cells do not circulate,
peripheral CD8+ T cell tolerance likely occurs in the T cell rich regions of the
lymph node or secondary lymphoid tissue. However, DC chemotaxis into the T
cell areas of the draining lymph organs, enabled by the upregulation of CCR7,
requires a maturation stimulus57. Second, DC / T cell engagement is required
for active induction of antigen specific T cell tolerance. However, iDCs do not
acidify their endosomal system and as a result the antigen captured is
maintained in an unprocessed holding compartment until a maturation signal is
received82. Therefore, it is difficult to envision how antigen captured in the
periphery can be efficiently presented to T cells for the induction of antigen
specific tolerance by iDCs.
Instead, it has been demonstrated that mDCs can mediate both activation

and tolerance depending on the presence of 'signal 3' stimuli62. Using an in vitr
cross-presentation system, both activation (defined by proliferation and CTL
activity) and tolerance (defined by T cell division and death) required
phenotypically (i.e. CD83+, CD25+, CD%6^, HLA DR *&) and functionally (i.e.
potent inducers of allogeneic mixed leukocytes reaction) mature DCs62. The
crucial switch between DCs inducing T cell activation or tolerance is not
maturation, but rather 'signal 3' provided by CD40 engagement on the DC. IL-12
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production in response to C D 4 0 engagement m a y act as a 'signal 3' in skewing
cross-tolerance to cross-priming76,83.
The regulation of T cell activation versus T cell tolerance in HCV infection
is not well understood. The lack of a small animal model creates a significant
obstacle for extensive characterization of the immune response. In lieu of this
model, I evaluate, in chapters 3 and 4, the role that CD4+ T cells and virally
induced IFNa/p play in modulating these signals to control the immunological
outcome.

DC interaction with viruses
Infection of DCs can alter function. Some viruses, such as influenza,
promote maturation M. In the case of influenza, maturation may protect from
viral cytopathicity as well as enable DC migration for T cell engagement. This
maturation response, however, is not common to all viruses and may even
depend on the multiplicity of infection. Infection of DCs with herpes simplex
virus (HSV) and measles virus (MV) leads to submaximal DC maturation and
impaired T cell activation85"87. In contrast, two flaviviruses, bovine viral
diarrheal virus (BVDV) and classic swine fever virus (CSFV) do not induce

maturation or disrupt the ability to stimulate T cells88,89. Similar results are
with a related flavivirus, yellow fever 17D 90(see Appendix 3).
There is precedent for DC-specific interactions with flaviviruses—
specifically dengue virus (DV). DV selectively infects a DC population in the
skin called langerhan cells (LCs) and causes infected LCs to migrate out of the
tissue 91. DC specific ICAM-3 grabbing non-integrin (DC-SIGN) is sufficient for
DV infection92 and accounts for the selectivity of DV for LCs and iDCs 93.
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Interestingly, H C V E2 interacts with DC-SIGN94,95. O n e report suggests that V S V
El /E2 pseudotype particles enter DCs via DC-SIGN 96, but the same results are
not seen with HCVpp13"15. In addition to infection, binding of HCV to DCs may
also play a role in pathogenesis. For example, interaction of HIV with DC-SIGN
for binding but not for entry has suggested a mechanism whereby HIV migrates
with DCs to the lymph node to gain access to CCR5 positive CD4+ T cells97. DC-

SIGN interaction is not, however, a general feature of flavivirus host interactio
It is not sufficient for yellow fever infection or necessary for West Nile virus
(WNV) infection92. A recent report shows avP3 integrin as the receptor for
WNV98.
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1.4. Interferon (IFN)-o/p
In addition to the data from natural resolvers, another patient population
provides important data for understanding the components of a successful
response—sustained virologic responders (SVRs). SVRs are defined as patients
that have cleared HCV following IFNa therapy and remain HCV negative 6

months after discontinuation of therapy. The second major aim of my thesis is to
understand the role that IFNa may play in modulating the immune response at
the DOT cell interface, during pathogenesis and therapy.

IFNa: The standard of care
Currently, the most effective treatment for HCV is pegylated IFNa. It
slows progression of liver disease and eradicates virus in approximately 50% of
cases99. IFNa was originally defined as an antiviral agent, but has been used
therapeutically for the treatment of viral and non-viral diseases. The original
IFNa monotherapy for chronic HCV with three injections per week was
approved in 1990 and the latest regimen, combination of ribavirin and pegylated
IFNa was approved in 2002 10°. Response rates to IFNa therapy stratify by
genotype with SVR rates of 42-46% for genotypes 1 and 4; 76-80% for genotypes
2 and 3 101,102. Analysis of sequence determinants correlating with response to
IFNa therapy revealed an interferon sensitivity-determining region (ISDR)
within genotype lb seen in some cohorts103,104 but not others105.
IFNs were discovered by Alick Isaacs and Jean Lindemann in 1957 as an
undefined substance with antiviral activity106. They showed that supernatant
from influenza-infected chicken embryos cleared of virus was able to inhibit
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influenza infection w h e n added to a fresh set of chicken embryos. W o r k within
the last several decades has defined this antiviral substance more carefully as

type I IFNs in contrast to type II IFNs (IFNy). There are seven different classes

type I IFNs (a, p, 6, e, k, co, and x). IFNa and IFNp are best characterized of t
type I IFNs. While most cells can produce both, depending on the stimulus, the
primary producers of IFNa and IFNp are leukocytes and fibroblasts,

respectively107. At least 14 IFNa subtypes exist, but only one IFNp. For the most

part, the antiviral and antiproliferative effects of the multiple IFNa subtypes a
functionally redundant; however, large differences exist in their ability to
activate NK cells108. Nonetheless, all use a single IFNa/p receptor (IFNAR).
The molecular mechanisms associated with IFNa/p's defining antiviral
effect are numerous; however, four proteins play an important role—2,5oligoadenylate synthetase (2',5'-OAS), protein kinase R (PKR), myxovirus
resistance protein A (MxA), and RNA-specific adenosine deaminases (ADAR).
2',5'-OAS induces an antiviral state by activating RNase L, a cellular
endoribonuclease, which degrades viral RNA 109. PKR is a double-stranded
RNA-dependent protein kinase which inhibits peptide chain initiation and viral
translation by phosphorylation of eIF-2a n0. MxA is an IFN-induced GTPase

originally characterized by its ability to block influenza A infection111. Althou
the mechanism of its antiviral activity is not completely understood, MxA

antagonizes viral polymerase activity112 and blocks redistribution of viral caps
proteins113. Finally, the activation of ADAR inactivates viral RNA by RNA
editing114.
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The signaling mechanisms associated with the induction of this antiviral
response have been extensively characterized (Fig. 1.6). The IFNAR is a
heteromdimeric receptor consisting of subunits IFNAR1 and IFNAR2. IFNAR2
exists in three different forms: IFNAR-2a (short), IFNAR-2b (soluble), and
IFNAR-2c (long)115. IFNAR1 and IFNAR2c are constitutively associated with
intracellular Janus kinases 0AKs), Jakl and Tyk2, respectively116. IFNa/p
engagement causes IFNAR dimerization and/or oligomerization. This
rearrangement enables Jakl and Tyk2 activation by trans-phosphorylation.
Subsequent phosphorylation of receptor cytoplasmic tails enables STAT2
recruitment. In contrast to activation of ST ATI by IFNy, IFNa/p signaling
requires STAT2 for ST ATI phosphorylation117. Tyrosine phosphorylation
enables STAT1/STAT2 heterodimerization and interaction with p48 (IRF-9)
forming interferon-stimulated gene factor-3 (ISGF-3). ISGF-3 translocates to the
nucleus, binds to interferon stimulated response elements (ISRE), and activates
transcription118. IFNa/p also activates STAT3 and STAT4. Similar to STAT2,
STAT3 can form heterodimers with ST ATI to activate ISRE. In contrast, STAT4
homodimerizes and binds to (IFN)-gamma-activated sequence (GAS) elements119.
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Figure 1.6. IFNo/P signaling. Engagement of the IFNa/p receptor
activates Jakl and Tyk2 which in turn phosporylate STA T I and
STAT2. Heterodimerization and association with IRF9 to form ISGF3
results in translocation to the nucleus and activation of gene
transcription from interferon stimulated response elements (ISRE).
ISRE transcription drives the IFN priming loop as well as other antiviral and innate immunity effector functions.
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IFNa/p production triggered by virus detection
The production of IFNa/p by an infected cell is highly regulated by the

activation of pre-existing transcription factors. Although nuclear factor-KB (NFkB) and ATF-2-c-Jun may play a role, an absolute requirement for interferon
response factor (IRF) 3 has been demonstrated120 (Fig. 1.7). Inhibitor of NF-kB
kinase-E (IKKe) and TANK-binding kinase 1 (TBK1) play an important role in
IRF3 activation, which results in transcriptional activation of both IFNp and
IFNa4 genes121. The production of IFNa4/p induces IRF7 transcription by both
paracrine and autocrine signaling via canonical ST ATI signaling disccused
above. Activation of IRF7 during viral infection enables cells to activate
transcription of other IFNa genes besides the a4 subtype. This priming loop is
crucial for robust production of IFNa 122.
The host response has evolved several mechanisms to link viral detection
with production of IFNa/p. This response is triggered by pathogen-associated
molecular patterns (PAMPs) (e.g. single stranded (ss) or double stranded (ds)
RNA) engagment of PAMP receptors on the host cell. Classically, toll receptor
(TLR) 3 was thought to be important for viral detection as it was required to
trigger IFNa/p production in response to dsRNA 123. However, the location of
TLR3 facing the lumen of the endosome does not put it in prime location for
detecting ssRNA viruses. Another toll receptor, TLR9 was originally defined to
detect non- methylated CpG motifs specific for bacterial DNA124. Although TLR9

agonists are a strong trigger for IFNa/p, it was not originally clear how they we
involved in a viral response. Subsequently, it was found that in addition to
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Figure 1.7. P A M P receptors detect viral infection and trigger
IFNq/p response via the IFNo/P priming loop. Three key P A M P
receptors, TLR3, TLR7, and TLR9, detect d s R N A , ssRNA, and C p G
D N A , respectively, in endosomal compartments. Intracellular
s s R N A triggers RIG-I and activation of IKKs as well as NF-kB via
Cardif. T L R 3 activates NF-kB and T B K 1 via TRIF. Phosphorylation
of IRF3 by IKKe and T B K 1 allows for dimerization and interaction
with CBP/p300 to trigger IFNp transcription. IFNP signaling triggers
IRF7 expression. T L R 7 and T L R 9 signal via M y D 8 8 to activate NF-kB
and phosphorylate IRF7. The molecules involved in M y D 8 8
dependent IRF3 activation are not known.
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bacterial C p G motifs, viral D N A from herpesviruses (eg. HSV-1 and M C M V ) can
also directly engage TLR9 to trigger IFNa/p production125. Recently, TLR7 was
proposed to play a key role in triggering IFNa/p production in response to
ssRNA virus influenza and specific ssRNA motifs126. Adaptors MyD88, IRAK,
and TRAF6 mediate signaling for TLR7 and 9; however, TLR3 may utilize
Toll/IL-1 receptor domain-containing adaptor, TRIF, which has the potential to
directly activate IKKe and TBK1127.
Intracellular detection of PAMPs also plays a significant role in triggering
IFNa/p production. As mentioned above, PKR can detect intercellular dsRNA
and may also play an important role in triggering IFNa/p production128;
however, recent reports have demonstrated the function of another crucial

intracellular dsRNA sensor, retinoic-acid-inducible gene I (RIG-I)129 or melanoma
differentiation-associated gene 5 (mda-5)130. RIG-I contains a N-terminal tandem
caspase activation and recruitment domain (CARD) that signals IRF-3 and NF-kB
activation and a C-terminal DEx/D box RNA helicase domain which binds HCV
RNA131. A recently described CARD containing adaptor protein, Cardif /IPS1 /VISA/MAVS, binds to RIG-I and recruits IKKs for IRF3 and NF-kB
activation .

IFNa/p during HCV infection
In light of the potent antiviral effects of IFNa/p on HCV replication, it is
understandable why HCV has evolved numerous mechanisms to disrupt IFNa/p
signaling. Both and NS5A 133 and E2 134 have been shown to inhibit PKR via direct
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interaction. M o r e recently, the NS3-4A protease has been s h o w n to play a key
role in disrupting IRF-3 phosphorylation135 by cleaving Cardif136 and TRIF137.
Despite the multiple strategies to inhibit IFNa/p signaling, intrahepatic
IFNa/p production during HCV infection is a unique characteristic of HCV

infection. In contrast to hepatitis B virus (HBV) infection, HCV reaches high vir
titers within 1 week of infection138 and induces a robust IFNa/p response
detected by IFN stimulated gene (ISG) expression139. Notably, induction of ISGs
following infection does not correlate with viral titer and outcome suggesting

that other factors such as genetics or concomitant risk factors play an important
role. Alternatively, other features of IFNa/p's complex role in immunoregulation
may impact the outcome of HCV infection140.
The main producers of IFNa/p during HCV infection have not been
identified. Clearly, hepatocytes are the main target of infection141 and posses
both RIG-I and TLR3 signaling pathways for triggering IFNa/p production142.
However, although induction of ISGs are seen in liver tissue, IFNa/p transcripts
are seen in PBMCs suggesting that a cellular component of PBMCs may be
responsible for ISG induction in liver tissue during acute infection143.

Plasmacytoid DCs: The Interferon Producing Cells
Although many cells are capable of producing IFNa/p in response to
appropriate stimuli, the natural interferon producing cell (NIPC) has long been
recognized as the most potent producer of IFNa/p among PBMCs144. These cells
remained poorly characterized until the observation was made that NIPCs were
a DC subset called plasmacytoid DCs (pDCs)145. In humans, pDCs were first
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described as a CDllc negative D C subset146147 and proposed to be the poorly
characterized plasmacytoid T cells long described by pathologists in lymphoid
tissue 148. These cells were originally characterized by their location in the T
rich extra-follicular regions and high expression levels of IL-3Ra (CD123)149.
Subsequent studies have shown that IL-3 acts as a survival factor, but the
immunological significance of pDC location is not clear.
Originally, pDCs were identifiable only by lineage negative and nonspecific markers CD4, CD 123, and HLA-DR. The generation of antibodies
specific for pDCs allowed the direct enumeration, purification, and functional

assessment of pDCs in circulating blood 150. One of these antibodies recognizes a
type II C-type lectin called blood DC antigen (BDCA)-2 151. Importantly, BDCA-2
is downregulated upon activation and antibodies to BDCA-2 inhibit IFNa/p
production. Recently, antibodies against specific mouse pDC markers were
developed (120G8 and PDCA-1)152. Hopefully, these reagents will give us a clear
sense of pDC and pDC-derived IFNa/p in coordinating adaptive immunity.
As the most potent producers of IFNa/p, these cells play an important role

in the response to viral infection. Notably, they are capable of producing robust
amounts of IFNa/p after exposure to DNA and RNA viruses as well as bacteria.
Further work showed that human pDCs express TLR7 and TLR9 153, making
them poised to respond to infectious pathogens. Interestingly, pDCs

constitutively express IRF7 154 allowing faster IFNa/p production, independent of
feedback. Following activation by TLR or CD40L engagement, pDCs move to
lymph nodes and produce IFNa/p in the T cell-rich areas 155,156. A recent report
describing the IRF7-/- mouse links a defect in pDC activity to a decrease in CpG
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adjuvant effect on transgenic C D 8 + T cells, but the immunologic significance of
the pDC response in coordinating T cell activation is not well defined157.
The role for pDCs in HCV pathogenesis is an area of intense research. As
the main producers of IFNa/p, pDCs serve as a likely target for immune evasion
strategies. As such, in chapter 2,1 evaluate pDC function during chronic HCV
infection. The question of pDC function is critical not only for understanding
pathogenesis but also for evaluating the rationale of TLR7 and TLR9 agonist
therapies for chronic HCV. A better understanding of the role for pDCs and
IFNa/p in regulating HCV-specific T cell immunity may offer insight into
pathogenic and therapeutic strategies for HCV.
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1.5. T h e questions
In this thesis, I have endeavored to explore the role of DCs in HCV
pathogenesis and the factors that act on DCs to regulate the immunologic
outcome during HCV infection. I began these studies by setting up a clinical

study at the Rockefeller University Hospital, CRI-0505, to explore the function o
DCs in chronic HCV. The results of this study, discussed in chapter 2, pushed us
to redefine the mechanisms by which HCV may affect DC function and
immunologic outcome. In particular, I focused on the interplay between
IFNa/p and CD4 help acting on DCs to regulate CD8+ T cell priming. Our
surprising results, discussed in chapter 3, led us to explore the regulation of
IFNa/p signaling by DC maturation and the implications of spatial location in
dictating effects of cytokines on immunological outcome. In light of these

results, I set up in vivo models to evaluate the ability of pDC IFNa/p production
in the lymph node as a source of helper signals for CD8+ T cell priming,
discussed in chapter 4. The results presented here offer significant support for
HCV immunotherapy trials and provide a unique mechanism for IFNa/p in
pathogenesis and immunity. It is my hope that these results will inspire support
for new therapeutic strategies for HCV.
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C h a p t e r 2: R e d e f i n i n g the role for D C s in H C V pathogenesis:
N o r m a l D C function in patients chronically infected w i t h

H C V

2.1 S u m m a r y
HCV-specific T cell responses and IFNa play important roles in HCV immunity.
Since conventional DCs (cDCs) are required for priming T cells in vivo and pDCs
(pDCs) are the principal cell type responsible for endogenous IFNa/p
production158, an understanding DC function during HCV infection may offer
insight into the crucial components of immunity. Initial reports showed
impaired maturation and allostimulation of monocyte derived DCs159"161 and
pDCs162 from chronic HCV patients suggesting a model of "DC dysfunction" to
account for impaired immunity in chronic HCV. In order to evaluate the HCV

specificity of these reports, we did a more careful analysis of absolute numbers,

phenotypic markers, and functional activity of these DCs. In contrast to previous
reports, we find no overt phenotypic or functional changes in monocyte derived
DCs or circulating cDCs from chronically infected patients. Although our
findings agree with previous reports of lower percentages of circulating pDCs in
chronic HCV infection, single cell analysis suggests no overt defect in pDC IFNa
production. This data challenges the old model of "DC dysfunction" in
accounting for impaired HCV immunity. Furthermore, our analysis supports
alternate models for weak T cell immunity in chronic HCV and offers data in
support of cDC and pDC immunotherapy for chronic HCV.
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2.2 Introduction
Role for DC subsets in HCV infection
As mentioned above the CD8+ T cell response has been identified to correlate
with response to HCV infection. In light of the crucial role for cDCs in priming
these CD8+ T cells, attention in the HCV field has been given to understanding
the interaction of HCV with DCs (Fig. 2.1). The key questions in understanding

this interaction center around infection of DCs as well as modulation of functio
The prior lack of an infectious viral system and the technical difficulty in
establishing reliable negative strand detection assays has precluded sound
conclusions regarding DC infection141163. In contrast, many tools exist to study
the function of DCs both in vitro and ex vivo—but the data remain controversial
as to the effect of chronic HCV infection on DC function.
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Figure 2.1. D C s play a pivotal role in H C V immunity. cDCs play a
pivotal role in presenting antigen to the adaptive i m m u n e system.
Antigen capture by direct infection or phagocytosis allow D C s to
traffic antigen to the lymph node for T cell priming. p D C s are the
main producers of IFNa/p and m a y influence infection in the tissue
or immunity in the lymph node.
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The old model: D C dysfunction in chronic H C V
Several groups have reported a maturation defect in monocyte-derived
DCs generated from chronic HCV-infected donors159"161. These observations led to
a model where ineffective DC maturation results in the lack of HCV-specific
CD8+ T cells in chronically infected patients160 (Fig. 2.2). However, this model

does not account for the selective impairment of HCV-specific T cell responses as
chronically infected HCV patients are immune competent. Additionally, in vivo
data indicating the absence of HCV RNA in peripheral blood mononuclear cells
(PBMCs) is inconsistent with a defective DC precursor141. In this chapter, we
have re-examined the phenotype and function of monocyte-derived DCs
generated from chronically infected HCV patients using more stringent criteria
for the definition of DC maturation. In contrast to previous reports, we observe
no defect in DCs from chronically infected HCV individuals and offer an
alternate model for the role of DCs in HCV pathogenesis.
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\

m D C p r i m e s C D 8 + T cells

W e a k C D 8 + T cell i m m u n i t y

How does global dysfunction of DCs contribute to a model
for HCV-specific C D 8 T cell deficiency?

Figure 2.2. T h e "old m o d e l " for D C s in H C V pathogenesis. Previous
reports have suggested that H C V inhibits D C maturation and
consequently efficient T cell priming. However, this model does not
account for the selective impairment of HCV-specific T cell responses
as chronically infected H C V patients are i m m u n e competent.
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Circulating cDCs and p D C s in human blood
A significant caveat of all the studies mentioned above is that they focus on in
vitro derived DCs. In fact, the majority of human DC studies are based on
monocyte-derived DCs due to the low frequency of and paucity of positive
markers for circulating blood DCs (BDCs)146. Recent characterization of the BDC
groups showed that a CDllc+ subset expressed CDla (also referred to as

BDCA-1)164,165. CDla is not unique to circulating DCs (e.g. it is highly expresse
on B cells), but it can be used to differentiate CDllc+ from CD lie- DCs.
Although these markers allow for the isolation of circulating cDCs, these cells
make up only 0.5-1% of the total PBMC fraction and, thus, require large numbers
of PBMCs for functional analysis.
The other DC subset of interest in circulating blood is the pDC. pDCs
recently received the spotlight in HCV biology in light of their robust IFNa/p
production145. During the course of natural HCV infection, robust expression of
IFNa/p response genes are seen in the liver139 and pDCs may play a role in this

process143. HCV replication is very sensitive to IFNa, both in vitro and in vivo,
but while HCV has numerous mechanisms to avoid the downstream effects of
IFNa166, direct modulation of pDC function by HCV has not been shown.
Furthermore, the immunoregulatory role of IFNa/p during HCV infection is not
well understood.
pDCs may be distinguished based on surface expression of CD123, BDCA2 or BDCA-4150. Although they exist at very low frequency (0.2 to 0.5% of
PBMCs), cytometric analysis permits simultaneous gating of cell populations of

interest and determination of functional activity (e.g. production of IFNa)167. I
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this chapter, w e provide a careful analysis of both cell populations in chronic
HCV infection and conclude that there are no phenotypic or functional defects in
the cDCs and no decrease in the amount of IFNa produced on a per pDC basis.

2.3 Study Design
CRI-0505: Chronically Infected HCV Patients (see Appendix 3)
Patient material was obtained as per Weill Medical College of Cornell University
and The Rockefeller University Hospital Institutional Review Board approved
protocols and all patients gave written informed consent. HCV infection was
confirmed based on serology and/or plasma HCV titers. Chronic HCV was
defined as detectable HCV viral load and sustained liver injury for greater than
months (as monitored by liver function tests and/or liver biopsy). IFNa /
ribavirin therapy had been discontinued at least 6 months prior to sample
collection. In addition, patients had not received any immune modulators or

suppressors within 30 days prior to study entry. All patients tested negative for
HIV, syphilis, and HBV within 30 days prior to study entry and were free of
uncontrolled medical illness (including decompensated cirrhosis and any
rheumatologic or immunologic disease). Cohort 1 (n = 16) was used to analyze
monocoyte derived DCs (Table 2.1) and cohort 2 (n = 17) was used to evaluate
circulating DC populations (Table 2.2). Samples were also collected from 17 nonHCV healthy donors. Sustained virologic responders (SVR, n=6) were HCV
RNA negative six months after completion of pegylated-IFNa/ribavirin therapy.
PBMCs were also obtained from patients with non-HCV liver disease (n=7)
including hepatitis B, granulomatous hepatitis, and cirrhosis.
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2.4 Materials and Methods
Isolation and preparation of cells
PBMCs, DCs, and T cells were prepared as previously described168. Briefly,
PBMCs were isolated from whole blood by sedimentation over Ficoll-Hypaque
(Amersham Pharmacia Biotech, NJ). T cell enriched and T cell depleted fractions
were prepared by adherence to plastic in 1% single donor plasma. iDCs were
prepared from the T cell depleted fraction by culturing cells in the presence of
1000 U/mL GM-CSF (Berlex, Seattle, WA) and 500-1000 U/mL IL-4 (R&D
Systems, Minneapolis, MN) for 6 days169,170. To generate mDCs, cultures were
stimulated on day 6 with 50 ng/mL TNFa (Alexis Biochemicals) and O.IjjJVI PGE2 (Sigma) for 36-48 hrs171. cDCs were isolated using a BDCA-1 Isolation Kit
(Miltenyi Biotec, Auburn, CA). Mature cDCs cultures were generated after
purification with 50ng/mL TNFa (AlexisBiochemicals, San Diego, CA) and
,171 hrs1
O.IjaM PGE-2 (Sigma, St. Louis, MO) for 36-48

Allogeneic Mixed Leukocyte Reaction (Allo-MLR)
2 x 105 purified T cells/well were plated with cDCs at indicated ratios in 5%
pooled human serum (Labquip LTD). Cultures were incubated for 4-5 days at

37°C and pulsed with l^iCi 3H-thymidine during the last 14-16 hrs of culture. 3H
thymidine incorporation was measured using a liquid scintillation counter
(Packard Topcount). Allostimulatory index was generated by dividing the
observed proliferation by the average maximal proliferation achieved when
using mature cDCs at a ratio of 30 T cells : 1 DC. In all cases, maximal
proliferation was > 100,000 counts per minute / IO6 T cells used.
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Detection of influenza-specific T cells by E L I S P O T

mDCs were infected with influenza A/PR/8 (Spafas, Conn.) for lhr at 37°C, as

described168. DCs and T cells were plated in 96-well Millipore plates coated with
5mg/mL of anti-IFNy mAb (Mabtech, Mab-1-D1K). Cultures were incubated for
24-36 hrs at 37°C, washed with mild detergent, and incubated with lfAg/mL
biotin-conjugated anti-IFNy mAb (Mabtech, MAB 7BG-1). Spots were visualized
using Vectastain Elite Kit (Vector Laboratories). Evaluation was performed in a
blinded fashion by an independent service (Zellnet Consulting, Inc., NY) using
an automated ELISPOT reader (Carl Zeiss, Inc., NY). Spots represent IFNy

production by single cells and are reported as spot forming cells (SFCs)/106 cell

Cell enumeration

Flow cytometric analysis was employed to enumerate different hematopoetic
lineages in PBMCs using a Blood Dendritic Cell Enumeration Kit (Miltenyi

Biotec, Auburn, CA). Briefly, scatter properties of the cells as well as CD 19 an
CD 14 staining enabled enumeration of B cells and monocytes, respectively.
Simultaneous labeling with anti-CDlc (BDCA-1) and anti-BDCA-2 monoclonal
antibodies (mAb) allowed selection of CD19 negative cells and enumeration of
the BDCA-1+ cDCs and the BDCA-2+pDC populations. Absolute numbers of the
respective cell populations were normalized to the total number of PBMCs
collected to obtain the relative percentage of each cell type.
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IFNa production by Intracellular Cytokine Staining (ICCS) and ELISA
PBMCs were resuspended in DMEM 10% FBS at 5 x 106/mL and stimulated with
either media alone; 50 hemagglutinin units (HAU)/ml Influenza A/PR8/1976; or
5ng/mL CpG (2216: 5'-GGGGGACGATCGTCGGGGGG-3'). Cultures were
incubated for 5 hrs, harvested and fixed using Cytoperm/Cytofix kit (BD
Pharmingen) and stained with anti-IFNa (MMHA-11, PBL Laboratories,
Piscataway, NJ) followed by goat anti-mouse PE (Jackson Immunochemical,
West Grove, PA). BDCA-2 FITC and BDCA-4 APC antibodies were used to label
pDCs in the PBMC fraction, post-stimulation. To measure the quantity of total
IFNa produced, supernatants from parallel cultures were collected after 24 or 48
hrs and assayed using a human IFNa ELISA (PBL laboratories, Piscataway, NJ).
Importantly, all PBMC samples used for IFNa assays were freshly prepared and
used within 12 hrs as IFNa production was significantly affected by freeze-thaw
(>10-fold decrease in IFNa production in parallel samples). IFNa production
was normalized per pDC based on the percentage of pDCs in the PBMC fraction.

Statistics

Two tailed non-parametric comparisons (Mann-Whitney test) were used to
calculate p values for differences in cDC and pDC enumeration, as well as total
IFNa production by PBMCs, as this method allows for data with a non-Gaussian
distribution, p values for normalized data in Fig. 2D was evaluated with a twotailed parametric comparison (unpaired t test, Welch corrected).
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J6/JFH-1 chimeric infections

High titer J6/JFH-1 chimeric HCV was obtained from Brett Lindenbach (Rice lab,
RU). Briefly, this virus was created from the JFH-1 HCV cDNA (which can
replicate in vitro without adaptive mutations18) recombined with core-NS2 region
from a related genotype 2a strain, J616. iDCs and a hepatoma cell line (Huh7.5)
were exposed to J6 / JFH chimeric HCV or mock virus supernatant for one hour
at 37°C at 106/mL. DCs were washed and resuspended in 1% human serum with
maturation cocktail TNFa / PGE-2. Huh7.5 cells were washed and fresh media
was added. Infection was assayed by FACS analysis of NS5A expression.

NS5A expression by FACS analysis

Indicated cells were resuspended at 106/mL, washed in PBS, and fixed for 10
minutes in lOOjxl cytoperm/cytofix (BD Pharmingen) per 105 cells at 4°C. Cells
were washed twice in lx perm wash (BD Pharmingen) and stained with mouse
monoclonal anti-NS5A (9E10, generated by Tim Tellinghuisen, Rice lab, RU) at
1:50 for 15 minutes at 4°C and goat anti-mouse IgGs PE (Jackson
Immunoresearch) at 1:400 for 15 minutes.

2.5 Results
Functional monocyte-derived DCs can be generated from patients with chronic HCV.

PBMCs were isolated from chronic HCV patients (cohort 1, Table 2.1) and used
for the generation of iDCs. Surface expression of CD14, CD25, CD40, CD54,
CD83, CD86 and HLA-DR measured by FACS analsysis showed similarity to
normal iDCs (Fig. 2.3A). Following exposure to TNFa and PGE-2, patient DCs
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Table 2.1. Characteristics of study participants for monocyte-derived D C s
(Cohort 1)
Patient ID

Ape

Sex

Geno
ty£e

ALT/
AST

Viral
Load
do*)-

Histolosv

Date of D x or Prior
Jx

3
(Chronic1')

52

M

la

41/42

189.0

Fibrosis: Stage 2

Dx in 2/99;
Peg-Ribavirin/IFN

33
(Chronic)

52

F

la

NA

4.6

Fibrosis: Grade 2,
Stage 2

Unknown

51
(Chronic)

47

M

la

76/48

6.9

Fibrosis: Grade 2,
Stage 2

Dx in '96;
Tx naive

104
(Chronic)

53

M

lb

45/41

14.8

Fibrosis: Grade 2,
Stage 2

Dx in '65;
Peg-Ribavirin x 3

126
(Chronic)

48

M

2a

59/31

NA

N o biopsy taken

Tx Naive

351
(Chronic)

61

F

lb

80/96

5.2

Fibrosis: Grade 2,
Stage 3

Tx Naive

402
(Chronic)

20

M

N/A

41/31

1.3

N o biopsy taken

Dx '01; Tx naive

689
(Chronic)

69

M

la

88/55

47.1

Fibrosis: Grade 2,
Stage 2-3

Peg-Ribavirin/IFN

794
(Chronic)

49

F

N/A

35/70

0.5

Cirrhosis: Grade 3,
Stage 4

Dx in '78; Tx naive

804
(Chronic)

22

M

lb

188/
113

11.6

Advanced Fibrosis,
Grade 2, Stage 4

D x in 3/02; Tx
naive

812
(Chronic)

65

F

1

51/42

16.2

Fibrosis: Stage 1

Dx in '60s;
Peg-Ribavirin/IFN

815
(Chronic)

68

M

N/A

247/
112

4.5

N o biopsy taken

Dxin9/01;Tx
naive

936
(Chronic)

42

F

la

19/14

9.6

Fibrosis

Dx in '95; Tx naive

237 (SVR§)

52

M

la

14/17

BD**

Cirrhosis: Stage 4,
Grade 4

Dx '00;
Peg-Ribavirin/IFN

813 (SVR)

42

F

4a

5/9

BD

N o biopsy taken

Dx in '97;
Peg-Ribavirin/IFN

976(SVR)

41

M

N/A

131/25

BD

N o biopsy taken

Dx '79;
Peg-Ribavirin/IFN

+ Chronic patient defined as individual with H C V viral load and sustained liver injury for greater than 6
months as monitored by A L T / A S T and/or liver biopsy.
§ Sustained Virologic Responder (SVR) defined as individual with evidence of H C V infection but
maintained undetectable viral load more than 6 months after termination of therapy.
* Viral load defined by quantitative P C R at time of blood draw (Roche Amplicor™). Data not available
(NA) for PT #126; prior data confirmed status as chronically infected.
** B D stands for below detection.
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Figure 2.3. Monocyte-derived D C s from chronic H C V patients undergo
normal T N F - a dependant maturation. A , B. Representative examples of
iDCs (A) and m D C s (B) from a chronic H C V patient #3 are shown.
Geometric m e a n fluorescence intensity (MFI) is indicated. C. Representative
examples of m D C s from a normal donor and chronic H C V patient #804 are
shown. Surface expression of the indicated marker (dark lines) is overlaid
with the isotype control (dotted line). All antibodies were obtained from B D
Biosciences. D. m D C s from chronic H C V patient #936 were adhered to
Alcian blue treated coverslips, fixed with 3.4% P F A and stained with antiM H C I I (clone 93C9), followed by secondary anti-mouse IgG Alexa 488.
Cells were visualized using a Zeiss Axioplan 200 microscope.
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expressed surface markers characteristic of m D C s (Fig. 2.3B). Direct comparison
of mDCs from chronic HCV patients and normal donors showed similar
expression of CD83, CD86, HLA-DR, and CD54 (Fig. 2.3C). Furthermore, patient
DCs displayed a stellate morphology characteristic of mDCs (Fig. 2.3D).
Maturation was TNFa-dependent, as PGE-2 alone did not induce phenotypic
maturation.
We next evaluated patient DCs for their ability to prime allogeneic T
lymphocytes as a measure of their functional capacity. Notably, proliferation

was robust (>105 CPM at 90:1 T:DC ratio, Fig. 2.4A) and specific, as demonstrated
by the lack of proliferation in syngeneic T cells (data not shown). Comparison of
T cell priming capacity of phenotypically normal iDCs and mDCs from chronic
HCV and normal donors provides functional data to support the normal TNFadependent maturation in both patient populations (Fig. 2.4A). Normalized
allostimulatory capacity of DCs from healthy versus chronic HCV-infected
donors is shown (Fig. 2.4B). We conclude that monocyte-derived DCs generated
from patients chronically infected with HCV are phenotypically and functionally
normal.
While it is difficult to demonstrate DC function in vivo, one measure
employed is the evaluation of circulating memory T cells. We show that

influenza-reactive T cells derived from patients can be effectively re-stimulated
using syngeneic mDCs, as measured in an IFNy ELISPOT (Fig. 2.4C). Precursor
frequency of influenza-reactive T cells in HCV patients (n=5), measured by spot
forming cells (SFCs) / IO6 T cells, fell within the range of normal individuals
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Figure 2.4. Mature DCs derived from chronic HCV patients prime
allogeneic T cells and stimulate antigen specific syngeneic m e m o r y T
cells. A. Allo-MLR T cell priming by iDCs and m D C s from normal (Nl)
donor 3 and chronic H C V patient #794 are shown. Error bars indicate +/SD. B. Allostimulatory responses of m D C s from all tested normal donors
and chronic H C V patients were normalized to values of the normal donor at
30:1 to generate an allostimulatory index and plotted as thin lines with
patient identification numbers noted. Thick black line represents m e a n
allostimulatory capacity. C. IFN-y production by influenza-specific T cells
stimulated with either uninfected (white portion of bar) or infected m D C s
(black bar) from all patients tested. Data from normal, responder and
chronic H C V patients are s h o w n as spot forming cells (SFCs) per IO6 T cells,
plotted on a logarithmic scale. N R indicates <50 SFC per IO6 T cells.
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(pCTL range in h u m a n s is 0.02-0.15% based on seven control patients studied
here and >350 ELISPOT assays performed in our laboratory).

Lower numbers of circulating DCs in chronic HCV patients
Despite the in vivo implications of this work, the caveat remains that these

are data for in vitro derived cells. In order to explore the small populations of
circulating DCs in vivo during chronic HCV infection (cohort 2, Table 2.2), we

employed flow cytometric analysis. Using the scatter properties of the cells (siz
and granularity), as well as staining with anti-CD19 and anti-CD14 mAbs, it was
possible to enumerate B cells (Fig. 2.5A, R2) and monocytes (Fig. 2.5A, R3),
respectively. Cells were simultaneously labeled with anti-CDlc (BDCA-1) and
anti-BDCA-2 mAbs, thus allowing selection of CD19- cells (Fig. 2.5A, R4) and
enumeration of the BDCA-1+ cDCs (Fig. 2.5A, R5) and the BDCA-2+pDC (Fig.
2.5A, R6) populations. Absolute numbers of the respective cell populations were
normalized to the total number of PBMCs collected to obtain the relative percent
of each cell type (Fig. 2.5B). Despite greater heterogeneity in the percentage of
cells in HCV patients, seen here, as well as previous studies28, we observed no

statistical differences in the median percentage of B cells or monocytes. We did,

however, reveal a small but marginally significant difference in the percentage o
cDCs in chronic HCV compared to normals (0.62 vs. 0.83, p=0.05, respectively).
In addition, the data indicate a reduction in the percentage of pDCs in chronic
HCV patients (0.11 vs. 0.34, p=0.004) as compared to normal individuals. While

potentially important to disease progression, this observation is not specific fo
chronic HCV infection. We find lower numbers of DCs in sustained virologic
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Table 2.2. Characteristics of H C V patients in D C subset evaluation
(Cohort 2)
Age,
Patient
years
1181°
55
347°-d
51
1142 '•" 46
1060°
38

107
1128
1127"

959
967
1133

840
501
522
573d
1166°
1161°
400d

33
57
54
29
64
47
43
58
60
52
46
70
53

Sex
M
F
F
F
M
F
F
M
M
M
M
F
F
M
M
F
M

Genotype

NA
1a
1b
1
1a
1b
2a/c

2b
1a
1a
1b
2b
1b
1a
la/b

1a
1a

ALT/AST score
60/89
207/145
40/43
129/77
74/28
51/NA
138/93
235/87
48/31
48/42
66/40
29/30
82/60
24/33
63/51
204/113
104/106

H C V load, lU/mL
(X10')a
62.5

431
128
42.2

2.5
45
14.6

385
NA
182
222.2
>100
27 7

NA
872
264
13

Histological findingb

NA
Grade 3, stage 2
Grade 2, stage 3-4
Stages 1-2
Grade 3, stage 3
Stage 2
Grade 1, stage 1
Grade 3, stage 3
Grade 3, stage 3

NA
Grade 1, stage 3
Grade 3, stage 1
Grade 2, stage 2
Grade 2, stage 2

NA
Grade 2, stage 1
Grade 3, stage 4

Treatment
Naive
Peg-IFN/RBV
Naive
Naive
Peg-IFN/RBV (treated in 2003)
Naive
Naive
Naive
Naive

NA
Naive
Naive
Naive
Peg-IFN/RBV (treated in 2003)
Naive
Naive
Naive

NOTE, A patient with chronic HCV infection was defined as an individual with a detectable HCV load and sustained liver injury for >6 months, as monitored
by liver function tests (alanine aminotransferase [ALT]/aspariate aminotransferase [AST]) anchor liver biopsy. IFN, interferon; NA, not available; PEG, pegylated;
RBV, ribavirin.
a HCV load defined by quantitative polymerase chain reaction at the time of collection of blood samples (Roche Amplicor). Data were not available for patients
967 and 573; prior data confirmed that they had chronic HCV infection.
b Histological criteria defined as in [16].
c Indicates leukapheresis sample.
d Indicates fresh sample used for analysis of IFN-a production; no marking indicates a frozen sample.
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Figure 2.5. D C Enumeration in chronic H C V . A. Cytometric-based
enumeration strategy. P B M C s are gated in Rl based on Forward Scatter
(FSC)/Side Scatter (SSC). B cells and monocytes are identified by C D 1 9 and
C D 1 4 Cy5 labeling, respectively, and are differentiated based on SSC
profile. B cells are gated by R 2 and monocytes are gated by R3. CD19- and
C D 1 4 low cells are gated by R 4 and used to enumerate B D C A - 1 P E D C s (R5)
and B D C A - 2 FITC (R6). B. The percentage of monocytes and B cells are
graphed for normal (filled triangles) or chronic H C V (filled circles) donors.
The percentage of D C s (BDCA-1+) and plasmacytoid D C s (BDCA-2+) in
normal, chronic H C V (HCV), sustained virologic responders (SVR, filled
squares), and n o n - H C V liver disease (filled diamonds) are also displayed
graphically. A Mann-Whitney test w a s used to generate p values for
comparison of normal donors (n=17) and individuals with chronic H C V
(n=17).
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responders (n=6) as well as patients with n o n - H C V liver disease (n=7). L o w
numbers of pDC have also been observed in patients with HIV/AIDS 172.

Normal phenotype and function of circulating cDCs and pDCs
In order to isolate cDCs and evaluate their functional characteristics, large
numbers of PBMCs were collected by leukapheresis from four chronically
infected patients. Surface expression of phenotypic markers was measured by
flow cytometric analysis and indicated a phenotype suggestive of immature
DCs—CD14", CD25", CD40", CD8310, CDSe1"' and HLA-DR"1 (Fig. 2.6A, gray line).
Following exposure to TNFa, upregulation of maturation markers CD25, CD40,
CD83, CD86, and HLA-DR was observed (Fig. 2.6A, thick black line). This
upregulation corresponded with a functional change in allostimulatory potential
characteristic of a mDC (Fig. 2.6B). Of note, the phenotype and priming capacity
of cDCs derived from patients with chronic HCV was equivalent to that
observed in normal individuals (Fig. 2.6B).
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Figure 2.6. Normal phenotype and function of myeloid D C s in chronic
H C V patients. A. F A C S phenotype of myeloid D C s (BDCA-1+) is s h o w n for
representative chronic H C V patient #1181. Analysis w a s performed
following C D 1 9 depletion and B D C A - 1 positive selection (90% purity, data
not shown). Thick black line, myeloid D C s + T N F a ; thick gray line, myeloid
D C s ; thin black line, isotype control. B. Allostimulatory responses for
myeloid D C s purified from 4 chronic H C V patients and 3 normal
individuals were evaluated. BDCA-1+ purified cells alone or cells exposed
to T N F a , were placed into co-culture with allogeneic T cells, and cultured
for 5 days. Proliferation w a s monitored by thymidine incorporation and
data w a s normalized to the average m a x i m u m stimulation by mature
myeloid D C as described in the study design section. O p e n circle, myeloid
D C s or filled circle, myeloid D C s + T N F a ( H C V patients); open triangle,
myeloid D C s or filled triangle, myeloid D C s + T N F a (Normal controls).
Average proliferation responses across the patient populations are indicated
by solid lines.
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W e next addressed the function of the p D C s in chronic H C V patients. In
humans, pDCs produce robust amounts of IFNa after engagement of TLR7, a
receptor for ssRNA, or TLR9, a receptor for CpG motifs153. We stimulated the
PBMCs with live influenza virus or CpG-2216 and measured IFNa production by
ELISA (Fig. 2.7A). Notably, IFNa production was lower in patients with chronic
HCV as compared to normal individuals when stimulated with 50 HAU of
influenza (3.9 ng/ml vs. 12.3 ng/ml, p=0.07, respectively) or CpG-2216
(4.9ng/ml vs. 26.1 ng/ml, p=0.04, respectively). However, when normalized to
the respective percentage of pDCs in the PBMC sample, the difference in IFNa
secretion was no longer statistically significant between chronic HCV patients
and normals for influenza (1.3 pg/ml vs. 1.9 pg/ml, respectively) or CpG (2.0
pg/ml vs. 2.9 pg/ml, respectively) (Fig. 2.7B). These findings suggest that while
lower in number, the pDCs are unimpaired in their production of IFNa in
response to TLR ligands.
In order to verify IFNa production by pDCs and to evaluate the
percentage of IFNa-i- pDCs, we assayed stimulated PBMCs for intracellular IFNa
by flow cytometric analysis after 5 hr of stimulation with influenza or CpG-2216
(Fig. 2.7C). Only the pDCs produced measurable IFNa under these conditions
and by gating on this population, the percentage of IFNa producing pDCs could
be assessed (Fig. 2.7D). The data indicate that despite the decreased percentage
of pDCs in the circulating blood, the pDCs respond equally well to influenza
virus and CpG motifs on a per cell basis (Fig. 2.7B, D).
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Figure 2.7. p D C s from chronic H C V patients produce I F N a in response to
T L R stimulation. A. I F N a production in the supernatant of P B M C s
stimulated with 50 H A U of influenza or 5fxg/ml CpG-2216 w a s evaluated
by ELISA. Median values are indicated by black lines and p-values were
determined using a Mann-Whitney test. B. Data from the ELISA w a s
normalized based on the respective percentage of p D C s present in the
P B M C fraction, p-values were determined using an unpaired t test, Welch
corrected. C. p D C s were identified in the P B M C population using lineagespecific markers B D C A - 4 A P C and B D C A - 2 FITC (Gate Rl). Intracellular
I F N a staining in unstimulated or stimulated (50 H A U influenza) conditions
w a s measured by cytometric analysis and the percentage of IFNa+ p D C s is
represented in a dot-plot. Patient #1166 represents a chronic H C V donor
with normal p D C (BDCA-2+) numbers (0.62%). Patient #1138 represents a
chronic H C V donor with low p D C (BDCA-2+) numbers (0.05%). D. The
percentage of p D C s responding to influenza stimulation and producing
I F N a in 6 chronic H C V and 4 normal donors is graphically represented.
Black lines indicate average percentage of IFNa+ p D C s across the respective
patient population tested.
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N o robust infection of D C s in vivo or in vitro
Finally, we evaluated productive infection in these DC subsets as detected by
non-structural protein expression. Although RNA and structural proteins may
stick to circulating DCs via binding receptors such as DC-SIGN, non-structural
protein expression indicates viral replication. Purified cDCs and pDCs were
permeabilized and stained with anti-NS5A. In all cases, neither cDCs nor pDCs
showed expression of NS5A as monitored by FACS analysis (Fig. 2.8A).
Recently, infectious chimeric HCV J6/JFH was reported to infect and

replicate in hepatoma cell lines in vitro16. In order to test if this virus coul
DCs, monocyte derived DCs were exposed to virus and analyzed after 3 days.
Despite robust infection of Huh7.5 hepatoma cells, no infection of monocyte
derived DCs was seen 3 days post-infection, as monitored by intracellular NS5A
staining (Figure 2.8B).
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Figure 2.8. N o robust replication of H C V in D C s ex vivo or in vitro. A.
p D C s or B D C A - 1 + myeloid D C s were purified from an H C V + donor and
stained for N S 5 A expression. B. Monocyte derived D C s or Huh7.5
hepatoma cells were exposed to J6/JFH chimeric virus. N S 5 A expression
w a s monitored after 3 days.
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2.6 Discussion
Controversial results in monocyte-derived DCs
In this study, we have characterized HCV patient DCs, demonstrating
phenotypically normal and functionally active mDCs. This finding differs from
previous reports159'161, which we suggest is due to differences in culturing
conditions. It is possible that incomplete maturation resulted in a perceived
functional defect in the study by Auffermann-Gretzinger et al., as suggested by
the presence of contaminating CD83" cells in the FACS plots of normal

individuals mDC cultures160. Specifically, we do not find evidence for a defect i
TNFa mediated DC maturation as demonstrated by a clear shift in allostimulatory capacity when iDC are effectively matured (Fig. 2.4A). T cell
priming with mDCs (Fig. 2.4A, B) contrasts other studies where reported
thymidine incorporation was 10-fold lower than typically observed159, again

reflecting poor growth conditions for DCs and or T cells in allo-MLR cultures. In
our study, using adequate conditions for DC maturation and T cell priming,
monocyte-derived DCs from chronic HCV patients are found to be both
phenotypically normal and functionally active. Although these findings are from
in vitro derived DCs, the presence of robust influenza specific T cell responses

suggests that in vivo, chronic HCV patients maintain the ability to support centr
memory T cells. It also offers additional evidence for functionally competent
mDCs in chronic HCV patients, and illustrates that the observed defect in the

HCV-specific T cell repertoire does not extend to other viral antigens (Fig. 2.4C)
These data are consistent with the current understanding of immune function in
and pathogenesis of HCV, which suggests that the immune defect is HCV-

specific. These results are also consistent with the growing belief that in vivo,
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P B M C s are not typically infected by H C V (141 and data not shown). Moreover,
they offer crucial support for DC-based immunotherapy strategies for HCV.
Despite our description of functional monocyte-derived DCs in chronic
HCV, this data does not rule out a possible in vivo DC (or DC subset) defect. For
example, as mentioned in chapter 1, HCV may directly interact with DCs via DCSIGN94'95 to modulate DC function in an HCV-specific fashion. Initial reports

evaluating circulating cDCs suggest that functional defects in DCs are associated
with HCV infection, but no direct mechanism for the putative DC dysfunction
has been demonstrated173174. Furthermore, these reports do not account for the
HCV-specificity of the immune defect. In order to evaluate these results in
circulating DCs, we designed and inititated a clinical trial, CRI-0505, which
allowed for the procurement of large numbers of PBMCs for BDC analysis.

Lower numbers of circulating DCs in chronic HCV patients
Similar to several recent studies162174, our data support the finding of lower
percentages of circulating cDC and pDCs in PBMCs from chronic HCV patients
(Fig. 2.5). However, these findings do not necessarily seem specific for
HCV—SVRs and patients with non-HCV liver disease show similarly lower
numbers. Further, HIV patients are reported to have lower circulating numbers
of pDCs, which may suggest a general characteristic of chronic infection175.
Importantly, lower numbers may reflect relocalization of cDCs or pDCs to
inflamed tissue or lymph node following activation155 or dowregulation of BDC
specific markers used to identify these populations in blood. Several forms of

liver disease may cause decrease in circulating levels of cDCs due to migration t
inflamed liver 176. Analysis of both infected tissue as well as draining lymph
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nodes for p D C s and I F N a + cells m a y offer insight into this question; however,
access to high quality tissue is often limited.

Functional pDCs in chronic HCV infection
Consistent with previous reports 162, our data suggest that PBMCs from chronic
HCV patients produce less total IFNa when stimulated with pDC specific

agonist to TLR9 (Fig. 2.7A). However, in contrast to the interpretation by others,
we believe that this decrease reflects a decrease in absolute pDC numbers and
not inhibition of TLR9 specific signaling. First, we show that influenza, acting
an agonist for TLR7 (and possibly TLR3), produces similar levels of IFNa (Fig.
2.7A). Second, when we normalize the data for total IFNa production per pDC,
no statistical difference is seen between healthy controls and chronic HCV
infected donors, suggesting that lower numbers of pDCs in the bulk PBMC
cultures accounts for decreased IFNa production (Fig. 2.7B).
These findings suggest normal function of pDCs and functionally intact
TLR7 and TLR9-signaling pathways. In order to evaluate this formally, IFNa
production in pDCs was directly assayed using FACS-based ICCS (Fig. 2.7C, D).
Even in patients with low numbers of DCs, the same percentage of cells respond
to TLR7 and TLR9 agonists to produce IFNa.
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Important implications for immunotherapy
Strong CD8+ T cell response are associated with successful resolution of
HCV infection and protection41. These findings provide a rationale for
immunotherapy as well as vaccination strategies to augment HCV-specific CD8+
T cell response. Autologous DC immunotherapy has been used to induce CTLs
against tumor antigens177. Despite the limited success of DC vaccines in tumor
immunotherapy, infectious diseases may be more amenable to this type of
treatment. Our findings along with similar results in the chimpanzee model178
support the use of autologous monocyte derived or circulating cDCs loaded with
HCV antigen for these trials.
IFNa is the currently approved treatment for chronic HCV infection.
Although it is effective in approximately 50% of patients (depending on the HCV

genotype), treatment is associated with significant side effects including nausea
dizziness, and flu-like symptoms which may persists for the six month course of
treatment. TLR7 (Anadys Pharmaceuticals/Novartis) and TLR9 (Coley
Pharmaceutical Group/Pfizer) agonist therapy for chronic infection are currently

in clinical trials with multiple aims. First and foremost, it is necessary to eva

the efficacy of these therapies in achieving an antiviral effect (i.e. a reductio

viral load). Second, it is hypothesized that the specific and localized triggering
endogenous IFNa may provide more effective delivery as well as avoid many of
the side effects associated with systemic IFNa treatment. Our data suggest that
pDCs during chronic HCV are competent to respond to these types of agonists;
however, the effects of lower absolute pDC numbers need to be evaluated. An
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additional benefit of TLR7/9 agonist therapy m a y involve p D C s role in H C V specific T cell priming which will be addressed in chapter 4.

HCV antigen presentation in the absence of direct infection
Although the data regarding infection of PBMCs and DCs, in particular, is
controversial141163, our results suggest that circulating DCs are not robustly

infected (Fig. 2.8A). These findings are supported by the lack of robust infection
of monocyte derived DCs in vitro by the recently described J6/JFH virus (Fig.
2.8B). One explanation for this difference may be that our conclusions are mainly
based on intracellular staining for NS5A while contrasting data is based on RTPCR data163. Importantly, DCs do interact with E2 via DC-SIGN95. Thus, PCR
based assays for DC infection must differentiate between positive and negative
strand to conclusively show infection. Alternatively, cells should be washed
with EDTA before RNA is prepared to dissociate bound viral particles.
Although CD81, a key component required for HCV infection121618179, is
expressed on many cell types, the availability of particular cellular proteins
required for HCV replication may account for cell tropism. For example, certain
hepatocyte cell machinery may provide for efficient replication not available in
DCs. These cellular factors required for efficient HCV replication are currently
under investigation. Alternatively, the production of and response to antiviral
cytokines such as IFNa may play an important role in cell tropism.
In the absence of direct infection, DCs may still acquire antigen for
presentation to T cells via cross-presentation. A recent study has shown that
DCs can cross-present viral particles for stimulation of HCV-specific T cells
against structural proteins epitopes carried in the viral particles180. In light
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presence of C D 8 + T cells reactive against N S protein epitopes41, crosspresentation of infected hepatocytes may likely play a key role in generating
CD8+ T cell immunity. Thus, a detailed understanding of the mechanisms
regulating immunologic outcome of cross-presentation may offer insight into the
HCV immune response.

Finally, our data support the investigation of alternate roles for the DC in
HCV pathogenesis as we must account for the HCV-selective defect in the T cell
repertoire of chronic HCV patients. In the next two chapters, I consider two
important factors associated with HCV infection that may influence the
immunologic outcome of DC / CD8+ T cell engagement—namely, IFNa/p and
CD4+ T cell 'help'.
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C h a p t e r 3: D C maturation alters intracellular signaling n e t w o r k s
enabling differential effects of I F N q / P o n antigen crosspresentation

3.1 S u m m a r y
Type I interferons (IFN), produced largely by plasmacytoid dendritic cells
(pDCs), bridge innate and adaptive immune responses and modulate immune
function in complex ways. Here, we show that pDC-derived IFNa/p induces
opposing effects on the immunologic outcome of cross-presentation. Specifically,
IFNa/p acts on immature conventional dendritic cells (DCs) during antigen
capture to block IL-12 production and inhibit subsequent CD8+ T cell activation.
In contrast, exposure of mature DCs to IFNa/p enhances T cell activation.
Further investigation revealed a molecular switch in intracellular signaling
pathways, which occurs during DC maturation and accounts for the opposing
effects of IFNa/p on antigen cross-presentation. The alteration of signaling
networks offers a novel mechanism by which DCs modulate the integration of
signals from the surrounding environment and helps to explain the paradoxical
effects of IFNa/p on adaptive immunity.
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3. 2 Introduction

HCV infection, in contrast to other viral liver infections including HBV, induces
robust IFN response genes upon infection139. Although this interferon gene
signature is not predictive of clinical outcome, HCV replication is sensitive to
IFNa and pegylated-IFNa / ribavirin is a highly effective therapy for HCV101.
The difficulty in understanding the complex actions of IFNa/p during HCV

pathogenesis is reflective of the pleiotropic effects of IFNa/p140. Although most
widely known for its antiviral activity, IFNa/p is also a potent
immunomodulator. For example, exposure of natural killer (NK) cells and naive
T cells to IFNa/p during viral infection inhibits their production of IFNy181;
however, IFNa/p has also been shown to trigger NK cell cytotoxicity and

stimulate proliferation of certain T cell subsets182183. These polarized physiolo
and pharmacologic effects are mediated by the same heterodimeric IFNa
receptor.
This complexity extends to the effects of IFNa/p on conventional dendritic
cells (DCs). Considered the 'sentinels' of the immune system, DCs are
responsible for integrating immune responses. Tissue DCs, which exist in an
immature state of differentiation, are responsible for capturing and processing
antigen, as well as transmitting pro-inflammatory and immune regulatory

signals to cells within draining lymph nodes52. DCs also possess a unique ability
to cross-present exogenous antigen, offering a mechanism for priming CD8+ T
cells specific for viruses that do not directly infect DCs. Recent data suggests
type I IFNs may serve as a 'danger' signal during this process, facilitating DC
activation184 and licensing DCs to cross-prime185; however, IFNa/p has also been
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s h o w n to inhibit the production of IL-12 by DCs186, and m a y also inhibit D C s
from stimulating TH1 cell differentiation187.
pDCs are widely recognized for their role in sensing viral and bacterial
components and producing significant amounts of IFNa/p 188. In humans, pDCs
express TLR7 and TLR9, receptors for ssRNA126 and CpG189, respectively. Upon
activation, pDCs migrate to lymph nodes and produce IFNa/p, thus influencing
the afferent phase of T cell activation155156. During chronic inflammation and
infection, pDCs may also traffic to affected tissues190191. Although activated
pDCs may serve as a strong adjuvant for adaptive immune responses189, the
immunologic significance of pDC-derived IFNa/p in distinct spatial locations has
not been carefully evaluated.
Here, we evaluated the effects of IFNa/p on the cross-presentation of
antigen. Importantly, our consideration of the distinct compartmentalization of
IFNa/p production, in peripheral tissue versus the lymph node, led to a
surprising result. Immature DCs (iDCs) exposed to IFNa/p (referred to herein as
TFN-early')—mimicking the micro-environment of a tissue DC—were impaired
in their ability to activate CD8+ T cells via the cross-presentation pathway. In
contrast, mature DCs (mDCs) exposed to IFNa/p (referred to herein as TFNlate')—mimicking the micro-environment of DC : T engagement within the
lymph node—demonstrated enhanced T cell activation. Investigation into the
regulation of these opposing effects revealed a molecular switch in IFNa/p
signaling networks that is a consequence of DC maturation. Our findings offer
insight into how IFNa/p shapes the adaptive immune responses to cross-
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presented antigen and uncover a novel mechanism by which D C s modulate their
response to cytokine signals from the surrounding environment.

3.3 Materials and Methods
Isolation and preparation of cells

Peripheral blood mononuclear cells (PBMCs), DCs, and T cells were prepared as
previously described168. PBMCs were isolated from whole blood by
sedimentation over Ficoll-Hypaque (Amersham Pharmacia Biotech, NJ). iDCs

were prepared from the T cell depleted fraction by culturing cells in the presenc
of 1000 U/mL GM-CSF (Berlex, Seattle, WA) and 500-1000 U/mL IL-4 (R&D
Systems, Minneapolis, MN) for 6 days169170. To generate mature DCs, cultures
were stimulated on day 6 with 50 ng/mL TNFa (Alexis Biochemicals) and
O.lmM PGE2 (Sigma) or lOng/mL LPS (Sigma) for 36-48hrs171. At days 6-7, >95%
of the cells were CD14CD83HLA-DR10 DCs. After maturation, on days 8-9,
70-95% of the cells were of the mature CD14"CD83+HLA-DRhi phenotype. CD4+
and CD8+ T cells were purified to >99% purity by positive selection with the
MACS column purification system (Miltenyi Biotech, Auburn, CA). pDCs were
also purified by MACS with BDCA-4 microbeads. pDCs were stimulated with
CpG (2216: 5'-GGGGGACGATCGTCGGGGGG-3') in 1% single donor plasma.
After 24 hrs, cultures were harvested and supernatants purified by
centrifugation.
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Induction of apoptotic death

The mouse lymphoma cell line EL4 (number TIB-39, ATCC, Rockville, MD) was

used as a source of apoptotic cells because they can be efficiently infected with
influenza virus and do not induce marked background T cell activation to mouse
antigens. EL4 cells were infected with influenza and apoptosis was triggered
using a 60UVB lamp calibrated to provide 2 mj/cm2/s.

Endogenous and exogenous loading of DCs with antigen

For endogenous loading, mDCs were infected with 0.002 HAU influenza
A/PR8/1976 (Charles River, Spafas Conn) per cell. Virus was quenched and
removed with 2 washes of media with 5% pooled AB human serum (Labquip,
NY). For loading DCs with exogenous antigen, iDCs were co-cultured with
influenza infected EL4s that had been exposed to UVB62. Co-cultures were
incubated in the presence of TNFa / PGE2 to allow for phagocytosis of the
apoptotic EL4 cells, antigen processing and DC maturation to occur. mDCs were
then used for functional assays.

Detection of antigen-specific T cells: ELISPOT assay for IFNy release

Antigen loaded DCs were collected, counted and added to purified T cell
populations in plates that had been coated with lO^g/ml of anti-IFNy mAb
(clone Mab-1-D1K, Mabtech, Cincinnati, OH). In all experiments, 2 x IO5 T cells
were added to 6.6 x IO3 DCs to give a 30:1 T cell:DC ratio. The cultures were
incubated for 40-44 h at 37°C. Cells were washed out with mild detergent (0.5%
Tween-20 in PBS) and the ELISPOT plate was incubated with ljxg/ml of a biotin-
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conjugated IFNy m A b (clone M a b 7BG-1, Mabtech) for 2 hrs at 37°C. ELISPOT
plate was then washed with 0.1% Tween-20 in PBS and developed using the
Vectastain Elite kit (Vector Laboratories, Burlingame, CA) and 3-amino-9ethylcarbazole (AEC) substrate. Colored spots indicate the cells that had
released IFNy and data is reported as spot forming cells /106 CD8+ T cells. Data
from triplicate wells were averaged and mean data is reported. Error bars
represent one standard deviation.

Analysis of STAT phosphorylation
DCs were harvested, washed with PBS, resuspended in 10% FBS containing
media and stimulated with indicated concentration of rIFNa, purified IFNa/p or
IFNy (Sigma, St. Louis, MO) for 30 minutes at 37°C. For western blot analysis
and immunoprecipitation, lysates were prepared in RIPA lysis buffer (150mM
NaCl, 50mM Tris-Cl pH 8,1% NP40, 0.5% DOC, 0.03% SDS, 2mM EDTA) with
ImM Vanadate (Sigma), ImM PMSF, and Complete anti-protease tablet (Roche).
Total protein was determined using the Bradford assay (Biorad).
Immunoprecipitation was performed with 400^g of total protein and 0.2[ig of
anti-IFNARl (CD118) overnight at 4°C. Protein A and G beads were mixed 1:1
and incubated 4°C for 1 hour followed by three RIPA washes. Beads were boiled
at 95°C in 2x loading buffer and run on 8% SDS-PAGE. For IFNAR2 western
blot, 20pig of total protein was loaded on to 8% SDS-PAGE. Proteins were
transferred to PVDF membrane and blotted with indicated antibodies (Cell
Signaling Technologies). Blots were probed first with phospho-specific STAT
antibodies, stripped with low pH, and reprobed with total STAT antibodies to
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ensure p-STAT is monitored in the context of total S T A T . For intracellular F A C S
analysis, samples were fixed, permeabilized with Cytoperm/Cytofix (BD
Pharmingen). Cells were stained with STAT1-PE, STAT3-PE, and STAT4-APC
(Pharmingen) at 1:50 final dilution as indicated.

Affymetrix Microarray U133A (see Appendix 2)
Biotinylated cRNA fragments were prepared from monocyte derived DCs as per
affymetrix protocol192.107 cells were washed in PBS and lysed using Qiashredder
(Qiagen, Valencia, CA). Total RNA was isolated using RNeasy Mini Kit (Qiagen,
Valencia, CA). cDNA and fragmented biotinylated labeled cRNA were
subsequently prepared as per manufacturer's instructions (Affymetrix and Enzo
Life Sciences) and 20 [xg of fragmented cRNA was loaded onto Affymetrix
U133A. Data was analyzed using Microarray Suite 5.0 (Affymetrix, Santa Clara,
CA), and compiled using a Filemaker Pro-based customized database (adapted
from a database that was generously provided by Dr. Nir Hacohen, Harvard
University). Absolute expression, p-call, and p-value as calculated by MAS 5.0
software was exported to Excel spreadsheet and converted into a Filemaker Pro
document. Data from multiple runs was linked via Affy ID number.

IL-12 and IFNa ELISAs
IL-12p70 levels were confirmed in triplicate using IL-12 ELISA (R&D systems).
IFNa ELISA (PBL Biomedical, Piscataway, NJ) was performed in triplicate and
data from two donors was averaged.
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Analysis of IL-12 production in M C M V infected mice
C57BL/6 were obtained from Charles River (France); STAT1-/- (129SVE) from
Taconic; and STAT4-/- (Balb/c) from Jackson. IFNAR-/- mice on the C57BL/6
background were provided by D. Braun, Institut Pasteur. RB6-8C5 (anti-GR-1)
bioreactor supernatant was obtained from monoclonal antibody facility
(MSKCC) and mice were depleted with 500 pig at 36 hrs and 12 hrs before
infection. Mice were infected with 4 x IO5 PFU/mL of salivary gland prepared
MCMV. 36 hours after infection, spleens were harvested, incubated 1:50 dilution
of anti-FcyR (BD Pharmingen) to block non-specific antibody interaction in
mouse FACS wash buffer. Cells were surface stained with CD8 FITC (1:150
dilution, BD Pharmingen) and CDllc PE (1:150 dilution, BD Pharmingen), fixed
and permeabilized with cytoperm/cytofix (BD Pharmingen), and stained with
IL-12 APC (1:150, BD Pharmingen).

3. 4 Results
Maturation prevents IFNa/p mediated inhibition of cross-presenting DCs
In order to explore the effects of TPNa/p on antigen cross-presentation, we
employed an experimental system based on the activation of primary human
memory CD8+ T cells (Fig. 3.1). DCs cross-presenting antigen were generated by
co-culturing iDCs with apoptotic, influenza (flu)-infected MHC-mismatched cells
in the presence of maturation stimuli62. Antigen-loaded mDCs were then

cultured with purified CD8+ T cells and the activation of influenza specific IFNy
producing cells was monitored using ELISPOT. Maximal CD8+ T cell activation
by cross-presentation requires CD40L engagement, mimicking the effect of CD4+
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Figure 3.1. In vitro system for monitoring C D 8 + T cell activation
requires C D 4 0 ligation. D C s loaded with endogenously processed
antigen were prepared by direct infection with influenza (flu D C ) and
compared to uninfected D C s (DC alone). D C s loaded with exogenous
antigen were prepared by cross-presentation of influenza infected
apoptotic cells (flu-apoptotic cells) and compared to uninfected apoptotic
cells (apoptotic cells). D C groups were cultured with syngeneic purified
C D 8 + T cells. T cell activation w a s monitored by IFNy ELISPOT and
displayed as spot forming cell (SFCs) / IO6 CD8+ T cells. Recombinant
C D 4 0 L w a s added to cultures as indicated.
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T cell / D C interactions62 (Fig. 3.1). In order to model IFNa/p production in
peripheral tissue, leukocyte derived or recombinant IFNa was added to iDCs
during antigen capture and maturation (Fig. 3.2A) and then washed out prior to
DC : T engagement. Alternatively, to model the production of IFNa/p in the
lymph node, IFNa/p was added to mDCs during T cell engagement (Fig. 3.2A).
Surprisingly, the effect of IFNa/p on the regulation of T cell activation
depended on the maturation state of the DC. IFNa/p inhibited CD8+ T cell
activation when delivered to iDCs (Fig. 3.2B, IFN-DC), but no inhibition was
observed when adding the IFNa/p directly into the mDC : T cell cultures (Fig.
3.2C, mDC + IFN). In some experiments, high doses of IFNa (600-6000 IU/ml)

resulted in significantly increased T cell responses (data not shown). One caveat
in this comparison is that, in the latter culturing condition, IFNa/p may be
directly affecting the T cell.
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Figure 3.2. Maturation prevents I F N a mediated inhibition of crosspresenting D C s . A. Schematic depicting experimental setup. IFNa/p was
either added to iDCs during antigen capture and maturation (IFN-early)
or during D C : T cell engagement (IFNa-late). B,C. (B)IFNy ELISPOT with
D C s cross-presenting uninfected apoptotic cells (white bars) or D C s crosspresenting influenza antigen-expressing apoptotic cells (black bars)
exposed to 60 I U / m L IFNa/p during antigen capture (IFN-early: IFND C s ) or (C) during D C : T cell engagement (IFN-late: m D C + IFN) cultured
with purified C D 8 + T cells. Data are representative of ten experiments
and similar results were obtained w h e n using recombinant I F N a (data
not shown).
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The inhibitory effect of IFNa/p is selective for CD40-dependent cross-presentation

In order to evaluate if the inhibitory effect of IFNa/p on iDCs is specific for c
presentation, we compared DCs cross-presenting antigen to those directly
infected with influenza. iDCs were treated with increasing doses of IFNa/p (1060 IU/mL) during their maturation. These IFN-DCs were washed extensively
and exposed to live influenza virus. Again, IFNy production by influenzaspecific CD8+ T cells was used as a measure of the DCs capacity to stimulate T
cells. While the cross-presentation pathway was sensitive to IFNa/p (Fig. 3.3,
black line), no inhibition of CD8+ T cell activation was observed when IFN-DCs
were directly infected (Fig. 3.3, red line). Further, the IFN-mDCs loaded with
exogenous antigen showed no defect in stimulating influenza-reactive CD4+ T

cells (Fig. 3.3, blue line), thus providing an internal control that antigen had b
captured and that the DCs were capable of engaging T cells. From these
experiments, we conclude that IFNa/p has a selective effect on T cell activation
by cross-presenting DCs.
This selective effect may be due to decreased antigen capture, inefficient

DC maturation, or the skewing of activation signals specific for T cell activatio
by cross-presentation (e.g. CD40 engagement). In order to directly evaluate

antigen capture, apoptotic cells and iDCs were labeled with fluorescent lipophili
dyes as described193. Capture of the red-labeled apoptotic cells by the greenlabeled DCs was monitored by flow cytometry. After 5hr, -40% of the iDCs had
captured an apoptotic cell body / bleb (Fig. 3.4A). Addition of IFNa/p to the co-

cultures did not inhibit antigen capture (Fig. 3.4A), nor did it alter the kinetic
uptake (data not shown). We next evaluated the effect of IFNa/p on phenotypic
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Figure 3.3. Inhibition by IFNa/P is selective for cross-presenting D C s .
D C s were directly infected with influenza virus (flu D C ) or co-cultured
with apoptotic influenza-expressing apoptotic cells (DCs x/p flu-AC). In
each, the iDCs were exposed to a dose range of IFNa/p iDCs (cone. 0-600
IU/ml). C D 8 + T cell and C D 4 + T cell activation were monitored by IFNy
ELISPOT. Percent inhibition of T cell activation is displayed. Maximal
stimulation (no IFNa/p) in the experiment s h o w n is equivalent to 400 spot
forming cells / million T cells.
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Figure 3.4. IFNa/P does not alter phagocytosis, phenotypic or functional
maturation of D C s . A. Phagocytosis of P K H 2 6 (red dye)-labeled apoptotic
cells (AC) by P K H 6 7 (green dye)-labeled iDCs w a s monitored by flow
cytometry. iDCs and apoptotic T cells were distinguished based on forward
scatter (FSC) and side scatter (SSC) properties, as shown. Gating on iDCs
using scatter and FL-1 criteria permitted monitoring of cells that engulfed a
red-labeled dying cell, as based on their becoming double positive (lower
F A C S plots). Co-cultures were incubated in the presence of media, E D T A ,
or I F N a as indicated. Percent phagocytosis is indicated. B. F A C S analysis of
C D 8 3 , CD86, H L A - D R , and C D 4 0 expression levels on iDCs, m D C s , or D C s
matured in the presence of IFNa/p (IFN-DC). C. Allostimulatory potential
of m D C s or D C s matured in the presence of IFNa/p (IFN-DC) w a s
monitored by stimulation of T cell proliferation after 5 days of culture.
Proliferation w a s monitored by incorporation of 3H-thymidine. Triplicate
wells are averaged and +/- standard deviation is represented by error bars.
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and functional maturation of the DCs. Importantly, the addition of IFNa/p did
not affect TNFa-mediated maturation as monitored by expression of CD40,
CD83, HLA-DR and CD86 (Fig. 3.4B). Moreover, the allostimulatory capacity of
IFNa-mDC was equivalent to mDCs, as measured using a standard allogeneic
mixed lymphocyte reaction (Fig. 3.4C). The finding that antigen capture and DC

maturation are intact is consistent with the observation that CD4+ T cells may be
activated by IFNa early-DCs (Fig. 3.3). These data also suggest that IFNa/p
treatment of iDCs may be affecting the DCs ability to be 'licensed' by CD40, a
feature unique to the cross-priming of exogenous antigen in our model62system'

Maturation alters IFNa/p regulation of CD40L-induced IL-12

In order to evaluate the inhibitory effect of IFNa, we focused our attention on t

effect of 'IFN-early' on CD40L-induced gene changes. In order to screen for these
changes, we took advantage of the Affymetrix U133A microarray (see Appendix
2). Briefly, RNA was prepared from the samples of interest: iDCs or mDCs
matured in the presence or absence of IFNa/p and stimulated with or without
CD40L. RNA probes were prepared as per the Affymetrix protocol and the
microarray data was analyzed with MAS5.0 statistical software. Our array data
set was queried for gene changes in which: mDCs + CD40L > 2x mDCs; AND
mDCs + CD40L > 2x IFNa-mDCs + CD40L (n = 2) (see Appendix 2). With such a
Boolean search, we exclude gene changes that are simply a result of IFNatreatment of the DCs. From the list generated, genes were excluded if they did
not meet a 'p' call in mDCs or mDCs + CD40L in either or both of the
experiments, as per the Affymetrix MAS5.0 statistical package. Data on iDCs,
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m D C s , I F N a - m D C s , m D C s + C D 4 0 L and I F N a - m D C s + C D 4 0 L from the two
individual donors were averaged, and means are graphically represented to
reveal CD40L-induced transcription changes that distinguish treatment of mDCs
(blue) versus IFNa-mDCs (red). This analysis yielded nine candidate genes that
were inhibited by 'IFN-early' (Fig. 3.5).
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Figure 3.5. IFNo/p early alters C D 4 0 L gene induction profile. Affymetrix
data w a s queried for genes induced by C D 4 0 L that were blunted by
exposure of iDCs to IFNa/p during maturation. The top nine differentially
regulated genes are displayed graphically by relative expression in iDCs,
m D C , or m D C s exposed to C D 4 0 L ( m D C + 40L). Blue line, untreated. Red
line, IFNa/p treated.
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In light of the important role that IL-12 plays in cross-priming75,76194, w e
further explored the observation of differential IL-12p40 mRNA expression (Fig.
3.6A). Using an ELISA, we confirmed that CD40L-induced production of

bioactive IL-12p70 was inhibited by 'IFN-early' (Fig. 3.6B). In contrast, 'IFN-lat
synergized with CD40L, as even higher levels of IL-12p70 were produced by
mDCs under these conditions (Fig. 3.6B).
To determine the importance of IL-12 inhibition in the functional block of
CD8+ T cell activation, we evaluated the ability to overcome the IFN-early block
by adding rIL-12 to the IFN-DCs cross-presenting antigen. IFNy ELISPOT results
from three donors were normalized to the donor specific maximal T cell response
and the percent maximal T cell response is shown (Fig. 3.7). Indeed, IL-12
rescued the ability to stimulate antigen-specific CD8+ T cells via the crosspresentation pathway. While other factors may be involved, the decrease in

CD40L-induced IL-12 seems to be a critical component of the inhibitory effects of
IFNa/p. These data also suggest that cross-presentation per se remains intact in
IFN-DCs, and that the dominant mechanism of regulation is via inhibition of
CD40-dependent licensing of DCs. Thus, differential responsiveness of iDCs and
mDCs to IFNa/p regulates the production of cytokines that determine the
immunologic outcome of cross-presentation.
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83

100x
el

T

LJ

media

•

rIL-12p70

80o
60-

*g
+
H
oo
Q
U

40

20-

o *

A

i

D C x/p A C

DCx/pflu-AC

IFN-DC
x/pflu-AC

Figure 3.7. Exogenous IL-12 rescues inhibition by IFNa. T cell
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from three donors were normalized to the donor-specific maximal T
cell response and the percent maximal T cell response in the presence
or absence of IFNa/p and IL-12p70 is shown.
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D C maturation alters IFNa/p signaling by switching S T A T utilization

In light of the correlation of distinct DC maturation states with the paradoxical

effects of IFNa/p, we considered the possibility that intrinsic differences betwe
iDC and mDC IFNa/p responsiveness could account for the opposing effect on T

cell activation. Three possibilities were evaluated to directly test this hypothe

(i) differences at the level of IFNa/p receptor (IFNAR) expression; (ii) utilizat
of distinct signaling molecules; and (iii) altered CD40-mediated transcriptional
events, resulting from differences in IFNa/p signaling.
First, expression of IFNAR on iDCs and mDCs was evaluated by FACS.
Surface expression of both subunits, IFNAR1 and IFNAR2, were equivalent in
iDCs and mDCs (Fig. 3.8A). Immunoblot analysis of IFNAR1 and IFNAR2
confirmed that there are equivalent levels of both subunits in iDCs and mDCs
(Fig. 3.8B). Based on these data, we conclude that differential receptor
expression does not account for the distinct effects of IFNa/p on iDCs and mDCs.
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Figure 3.8. Maturation does not alter I F N A R surface expression. A.
iDC and m D C were stained with anti-CD83-Cy5 and m A b s specific
for I F N A R 1 (AA3, Biogen) or I F N A R 2 ( M M H A R - 2 , Calbiochem).
Anti-mouse IgG P E (Jackson) w a s used to visualize anti-IFNAR
binding. Dot plots representative of a single donor are shown. Three
individuals were evaluated and revealed similar results. M F I for xaxis is indicated. B. Immunoblot for I F N A R 1 and I F N A R 2
expression in i D C or m D C s by western and immunoprecipitation,
respecitively. D C s were either unstimulated or treated with
lOOIU/mL IFNa for 30 minutes.
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W e next considered the possibility of differential signaling downstream of
IFNAR. In order to screen for potential points of divergent regulation, we
analyzed transcriptional profiles of iDCs and mDCs from four individuals using
Affymetrix U133A microarrays. Analysis of genes known to be involved in
IFNa/p-signaling revealed possible differences in IFN-response (Table 3.1). Our
transcriptional analysis of DCs revealed a two-fold change in total Jakl and
Tyk2, the kinases associated with IFNAR and responsible for STAT
phosphorylation. In addition, transcriptional screening showed a 2-fold
downregulation of total ST ATI upon maturation and 2-fold upregulation of
STAT4. Consistent with the skewing of STAT expression, Affymetrix analysis
shows numerous differences in IFN-induced genes between iDCs and mDCs
exposed to IFNa/p (data not shown).
In order to evaluate IFNa/p signaling in DCs, we first looked at kinase
expression. As reviewed in chapter 1, IFNAR is constituitively associated with
Jakl and Tyk2. Engagement of IFNAR by IFNa/p induces dimerization and
oligomerization of the receptor, which allows for Jakl and Tyk2
transphosphorylation. Consistent with the transcriptional data, Jakl protein
expression is increased upon maturation (Fig. 3.9A). Although total changes in
protein expression of Tyk2 are not apparent upon maturation, phosphorylation
of Tyk2 in mature DCs is significantly decreased compared to iDCs in response
to IFNa/p stimulation (Fig. 3.9A).
We next investigated the effect of this differential kinase expression and
activation on STAT activation as monitored by phosphorylation of STAT
proteins by Western blot. Classically, ST ATI and STAT2 are phosphorylated in
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T a b l e 3.1. T r a n s c r i p t i o n a l p r o f i l e s o f I F N o / P a s s o c i a t e d g e n e s
Fold Charge
AffylD

iDC avg"

A/P*

pval+

mDCavg¥

A/P*

pval+

(mDC/iDC)§

IFNAR1

204191_at

124(55-188)

A/P

0.165

139(73-150)

A/P

0.133

1.1

IFNAR2

204786_s_at

126(51-279)

P

0.004

122(57-208)

P

0.003

1.0

<0.001 3782(2799-4632) P

<0.001

2.7

JAK1

201648_at

TYK2

205546_s_at

STAT1

200887_s_at

STAT1

97935_3_at

STAT2

1377(1227-1821) P

P

0.011

963(605-1229)

P

0.005

2.0

1306(892 -1597) P

<0.001

730(641-908)

P

<0.001

0.6

720(370 -924)

P

<0.001

474(310 -616)

P

<0.001

0.7

205170_at

164(132 -185)

P

0.003

156(109 -189)

P

0.009

0.9

STAT3

208991_at

928(670 -1179)

P

<0.001 2084(1458 -2467) P

<0.001

2.2

STAT4

206118_at

206(126 -297) A/P

STAT5A

203010_at

492(343 -675)

STAT5B

205026_at

110(87 -139)

STAT6

201331_s_at

STAT6

201332_s_at

¥

491(315-880)

0.092

430(319 -507)

P

0.024

2.1

P

0.037

994(772 -1143)

P

0.006

2.0

P

0.008

239(205 -285)

P

0.002

22

1975(1773 -2188) P

<0.001

1424(1252 -1681) P

<0.001

0.7

P

0.007

0.044

0.7

368(306 -428)

269(183 -302) A/P

R N A from iDCs and m D C s was anlayzed by Affymetrix microarray U133A. Affymetrix data was
compiled from four individual donors. Average relative m R N A expression for iDCs (iDC avg) and
m D C s ( m D C avg) are indicated with the range indicated in parentheses.

* + Determination of the absence or presence (A/P) of a gene transcript as well as p-values were calculated
using Affymetrix statistical package, MAS5.0
§

Fold change of average expression levels are expressed as a ratio of m D C avg / iDC avg.
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response to IFNa/p, forming a heterotrimer with IRF-9, which binds to interferon
sequence response element (ISRE) containing genes118. In certain cell types,
STAT4 may be phosphorylated in response to IFNa/p, leading to transcription of

distinct sets of genes119. Exposure of iDCs to IFNa/p, results in phosphorylation
of STAT1 and STAT2 (Fig. 3.9B). In contrast, despite the presence of total STAT1
and IFNa/p-induced STAT2 phosphorylation, mDCs showed reduced levels of
ST ATI phosphorylation. Notably, total STAT4 is significantly upregulated
during maturation and exposure to IFNa/p resulted in its phosphorylation (Fig.
3.9B).
Intracellular FACS analysis confirmed, on a per cell basis, that differential
IFNa/p-induced STAT-phosphorylation was dependent on the state of DC
maturation. Using CD83 as a marker, analysis of STAT1 versus STAT4
phosphorylation was evaluated in both iDCs and mDCs. Consistent with
Western blot analysis, iDCs phosphorylate ST ATI and not STAT4 in response to
IFNa/p (Fig. 3.9C), while mDCs phosphorylate STAT4 and show a significantly
reduced phosphorylation of ST ATI. The qualitative shift in IFNa/p signaling is
also reflected in the activation of STAT3. mDCs demonstrate increased STAT3
expression (Table 3.2), however, maturation results in a blunting of STAT3
phosphorylation in response to IFNa/p (Fig. 3.9D). Together, these results
suggest that DC maturation alters IFNa/p signaling through the modulation of
STAT utilization.
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Figure 3.9. Dendritic cell maturation alters IFNa/P signaling
network. A,B. iDC and m D C s were exposed to 60 IU/ml IFNa/p for
30 minutes. 20jig of protein from the total cell lysates were run on an
8 % S D S - P A G E , transferred to P V D F membranes, and blotted with
indicated antibodies. In selected experiments, blots were stripped
and probed for p-actin as a control for loading the gel (data not
shown). C,D. iDCs and m D C s were stimulated with media alone or
indicated concentrations of IFNa/p for 30 minutes. Cells were stained
with anti-CD83-FITC to identify CD83" iDCs and CD83+ m D C s . Cells
were fixed and permeabilized as described in Materials and methods
and stained for p-STATl-PE or p-STAT3-PE and p-STAT4-APC.
Percentage of events in each quadrant is indicated on the respective
plot. Data is representative of three independent experiments.
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Importantly, this finding is not dependent on maturation conditions, as
DCs matured with lOng/mL of LPS also showed impaired ST ATI
phosphorylation (Fig. 3.10A). Furthermore, the inhibition of STAT1 signaling is
also observed after TNFa-mediated maturation of BDCA-1+ circulating DCs (Fig.
3.10 A). In order to test if the inhibition of ST ATI phosphorylation in mDCs is
intrinsically impaired, we evaluated the ability of IFNy to trigger ST ATI
activation. Notably, IFNy-treatment of mDCs resulted in efficient

phosphorylation of ST ATI, indicating that inhibition of pSTATl is in fact specif
to IFNa/p signaling (Fig. 3.10B).

ST ATI required for IFNa/p inhibition of IL-12
In order to evaluate the role of the STAT signaling switch in this dual
regulation of IL-12 production, we took advantage of the fact that, similar to
IFNa/p in our in vitro system, IFNa/p during MCMV infection significantly
inhibits IL-12 production by CDllc+ DCs 195. We confirmed these results
showing significant increase in CDllc+/CD8- IL-12 production in both
IFNAR-/- and pDC depleted mice (Fig. 3.11A). In order to evaluate that STATdependence of this effect, ST ATI and STAT4 KO mice, with 129SVE and Balb/c

controls, respectively, were infected with MCMV Smith strain i.p. Analysis of IL12 production by CDllc high DCs in the spleen 36 hours post-infection by FACS
revealed that STAT1, but not STAT4 plays a crucial role in inhibiting the
production of IL-12 by CDllc high DCs (Fig. 3.11B). These results suggest that
the inhibitory effect of IFNa/p on IL-12 production by DCs is mediated by STAT1
and not STAT4.
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Figure 3.10. Failure to phosphorylate S T A T I is IFNo/P-specific and
characteristic of m D C s . A. iDCs and m D C s were stimulated with media
alone, 60 IU/ml IFNa/p, or 10 ng/ml IFNy for 30 minutes as indicated.
Cells were fixed, permeabilized, and stained for p-STATl (Pharmingen).
B. iDCs, D C s matured with T N F a / PGE2, or D C s matured with LPS
were stimulated with media alone or IFNa/p as indicated. Geometric
m e a n fluorescence intensity (MFI) of p-STATl w a s calculated using
FloJo statistical analysis. p-STATl activation index is represented as a
ratio of M F I IFN-stimulated / M F I media alone.
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Figure 3.11. S T A T 1 is required for IFNa/p inhibition of IL-12
production by D C s . A. Mice were untreated or infected with M C M V .
At 36 hours post-infection, spleens were harvested and stained with C D 8
FITC, CDllc PE, and IL-12 as described in Materials and Methods. The
percentage of C D l l c + / C D 8 - D C s that stained positive for IL-12 is
expressed as bar graph. B. STAT1-/- or STAT4-/- mice and their
respective controls (129SVE and Balb/c) were infected with M C M V .
Similarly, the percentage of C D l l c + / C D 8 - D C s that stained positive for
IL-12 is expressed as a bar graph.
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p D C IFNa/p differentially regulates C D 8 + T cell activation by cross-presenting D C s

In order to explore the effects of pDC-derived IFNa/p on antigen crosspresentation, supernatants from CpG-stimulated pDCs were added to iDCs
during antigen capture and maturation (Fig. 3.12A, iDC + pDC IFNa/p), and
then washed out prior to DC : T cell engagement. Alternatively, the pDC
supernatant was added to mDCs during T cell engagement (Fig. 3.12A, mDCs +
pDC IFNa/p). pDC-derived supernatants were prepared from BDCA-4 purified
cells that had been stimulated with 20^g/mL CpG-2116 for 24 hours and the
concentration of IFNa in the supernatant was quantified by ELISA (Fig. 3.12B).
Similar to the effects of recombinant IFNa, the effect of pDC-derived cytokines

on the regulation of T cell activation depended on the maturation state of the D
iDCs exposed to pDC IFNa/p were inhibited in their ability to stimulate CD8+ T
cells (Fig. 3.12C). In contrast, mDCs demonstrated enhanced CD8+ T cell
activation in the presence of pDC IFNa/p (Fig. 3.12C). This increase in IFNy
production was antigen specific, as pDC-derived IFNa/p alone did not directly
activate T cells. As a negative control for this experiment, supernatants from
unstimulated pDCs were employed (Fig. 3.12C). Exposure of iDC co-cultures to
CpG did not inhibit CD8+ T cell activation (data not shown).
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Figure 3.12. pDC-derived IFNo/P has a dual effect on cross-presenting
myeloid D C s . A. p D C IFNa/p w a s generated from B D C A - 4 purified pDCs.
A s illustrated, p D C IFNa/p was added to iDCs during antigen capture and
maturation, or to m D C s during C D 4 0 cross-linking and C D 8 + T cell
engagement. B. Quantitation of IFNa concentration in p D C supernatants
unstimulated (-) or stimulated with C p G . C. In all conditions, D C s crosspresenting (abbrev. x/p) antigen were cultured with purified C D 8 + T cells
and CD40L. The activation of influenza-specific C D 8 + T cells w a s
monitored by IFNy ELISPOT and reported as spot forming cells (SFCs).
D C s cross-presenting uninfected apoptotic cells (white bars) or D C s crosspresenting influenza antigen-expressing apoptotic cells (black bars).
Unstimulated (pDC) or CpG-stimulated p D C (CpG-pDC) supernatant w a s
added to the D C s as indicated. The data s h o w n here is representative of
two experiments. ELISPOT counts from triplicate wells were averaged and
m e a n data is reported. Error bars indicate standard error of the mean.
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In light of the dual effects of IFNa/p, w e wondered which effect would be
dominant. In order to address this experimentally, pDC-derived IFNa/p was
added to ELISPOT cultures of DCs exposed to IFNa/p during antigen capture
and maturation (Fig. 3.13). Notably, pDC-derived IFNa/p added during DC/T
cell engagement overcame the inhibition of IFNy production induced by IFNa/p
on iDCs. This increase in IFNy production was antigen specific, as pDC-derived
IFNa alone did not directly activate T cells.
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Figure 3.13. pDC-derived IFNa/P overcomes inhibitory effects of IFNa/P
on iDCs. D C s cross-presenting influenza antigen (flu ag) exposed to
IFNa/p during antigen capture (IFNa/p iDC) were cultured with purified
C D 8 + T cells and C D 4 0 L in an IFNy ELISPOT with p D C sup alone (-) or
CpG-stimulated p D C (CpG p D C ) as indicated. Pictures of duplicate wells
are s h o w n with corresponding bar graph indicating relative levels of IFNy
production as a function of total spot area (IFNy production = spot number
x average spot size).
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3.5 Discussion
Dual regulation of cross-priming by pDC IFNa/p
While it is widely accepted that pDCs and type I IFNs offer an important link
between innate and adaptive immune responses188, there exist contrasting data

regarding their immunoregulatory effects108. With respect to DC biology, there is
support for IFNa/p as a 'danger' signal, triggering DC maturation and enhancing
CD8+ T cell cross-priming 1%184185. These findings, however, must be reconciled
with evidence for IFNa/p as a negative regulator of IL-12 production and its
promoting TH2 skewing by DCs187. Our study offers new insight into these
paradoxical effects and provides a mechanism to account for how signaling via a
single receptor may act on a DCs to trigger distinct immunologic outcomes.
Here, we demonstrated that the maturation state of the DC is responsible
for determining the immunoregulatory effect of type I IFNs. When mDCs were
exposed to IFNa/p (Fig. 3.14B, 'IFN-late'), a pro-inflammatory response ensued,
as suggested by enhanced DC-mediated CD8+ T cell activation and greater
production of IL-12p70 (Figs. 3.2C, 3.6B and 3.12C). This observation is
consistent with the role of IFNa/p in enhancing TLR mediated cytokine

production197198 and the 'licensing' of DCs for cross-priming185. In contrast, we
discovered that iDCs exposed to IFNa/p during antigen capture and maturation
(Fig. 3.14A, 'IFN-early') are impaired in their ability to activate CD8+ T cells
3.2B). This inhibitory effect of 'IFN-early' is specific for CD40-dependent CD8+T

cell activation (Figs. 3.3 and 3.4), implicating the modulation of a 'third signa
produced by the DCs76.
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Figure 3.14. Spatial location of pDCs results in compartmentalization of
type I IFNs, and differential effects on cross-presentation due to a D C
maturation-induced switch in S T A T utilization. This schematic
represents our working model for h o w type I IFNs m a y exert their
paradoxical effect on cross-presentation though the compartmentalization
of IFNa/p. A. IFN-EARLY: IFNa/p produced in the tissue by infected cells
or T L R engagement of p D C s activates ST A T I dependent signaling in
immature myeloid D C s , which results in low IL-12p70 production and an
impairment of helper-dependent cross-priming. B. IFN-LATE: Altered
signaling networks in m D C s prevents STATl-mediated signaling. Instead,
IFNa/p produced in lymph organs results in S T A T 4 dependent signaling
in mature D C s , which facilitates enhanced production of IL-12p70 u p o n
C D 4 0 engagement. IFNa/p m a y also act directly on C D 8 + T cells.
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D C maturation alters IFNa/p signaling
How can IFNa/p achieve opposite effects on iDCs versus mDCs when a
single receptor exists? We show that a molecular switch in signaling networks is
coupled to DC maturation and regulates the differential effects of IFNa/p on
antigen cross-presentation. Specifically, iDCs phosphorylate ST ATI and STAT2
upon IFNa/p stimulation and seem to employ the canonical type I IFN signaling
pathway, while mDCs phosphorylate STAT4 and STAT2 (Fig. 3.9). This switch is
reflective of similar intracellular regulation in NK and T cells, which accounts
their paradoxical responses to IFNa/p 108'181199.
The molecular switch in signaling pathways selectively targets an IFNa/p
signaling network. This is supported by mDCs responding to IFNy by signaling
via STAT1 (Fig. 3.10). Interestingly, mDCs also show impaired phosphorylation

of STAT3 in response to IFNa/p stimulation (Fig. 3.9D). In light of the similarity
between ST ATI and STAT3, our findings demonstrate that the switch extends to
redundant pathways in order to offer a functional skewing of the IFNa/p
signaling network. Notably, IFNAR signaling requires STAT2 for activation of
both ST ATI117 and STAT4 20°, while IFNy receptor binds and directly activates
ST ATI. These differences may account for the selective regulation of pSTATl
downstream of IFNAR.
The master regulator of this switch in IFNa/p signaling remains unknown.

Although quantitative shifts in ST ATI inhibit STAT4 activation199, it is not cle
reciprocal increases in STAT4 are directly responsible for inhibiting ST ATI

activation. Alternatively, regulation may occur at the JAK level. Increase in tot
Jakl and the Jakl:Tyk2 ratio may skew downstream signaling (Fig. 3.9).
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Alternatively, Tyk2 m a y play a dominant role in STA T I phosphorylation201.
Interestingly, transcriptional changes in suppressor of cytokine signaling-2
(SOCS-2) and protein tyrosine phosphatase Nl (PTPN1) show 10-fold and 5-fold
increase upon maturation respectively (Fig. 3.15). Although SOCS-2 has not
been defined to play a role in the STAT signaling pathway, family members
SOCS-1 and SOCS-3 negatively regulate the JAK-STAT pathway by directly
inhibiting JAK activity202. PTPN1 may also play a role in skewing signaling by
promoting ST ATI dephosphorylation. Experiments are currently underway to
evaluate these candidate genes using retrovirally transduced shRNAs.
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Figure 3.15. Maturation alters IFNa/P signaling in D C s . This schematic
represents our working model for h o w type I IFNs signal in D C s . In iDCs,
phosphorylation of ST A T I and S T A T 2 allows formation of ISGF3 and
transcription of ISRE-dependent genes. In m D C s , striking upregulation of
S T A T 4 correlates with impaired response of S T A T 1 phosphorylation.
Formation of S T A T 4 homodimers leads to transcription of GAS-dependent
genes. Upregulation of suppressor of cytokine signaling-2 (SOCS2),
protein tyrosine phosphatase N l (PTPN1), and S T A T 4 as a result of
maturation m a y contribute to the signaling regulation. Histograms
indicate relative m R N A expression determined by affymetrix microarray.
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Altered signaling regulates outcome ofCD40 engagement via IL-12
CD4+ T cells, acting via CD40L : CD40 engagement, serve as a 'licensing'

signal for mDCs72,62 by triggering IL-12 production, a critical component of wha
has been termed 'signal 3'76. The contrasting effects of IFNa/p on crosspresentation resides at this point of regulation, with type I IFNs serving to

overcome CD4+ T cell help in some systems185, but acting as a potent inhibitor of
IL-12 in others187. We propose that the switch in STAT utilization may account
for this alternate regulation. IFNa/p stimulation of iDCs activates ST ATIdependent gene transcription (Fig. 3.14), which blunts CD40-induced IL-12
production (Fig. 3.6, and 3.11). The importance of this pathway is illustrated by

the ability of IL-12 to overcome the inhibitory effects of IFNa/p (Fig. 3.7). On
report suggests that pSTATl may be acting directly to inhibit TNFa-mediated IL12 production via inhibition of NF-kB activation203, however the precise
mechanism by which ST ATI versus STAT4 regulates IL-12 in human DCs
remains to be discovered.
Using STAT1-/- and STAT4-/- mice, it was possible to show that IFNa/p
mediated inhibition of IL-12 is dependent on ST ATI but not STAT4 signaling

(Fig. 3.11). The inhibition of IL-12 by IFNa/p is arguably occurring in the spleen
but the DCs analyzed are mostly resident DCs of the spleen that exist in an
immature state under steady state conditions81. In contrast, tissue DCs must
undergo maturation before migration to the lymph node. As such, we
hypothesize that inhibition of IL-12 production would not be seen in this
population. However, the ST ATI to STAT4 switch in mouse DC maturation has
not been fully analyzed. Similar to our human data, splenic DCs upregulate
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S T A T 4 upon maturation204; however, direct STA T I or S T A T 4 activation has not
been evaluated. Although early work suggested that IFNa-dependent STAT4

activation does not occur in mice due to a STAT2 minisatellite insertions200, mor
careful analysis revealed that the pathway for STAT4 activation is intact in
mice199, but variable expression may depend on genetic background205. STAT2
minisatellite insertion may still account for species specific STAT2-dependent
IFNa/p signaling.

Location, location, location: Physiologic implications of spatial compartmentaliz
IFNa/p production
Regarding the physiologic and pathologic relevance for our findings, we
suggest that spatial compartmentalization of IFNa/p production may offer a
resolution for its paradoxical immunoregulatory effects on conventional DCs.
Immature and mature DCs reside in different physiologic locations, with the

former residing within peripheral tissue and the latter homing to the T cell area

of draining lymphoid organs52. In situations of chronic infection, type I IFNs in
the tissue (produced by parenchymal cells, pDCs that have moved into sites of
chronic inflammation191 or by immature myeloid DCs themselves206) may exert a
counter-inflammatory effect on iDCs (Fig. 3.14A). Specifically, we suggest
IFNa/p produced in the tissue during antigen capture, inhibits subsequent T cell
activation by cross-presenting DCs. The restriction of this inhibition to crosspresentation is likely due to the CD40-dependence in our model system and may
be more broadly applicable to other IL12-dependent responses68.
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During some viral infections, P A M P engagement of p D C TLRs induces
migration to the lymph node and production of robust amounts of type I IFNs
(Fig. 3.14B). In this situation, IFNa/p would act on mDCs that had migrated from
the peripheral tissue with captured antigen. The exposure of mDCs to IFNa/p
may act directly on the DCs to synergize with other inflammatory stimuli and
enhance IL-12 production. Our model does not rule out an additional, direct
effect of IFNa/p or other pDC-derived cytokines on CD8+ T cell activation. For

example, recent data suggests that activation of STAT4 in antigen specific CD8+ T
cells may potentiate IFNy production207'208. Notably, the exposure of mDCs to
IFNa/p during DC : T cell engagement overcomes the inhibitory effect of IFNa/p
(Fig. 3.13). Thus, even if the cross-presenting DC had captured antigen in the
presence of IFNa/p, pDC IFNa/p in the lymph would enable that DC to prime a
T cell response.
Why would the host employ IFNa/p production as an innate immune
response if it interfered with the generation of adaptive immunity? The counterinflammatory roles of IFNa/p may play an important role in tempering the
immune response during acute periods of hyperactivity. For example, IFNa/p

inhibits bystander T cell activation209 as well as high levels of IL-12186 preven
cytokine toxicity. The inhibition of CD8+ T cell activation by cross-presenting
DCs may provide another level of regulation against non-specific activation
during viral infection. Delivery of inflammatory cytokines to draining lymph
nodes at the site of DC : T cell engagement by accessory cells such as pDCs,
therefore, may play an important role in regulating activation.
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Both pathogens and therapies m a y take advantage of the inhibitory effects
of IFNa/p on cross-priming. HCV, for example, induces robust levels of IFNa/p
production soon after infection139. Although it remains unclear whether DCs can
be infected by HCV, the high levels of IFNa/p in the liver may play an important
role in preventing effective CD8+ T cell response in chronically infected

patients41. Interestingly, the bacterial pathogen L. monocytogenes may also use t
host's IFNa/p response to prevent an effective immune response210. In addition

to its role in infectious immunity, the inhibitory effect of IFNa/p on tissue DCs
may account for the recent observation of an inverse correlation between length
of remission and pDC infiltration in early stage breast cancer211. Finally, the
results presented here may offer a more detailed mechanism for the therapeutic
use of type I IFN in multiple sclerosis to decrease T cell activation212.
In contrast, the therapeutic effects of IFNa for HCV are thought to
enhance T cell immunity to aid in viral clearance; however, recent reports
suggest that this may not in fact be the case101. Despite sustained virologic
response (SVR), T cell immunity to HCV may decrease with pegylated-IFNa /
ribavirin213. The decreased T cell reactivity may be beneficial in reducing the
hepatic inflammation and fibrosis during recovery. Several scenarios may
account for these findings including a simple decrease in antigen load during
SVR or the inhibitory effects of IFNa on iDCs when delivered systemically. In
contrast, the therapeutic activation of pDCs may enhance IFNa/p production in
lymph nodes and it will be interesting to see if comparative studies addressing
the effects of pDC-derived IFNa/p on HCV-specific T cell immunity produce
similar results.

107

Despite the potency of IFNa/p inhibitory effect on cross-presenting D C s ,
immune responses to viral infections do occur. As mentioned above, the
inhibitory effects on cross-presenting DCs are most pronounced for immunity
that depends on CD40 licensing of DCs and the production of IL-12 as a signal
for T cell activation. Although these signals serve as an important component of
the immune response in many infections, the number of infections that
absolutely depend on these signals may be quite limited. Moreover, IFNa/p
production is not restricted to the tissue in many viral infections that induce
PAMPs, which trigger IFNa/p production in the tissue, may also trigger pDCs to
produce IFNa/p at the DC/T cell interface, thereby overcoming the inhibitory
effects of tissue IFNa/p. Nonetheless, these findings offer a more detailed
understanding of the role of IFNa/p in both pathogenesis and therapy for all
infections.
In all, these findings show that DC maturation alters signaling networks,
enabling distinct effects of IFNa/p on the immunologic outcome of crosspresentation. This plasticity illustrates a novel mechanism by which DCs
modulate the integration of signals from the surrounding environment. These
findings suggest a rationale for spatial compartmentalization of pDCs during

viral pathogenesis and offer insight into more effective therapeutic delivery of
IFNa. As such, we turn in the next chapter to in vivo models to evaluate pDCderived IFNa/p in CD8+ T cell immunity.
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C h a p t e r 4: p D C - d e r i v e d I F N q / P s k e w s D C / T cell e n g a g e m e n t
f r o m tolerance to p r i m i n g in lieu of C D 4 + T cell 'help'

4.1 S u m m a r y
CD8+ T cell immunity is an important determinant in the clinical outcome of
HCV infection and depends on CD4+ T cell 'help'. IFNa has been shown to play
a role in overcoming the CD4 requirement for T cell priming; however, the role

for pDCs in providing a signal sufficient for T cell activation in the absence of
CD4+ T cells has not been demonstrated. Using the minor histocompatibility
male antigen (H-Y) model for CD4-dependent CD8+ T cell priming, we
evaluated the ability of MCMV- or CpG-mediated pDC activation to substitute
for the CD4 'help' requirement in CD8+ T cell priming. The results show that
pDC activation can offer priming signals. The pDC priming signal requires
IFNAR but is independent of IL-12 production. In contrast, viral stimulation of
non-pDC IFNa/p does not serve as a priming signal for CD8+ T cells. The model
of pDC 'help' could also be extended to CD4-dependent HCV NS31073.1081-specific
CD8+ T cell responses in transgenic mice expressing human HLA-A2.1. These
findings offer a mechanism for the role of pDC-derived IFNa/p in host
immunity, provide a rationale for therapeutic intervention to boost CD8+ T cell
responses, and may offer insight into how some viruses evade
immunostimulatory actions of IFNa/p.
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4.2 Introduction
In light of the fact that we find no overt defect in DC function in chronic HCV
donors, we hypothesized that other signals may act on DCs to regulate HCV

specific CD8+ T cell priming. As discussed in chapter 1, several lines of evidenc
suggest that CD4+ T cells play an important role in generating robust HCV
specific CD8+ T cell responses41. However, the absence of a small animal model
and the paucity of T cell reagents have precluded detailed evaluation of the
immunologic outcome of 'help'-less CD8+ T cells in an HCV specific model.
As detailed in the introduction, CD4+ T cells can directly support CD8+ T
cell activation (via IL-2 production or CD40 engagement214) or indirectly via DC
activation. This model for CD4 'help' affords a sense of specificity for CD8+ T
cell priming and prevents autoimmunity in the absence of a specific CD4+ T cell
response215. The flip side of this model, the absence of CD4 'help', affords a
model for peripheral tolerance by which DC / T cell engagement leads to

division, death, and consequent tolerance (see Fig. 1.5). Although the regulation

of CD8+ T cell activation versus tolerance by CD4+ T cells offers a mechanism for
antigen specific regulation, this model simply transfers the point of regulation
priming or tolerance of CD4+ T cells. In contrast, the "danger model" suggests
that regulation of activation versus tolerance is controlled by inflammatory
danger signals66.
In light of our observation concerning spatial compartmentalization of
IFNa/p on DC immunological skewing, we hypothesized that lymph node
IFNa/p may act to enhance T cell immunity (Fig. 4.1). pDC activation by TLR9
agonists result in pDC accumulation and IFNa/p production in lymph nodes and
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spleen216. The importance of this spatial localization in viral immunity is not
clear. Some reports suggests that pDCs may prime T cells in vivo217; however,
their movement from blood to lymph node does not make them well suited for

trafficking tissue antigens. Furthermore, the reason for IFNa/p production in the

lymph node when viral infection occurs in the periphery is not clear. Recent data
shows that IFNa/p itself may act as a key 'danger' signal by activating DCs as
well as serving as a third signal for T cell activation185,207. Not all IFNa/p,

however, is produced by pDCs 195'206. All cells have the capacity to produce type
IFNs and some (e.g. conventional DCs) will produce equally large amounts if
triggered appropriately. The immunological effects of IFNa/p production by

different cell types or by the same cell type in different locations is not clear
The role for activated pDCs in substitituting for CD4+ T cell 'help' has not

been evaluated. In order to address this question, I took advantage of two in viv
systems. The first system is based on the minor histocamptibility (H) antigens
that are associated with the Y chromosome (i.e. H-Y antigens)218. In C57BL/6
mice, an immunodominant Derestricted Uty epitope has been well defined. This

model is particularly fitting because the priming of Uty-specific CD8+ T cells is
CD4-dependent215 and transgenic T cells are available219. The second model is
one that I developed for HCV specific priming in transgenic mice expressing the
human HLA-A2.1 molecule. In both models, I have focused on the endogenous
T cell repertoire against these antigens. The findings show that activated pDCs
can offer priming signals for CD8+ T cell activation and suggest important
therapeutic implications for pDCs.
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Figure 4.1. Immunological significance of p D C IFNo/P production
in the l y m p h node. Following activation, p D C upregulated C C R 7
and migrate across the H E V to T cell zones of the lymph node. p D C
can prime C T L s in vivo but they can not cross-present antigen. The
antiproliferative effects of IFNa/p m a y play a role in preventing
bystander activation in the bulk T cell population. The interaction at
the D C / T cell interface is not well defined.
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4.3 Materials and Methods
Mice
Wild-type and MHCII-/- C57BL/6 mice were obtained from Jackson, Europe.
TCR transgenic mice (Matahari) with CD8+ T cell reactivity for
immunodominant Uty epitope were provided by Olivier Lantz (Institut Curie,
Paris). HLA-A2.1 HHD transgenic mice were provided by Francois Lemonnier
(Institut Pasteur, Paris). IFNAR-/- mice backcrossed onto the C57BL/6
background were provided by Deborah Braun. Disruption of IFNAR was

confirmed by PCR (Forward primer: aag atg tgc tgt tec ctt cct ctg etc tga; Revers
att art aaa aga aaa gac gag gcg aag tgg; 35 cycles; Annealing temperature: 55°C)
and gel electrophoresis of the neomycin insert. Functional confirmation was also
observed by day 5 lethality following i.p. infection with MCMV. IL-12B-/- mice
were obtained from Jackson, USA.

Media
For all mouse cultures and BMDCs, 10% FBS in RPMI-1640 was used
supplemented with lOmM HEPES, lOOmM non-essential amino acids, 66jiM pmercaptoethanol, ImM sodium pyruvate, and 2mg/mL of gentamicin (R-10).
HCV cell lines were carried in 10% FBS in DMEM with 20fxg/mL puromycin and
tetracycline (complete media) to suppress expression of HCV. Expression of
HCV was induced in complete media without tetracycline.
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Peptides

For monitoring HY-specific CD8+ T cell responses, immunodominant Dbrestricted Uty246.254 peptide (WMHHNMDLI) was used. For MCMV T cell
responses, immunodominant Derestricted M45 epitope (HGIRSNAFI) was used.
For influenza ANSI endogenous CD8+ T cell responses, Derestricted NP366.374
(NMEAMDSNT ) and Db-restricted PA^.^ (SCLENFRAYV) were used. All
peptides were synthesized by Genemed synthesis. For monitoring HLA-A2.1restricted HCV-specific T cell responses, the following peptides were used:
Core^ (YLLPRRGPRL), Core132.140 (DLMGYIPLV), NS31073.1081 (CVNGVCWTV),
NS31406.1415B (KLTGLGLNAV), NS31406.1415A (KLVALGINAV).

Antibodies

PDCA-1 PE, CDllc (HL3) APC, Vp8.3 PE, and CD8 FITC are from BD
Pharmingen. GK1.5 hybridoma supernatant was prepared in low serum media
(containing <1% FBS). Briefly, hybridoma was grown to confluency until 60-70%
death. Cultures were harvested and supernatant prepared by filtration. RB6-8C5

(anti-GR-1) for in vivo depletion of pDCs cells was obtained from the monoclonal
antibodies facility at MSKCC as bioreactor supernatant.

Cell lines

A human osteosarcomcell line with tetracycline-dependent full length HCV
expression (HOS 57.3) was generated by Benno Wolk in the laboratory of Darius
Moradpour (Basel, Switzerland). In order to induce HCV expression, cells were
washed well with PBS (4-5 times) to remove residual tetracycline and plated at
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20-30% confluency in complete media without tetracycline. Greater than 8 0 % of
cells expressed NS5A by FACS by 36hrs. 3T12 is a mouse fibroblast cell line
obtained from Peggy MacDonald (Rice lab, RU). 3T12 cells were grown in
DMEM with 10% FBS with lOmM HEPES, lOOmM non-essential amino acids,
and 100 units/mL penicillin and streptomycin.

Bone Marrow Derived DCs
Femurs and tibias were collected from C57BL/6 mice and bone marrow was
harvested by flushing with PBS. Bone marrow cells were collected by
centrifugation and lysed with 2.5mL 1.66% ammonium chloride for 5 minutes at
37°C. Cells were washed, filtered and resuspended at 106/mL in R-10 media
with 1:30 dilution of J558 hybridoma supernatant (mouse GM-CSF). 3mLs were

aliquoted per well into a 6-well dish and incubated at 37°C. On day 2, day 4, and
day 6, media was removed and replaced with fresh R-10 with J558. For
maturation, cells were harvested by blowing gently on the plate with a 5mL
pipette to collect loosely adherent DC clusters. Cells were centrifuged and
resuspended at 0.5 x 106/mL in R-10 media with 1:30 dilution of J558 hybridoma
and 12.5ng/mL of mouse TNFa (R and D systems). 2mL were added per well
and cells were allowed to mature for 36 hours. DC phenotype and maturation
was assessed by FACS phenotype using CDllc, CD80/86,1-Ab, and B220.

In vivo depletions and immunizations

GK1.5 hybridoma supernatant was used to deplete CD4+ cells and RB6-8C5
(Monoclonal Antibody Facility, MSKCC) bioreactor supernatant was used to
deplete GR-1+ pDCs. Mice were injected with 500[Ag i.p. at 36 hrs and 12 hrs
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before immunization. Depletion of C D 4 + T cell and p D C s w a s confirmed by
FACS from both peripheral blood and spleen samples.
For H-Y priming, mice were immunized with male splenocytes as
indicated. Spleens were harvested and mashed in ice cold PBS. Splenic debris
was removed, cells were spun, and red blood cells were lysed with 1.66%
ammonium chloride for 5 minutes at 37°C. Lysis was quenched with 20 volumes
of PBS and cells were pelleted. Cells were filtered and washed again.
Splenocytes were resuspended at 25 x IO6/ mL and 200[xL was injected i.d. on the
belly just medial to the inguinal lymph nodes.
For peptide immunization, lOmg/mL of crude peptide dissolved in 10%
DMSO was mixed 1:1 with titermax Gold (Sigma Aldrich). Mixture was
vortexed for 45 minutes at room temperature to form an emulsion. 30|oL was
injected into the footpad.
For full length HCV cell line immunization, HOS57.3 were induced to
express HCV proteins as described. After 36 hrs of induction, cells were
harvested and washed well with PBS. Cells were resuspended at 20 x 106/mL
and 250jaL injected i.p.

Preparation of MCMV Smith strain from salivary gland
1.5 x IO5 PFU tissue culture prepared MCMV was injected into 15 BALB/c. In
susceptible mice, MCMV is cleared from tissues within a week but persists in the

salivary glands for >3 weeks at high titers. Salivary glands were harvested at 17
days post infection and homogenized with a dounce homogenizer at 10% (w/v)
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in D M E M with 1 0 % FBS, 1 0 % D M S O . Aliquots were frozen at -80°C for long
term storage.

MCMV plaque assay
Mouse fibroblast cell 3T12 were plated as 70% confluence in 6-well dishes and
allowed to adhere for 5-6 hours at 37°C in DMEM with 10% FBS. Media was

removed from 6-well dishes and 200|xl of serial 10-fold dilutions were added for
1 hr with shaking. During incubation 1% (2x) NOBLE agar (DIFCO) was
prepared in water. Agar was autoclaved and allowed to cool in 56°C water bath.
Just before overlaying, 2x cMEM (2x MEM, 10% FBS, lOOunits /ml penicillin /
streptomycin) was mixed with 1% NOBLE agar solution. Agar was allowed to
cool to 37°C and 3mL was added to 6-well dish just before congeling with
swirling to evenly distribute. Plates were incubated upside at 37°C. An
additional overlay of 2mL was added on day 3. On day 6, agar overlay was
prepared with .0375% Neutral Red and 2mLs added for 16 hrs to allow for
visualization. Plaques were counted with a light box and enumeration used to
calculate PFU/mL.

Triggering and monitoring IFNa/p production in mouse serum
Various titrations of i.p. injection of both MCMV and influenza ANSI were done
to evaluate necessary PFU for maximal IFNa/p production. Based on these
results, 5 x IO3 PFU/mL of MCMV and 2 x IO6 PFU/mL of ANSI were used for
stimulation of IFNa/p production. CpG motif was prepared as previously

described 156. Briefly, 5 ng of CpG motif (5'- tcattggaaaacgttcttcggggcg -3') wi
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phosphorothioate backbone w a s mixed with 170(xL of PBS and 30fxL of D O T A P
Transfection Reagent (Roche Diagnostics) and delivered i.v. Retro-orbital
eyebleeds were done to collect blood samples at the indicated times. Blood was
allowed to clot at room temperature for 30 minutes and placed on ice for 10
minutes. Samples were spun at 13000 RPM 4°C in a micro-centrifuge for 10
minutes and serum supernatants were saved.

IFNy ELISPOT analysis of antigen specific T cell responses

Spleens or lymph nodes were harvested 7 or 12 days post-immunization as
indicated. CD8+ T cells were purified using MACS microbeads and plated with

indicated target cells. Syngeneic splenocytes from naive cells were used as targe
cells for ELISPOTs. Cells were pulsed lOmM of the indicated peptide at room
temperature for 1 hr. Purified CD8+ T cells were resuspended at 4 x 106/mL and
50|xL was added per well. Targets were resuspended at 106/mL and IOOjxL
added per well (CD8+ T cell: Target ratio was 2:1).
Cells were plated in 96-well Millipore plates previously coated with
5[xg/mL of anti-IFNy mAb (Mabtech, Mab-1 AN18). Cultures were incubated for
24-36 hrs at 37°C, washed with mild detergent, and incubated with lpig/mL
biotin-conjugated anti-IFNy mAb (Mabtech, Mab R4-6A2). Spots were visualized
using Vectastain Elite Kit (Vector Laboratories) and AEC substrate. Evaluation
was performed in a blinded fashion by an independent service (Zellnet
Consulting, Inc., NY) using an automated ELISPOT reader (Carl Zeiss, Inc., NY).
Spots represent IFNy production by single cells and are reported as spot forming
cells (SFCs)/106 cells.
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In vivo proliferation

Matahari spleens were harvested and red blood cells were lysed as described
above. Splenocytes were resuspended in PBS and labeled with 5mM CFSE for 5
minutes at 37°C. Cells were washed 3 times with PBS, resuspended in PBS at
107/mL, and 100|jL was injected i.v. 6 hrs before immunization. 3 days after
immunization, the draining inguinal lymph nodes and spleens were harvested.
Matahari cells were identified by CD8, VP8.3, and CFSE staining described
below.

In vivo CTL
Splenocytes were generated as above and resuspended at 107/mL in PBS with
either 1 or 6mM CFSE for 10 minutes at 37°C. Cells were washed 2 times with
PBS and incubated with or without lOmM of the indicated peptide for 1 hr at
room temperature. Cells were washed twice with PBS and resuspended at
108/mL. Cells were mixed 1:1 and injected i.v. into immunized animals. Spleens
were harvested after 16 hrs, red blood cells lysed, and splenocytes analyzed for
ratio of CFSE low to CFSE high population. Percent killing = 1 - (sample peak
pulsed targets/sample peak unpulsed targets) / (control peak pulsed
targets/control peak unpulsed targets).
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F A C S analysis of H C V expression, C F S E proliferation, tetramers, and p D C
accumulation
For HCV expression, cells were induced as above and resuspended at 2xl06/mL.
Cells were washed with PBS and fixed/permeabilized with Cytoperm/Cytofix
(BD Pharmingen) for 10-15 minutes. Cells were washed with permeabilization
wash buffer (BD Pharmingen) and incubated with 1:200 dilution of mouse
monoclonal against NS5A (9E10, generated by Tim Tellinghusien) or 1:100 NS3
(Maine Biotechnology). A 1:400 dilution of goat anti-mouse PE secondary
(Jackson Immunoresearch) was used to detect HCV expression.
For CFSE proliferation and tetramer analysis, CD8 purified cells were
incubated with lOfxg/mL of FcyR-block (BD Pharmingen) to block non-specific
antibody interaction in mouse FACS wash buffer (PBS with 5% FBS and 5% goat
serum). Cells were stained with anti-CD8 FITC (1:150 dilution, BD Pharmingen),
antiVp8.3 PE (1:150 dilution, BD Pharmingen), NS31073.1081 HLA-A2.1 tetramer-PE
(1:10 dilution, F. Lemaitre, Institut Pasteur, Paris), or Core35_44 HLA-A2.1
tetramer-PE (1:10 dilution, F. Lemaitre), as indicated for 45 minutes at 4°C and
analyzed using FACS analysis.
Spleens were harvested at indicated times following stimulation or
infection. Spleens were homogenized by mashing and debris was removed.

Cells were collected by centrifugation and red blood cells were lysed with 1.66%
ammonium chloride for 5 minutes at 37°C. Following lysis, cells were washed
and incubated with lO^ig/mL of FcyR-block (BD Pharmingen) to block nonspecific antibody interaction in mouse FACS wash buffer. Cells were stained
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with anti-CD45.2 FITC (1:150 dilution, B D Pharmingen), anti-CDllc A P C (1:150
dilution, BD Pharmingen), and anti-PDCA-1 PE (1:150, BD Pharmingen).

4.5 Results: H-Y model

CD4+ T cell 'help' is required for in vivo priming of H-Y specific CD8+ T cells by
endogenously loaded DCs
In order to setup a model antigen system for CD4-dependent CD8+ T cell
priming, we employed the male antigen (H-Y) system. Various routes of
immunization with syngeneic male splenocytes were evaluated by assaying
CD8+ T cell responsiveness to the immunodominant Uty epitope using IFNy
ELISPOT. Intradermal (i.d.) immunization yielded the most reproducible
priming and was the route of immunization employed in all of these studies.
First, we verified previous results suggesting that CTL effector function

required CD4+ T cell 'help' during priming215. In order to evaluate this in vivo,
female WT or MHCII-/- C57BL/6 mice were immunized i.d. with 5 x IO6
syngeneic male splenocytes. Spleens were harvested at 12 days and CD8+ T cells
were purified with MACS magnetic beads. IFNy ELISPOT analysis using Uty
pulsed splenocytes as targets showed WT but not MHCII-/- mice could generate
Uty-specific CD8+ T cell IFNy-production (Fig. 4.2). Importantly, Uty-specific
responses generated by immunization of male splenocytes vary significantly
from mouse to mouse, but Uty-specific IFNy responses were never seen in
MHCII-/- animals. Notably, MHCII-/- females were primed with MHCII-/-

male splenocytes to eliminate allo-reactivity. In order to confirm that this CD4-

dependence is not merely the result of differential expression of H-Y antigens in
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Figure 4.2 Uty-specific C D 8 + T cell IFNy production requires C D 4
help during priming. Host C57BL/6 females were primed with male
splenocytes from indicated C57BL/6 mice. The table shows spot
forming cells (SFCs)/106 C D 8 + T cells measured by IFNy ELISPOT 12
day post-immunization. Each circle represents an individual mouse.
C D 4 depletion indicates GK1.5 depletion as described in Materials
and Methods.
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MHCII-/- male mice, female mice depleted of C D 4 + T cells with GK1.5 (antiCD4) were similarly immunized with male splenocytes. IFNy ELISPOT shows
that CD4 depletion also prevents priming of IFNy-producing Uty-specific CD8+
T cell responses (Fig. 4.2).
In order to evaluate if IFNy ELISPOT was representative of CTL function,
specific killing in vivo was evaluated using Uty pulsed and unpulsed splenocytes
that were differentially labeled with CFSE and injected 12 days following
immunization (Fig. 4.3A). Similar to ELISPOT results, i.d. immunization with
syngeneic male splenocytes induces robust Uty specific CTL activity (Fig. 4.3B,
C). Priming of MHCII-/- females abgrogates in vivo killing suggesting that CD4
'help' is required for CTL function. CD4 depletion also abrogates in vivo CTL
function confirming the CD4-dependence of CTL priming.
Further characterization of this system was done to evaluate the nature of
the antigen presenting cell involved in Uty-specific T cell priming by male
splenocytes. In order to test the contribution of endogenously loaded male DCs
in Uty-specific priming during i.d. male spenocyte immunization, splenocytes
were compared to CDllc-enriched or depleted splenocytes. CDllc+ enrichment
enhanced Uty-specific CD8+ T cell IFNy production 12 days post-immunization
while CDllc-depletion virtually abrogated the response(Fig. 4.4). Consistent
with other reports218, this suggest that direct presentation is the dominant
mechanism for Uty-specific priming.
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Figure 4.3. In vivo C T L requires C D 4 + T cell 'help'. A. Schematic for
in vivo C T L as described in Materials and Methods. Briefly, mice
were immunized with male splenocytes. After 12 days, target
splenocytes were pulsed with two different levels of C F S E and
pulsed or unpulsed with peptide. Pulsed and labeled splenocytes
were injected i.v. and spleens were harvested after 16 hrs. Specific
killing w a s assessed by disapperance of target population as
monitored by F A C S . B. F A C S plots showing gated C F S E populations
16 hours after transfer to indicated mice. N u m b e r s indicated percent
of total C F S E positive cells. C. Percent killing in indicated mice w a s
calculated as described in Materials and Methods in the indicated
mice and is displayed as a dot plot. Each dot represent an individual
mouse.
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Figure 4.4. C D l l c + D C s required for efficient Uty-specific priming
by male splenocytes. C57BL/6 W T female mice were either not
immunized or immunized with total splenocytes, CDllc+ cell
purified by two rounds of positive selection (CDllc+), or CDllc
depleted cells remaining after CDllc+ purification (CDllc-) from
syngeneic males. Spleens were harvested after 12 days and the T cell
response monitored by IFNy ELISPOT. Irradiated mouse t h y m o m a
cell line (EL4) w a s pulsed with Uty peptide and used as targets for T
cells.
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The absence ofCD4+ T cell 'help' leads to antigen specific C D 8 + T cell tolerance
In light of the role of CD4+ T cell 'help' for CTL function, I wanted to
address the question of what happens to antigen specific CD8+ T cells in the
absence of CD4 'help' signals. The majority of assays designed to monitor CD8+
T cell function focus solely on the absence or presence of a response. These
assays do not evaluate what happens to the CD8+ T cells when no response is
present. Thus, in this system, I asked if the lack of response in the absence of
CD4+ T cells was simply the result of ignorance or the absence of a priming
signal.
To address this question, I used TCR transgenic Uty-specific CD8+

(Matahari) T cells to monitor division in the presence or absence of CD4+ T cells
Matahari cells were CFSE labeled and adoptively transferred i.v. 6 hrs before
immunization (Fig. 4.5A). In addition to the CFSE label, Matahari T cells can be
identified by antibodies to TCR VP8.3. Lymph nodes and spleens were
harvested 3 days post-immunization and division of CD8+/VP8.3+ CFSE labeled
cells was analyzed by flow cytometry. In the presence of CD4+ T cell, CFSE
division and expansion of Matahari cells was seen at day 3 in inguinal lymph
nodes (Fig. 4.5B). Expansion was restricted to the draining lymph node and not
seen in the spleen as primed T cells do not begin to circulate until day 4 postimmunization78. Similarly, in MHCII-/- animals, CFSE division and expansion
of Matahari was apparent after 3 days suggesting that antigen presentation and T
cell engagement was intact in the absence of CD4+ T cells; however, the number
of divisions lagged slightly behind wild type hosts and expansion was not as
robust. Although we did not directly evaluate death in the 'unhelped' dividing
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Figure 4.5. C D 8 + T cells divide in response to immunization in the
absence of C D 4 + T cells. A. A schematic representation describing
the use of C F S E staining to monitor cell division T C R transgenic
Matahari cells are C F S E labeled and injected into a female mouse 612 hrs before immunization. 3 days after immunization proliferation
of cells is monitored by C F S E dilution and increase in cell numbers.
B. C F S E labeled Matahari cells were transferred to W T or MHCII-/female mice and either not immunized or immunized with male
splenocytes as indicated. L y m p h nodes were harvested at day 3
post-immunization and Matahari cells were idenitified by C D 8 ,
VP8.3, and C F S E staining. Histograms illustrate dilution of C F S E in
each case.
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C D 8 + T cells, animals primed in the absence of C D 4 + T cells were functionally

non-responsive following re-challenge. These results suggest, therefore, that the
lack of CTL effector function when primed in the absence of CD4+ T cells is not

the result of ignorance, but rather the lack of specific priming signals. With th
system in place, I setup to evaluate my hypothesis that lymph node IFNa/p
produced by pDCs may act as a priming signal.

CpG and MCMV induce pDC IFNa production and migration to spleen
In order to establish a system for pDC-induced IFNa/p secretion, serum
IFNa was measured following i.v. delivery CpG or i.p. delivery of MCMV.
Intravenous injection of CpG rapidly induces high level of IFNa in serum within
6 hrs of treatment (Fig. 4.6A). IFNa production is transient and disappears by 24

hrs. In contrast, IFNa serum levels do not peak until 36 hrs after i.p. infection
with MCMV (Fig. 4.6B) with maximal production seen with IO4 PFU/injection
(Fig. 4.6C). The difference in time course is likely due to the replication time
required to amplify the viral DNA which stimulates pDCs125.
Despite the difference in time course, IFNa induction in both settings is
dependent on pDCs156195,220. In order to evaluate this in our system, serum IFNa
for both CpG and MCMV stimulated animals was evaluated in pDC depleted
mice. As reported previously, pDC depletion abrogates the IFNa response to
both stimuli (Fig. 4.6D). In order to determine the requirement for the IFNadependent priming loop discussed in chapter 1, IFNa production was also
monitored in IFNAR-/- mice challenged with CpG and MCMV. Interestingly,
although CpG induced IFNa production requires IFNAR, MCMV triggers robust
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either W T , p D C depleted (dep), or IFNAR-/- C57BL/6 mice.
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IFNa even in the absence of IFNAR. Although the IFNAR-/- mice are on the
MCMV-resistant C57BL/6 background221, challenge with 3 x IO5 PFU of MCMV

i.p. was lethal in 5 out of 5 mice (data not shown) and subsequently could not be
used for evaluation of adaptive immunity. Evaluation of splenocytes
following stimulation confirmed accumulation of pDCs in the spleen. Using a
pDC-specific marker, PDCA-1, and CDllc to identify pDCs, five to six-fold
expansion of pDCs was seen by FACS at 6 hrs following CpG injection (Fig.
4.7A). CpG stimulation did not alter the percentage of CDllc111811 cells in the
spleen. Similarly, as reported previously222, MCMV infection dramatically

increases the percent of PDCA-1+ CD11C+ cells in the spleen at 36 hrs (Fig. 4.7B).
FACS staining confirmed that RB6-8C5 treatment depleted splenic PDCA-1+
pDCs. RB6-8C5 depletion does not affect CDllc1^ DCs (data not shown).

pDC activation by MCMV can offer priming signals for Uty-specific CD8+ T cells
Due to the accumulation of pDCs in the lymph nodes during DC / T cell

engagement and the possible role of IFNa in substituting for CD4+ T cell signals,
we next tested if pDC activation using a viral stimulus could provide priming
signals in the absence of CD4s. Using the H-Y system described above, we

evaluated the ability of MCMV infection to facilitate the priming of Uty-specific
CD8+ T cells in MHCII-/- mice. Briefly, MHCII-/- females were immunized
with male splenocytes 36 hrs after MCMV infection to maximize pDC activation
and accumulation in spleen and lymph nodes (Fig. 4.8A). After 12 days, Utyspecific CD8+ T cell responses were monitored by IFNy ELISPOT. Infection with
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immunization schedule for M C M V triggered p D C activation at the
time of immunization. p D C s are depleted with anti-GR-l+ antibody
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M C M V enabled the generation of Uty-specific C D 8 + T cells in MHCII-/- animals
(Fig. 4.8B). Although the absolute number of spot forming cells was less than
wild type animals immunized with male splenocytes, the CD8+ T cell responsein
MCMV treated MHCII-/- was antigen specific and significantly above
background. In order to evaluate if this effect was dependent on pDC activation,
pDCs were depeleted prior to MCMV infection using RB6-8C5 (anti-GR-1). As
depicted in the figure, pDC depletion prevented the generation of Uty-specific
CD8+ T cells in response to MCMV infection. Infection with MCMV alone in the
absence of male splenocyte immunization did not induce any Uty-specific crossreactivity.
In contrast to a recent report describing the importance of pDCs in HSVspecific CTL priming223, pDC depletion during MCMV infection did not effect
CD8+ T cell IFNy production to the immunodominant M45 epitope as monitored
by ELISPOT (Fig. 4.8). M45 reactivity was dependent on MHCII, however, a
strong response was still present in the absence of CD4+ T cells and pDC
depletion did not abrograte this response.

CpG stimulation also offers priming signals for Uty-specific CD8s

In order to confirm that priming signals offered by MCMV-stimulated
pDCs were not unique to MCMV, the ability of CpG stimulated pDCs to
substitute for CD4+ T cells was also evaluated. Due to the difference in time
course of IFNa/p production, CpG was delivered at the same time as
immunization with male splenocytes and Uty-specific immune responses were
monitored after 12 days. Similar to the results with MCMV, CpG stimulation in
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CD4-depleted females immunized with male splenocytes primed Uty-specific
CD8+ T cells as monitored by IFNy ELISPOT (Fig. 4.9).
Importantly, some reports suggest that mouse pDCs may have low level
of CD4 expression; therefore, we evaluated the effect of CD4 depletion on pDC
numbers and IFNa production following stimulation. CD4 depletion did
slightly decrease the absolute numbers of PDCA-1 + cells in spleen and total
IFNa levels in the serum (Fig. 4.10A,B), but it did not abrogate the response to
CpG as IFNa production was still significant and pDC migration to the spleen
remained intact (Fig. 4.10B,C). Moreover, the slight decrease in pDC numbers
and IFNa levels was seen in MHCII-/- as well as CD4 depleted mice (Fig. 4.10A)
suggesting that these findings may be secondary to changes induced by lack of
CD4s (i.e. lymph node architecture changes). Despite these differences, the
functional ability of CpG to provide 'help' following CD4 depletion remains
intact.
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pDC-dependent C D 8 + T cell priming requires I F N A R but not IL-12
In mice, pDCs can secrete IL-12 in addition to IFNa216. Given the potent
role of IL-12 acting as a third signal for CD8+ T cell priming, we wanted to
evaluate the respective roles for IL-12 and IFNa in the ability of pDCs to
substitute for CD4+ T cell priming cells. CD4-depleted IFNAR-/- or IL-12B-/(p40 subunit of IL-12 and IL-23) mice were immunized with male splenocytes
with or without CpG. IFNy ELISPOT showed that immunization of IFNAR-/females with WT male splenocytes was capable of priming Uty-specific T cell
responses in a CD4-dependent fashion(Fig. 4.11); however, CpG stimulated
pDCs were not able to prime in the absence of CD4 'help' suggesting that IFNAR
is required for CpG to act as an adjuvant.
In contrast to IFNAR, IL-12B was not required for CpG to trigger priming
signals in the absence of CD4+ T cells. Immunization of female IL-12B-/- mice
with male IL-12B-/- splenocytes primed Uty-specific T cells response in a CD4dependent fashion similar to other experiments, but CpG stimulation enabled
Uty-specific priming, suggesting that IL-12 production by pDCs is not a critical
component of this priming signal(Fig. 4.11). Notably, however, the ability of
IL12B-/- male splenocytes to prime IL-12B-/- females suggests also that IL-12/23
is not a crucial component of helper-dependent Uty-specific priming.
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IFNa production by influenza A N S I does not enable C D 8 + T cell priming
In efforts to examine the effects of non-pDC derived IFNa on CD4dependent immunity, we examined induction of IFNa following influenza ANSI
infection. The NS1 protein of influenza binds dsRNA and prevents IFNa
production in mice infected with wild type influenza; however, infection with
influenza ANSI triggers IFNa production224. The kinetics of IFNa production is
faster than MCMV and peaks around 12 hrs post-infection, consistent with the
faster replication time of influenza (Fig. 4.12A). In contrast to MCMV, pDC
depletion did not significantly inhibit IFNa production suggesting that a nonpDC is responsible for the IFNa production (Fig. 4.12B). The IFNa production,
however, was dependent on IFNAR.
In light of the different cell type responsible for IFNa production, we
evaluated if infection with influenza ANSI is capable of providing priming
signals for CD8+ T cells. Similar to the experimental setup for the MCMV
experiment, MHCII-/- female mice were infected with influenza ANSI 12 hrs
before immunization with male splenocytes. IFNy ELISPOT shows that, in
contrast to MCMV, influenza ANSI does not enable priming of Uty-specific
CD8+ T cells (Fig. 4.12C). Responses against endogenous MCMV (M45) or
influenza (PA) epitopes were monitored to provide an internal control for
exposure to virus. Despite the differential adjuvant effects on Uty-specific
priming, both MCMV and influenza ANSI generated antigen specific T cell
responses against their respective endogenous epitopes. These data suggest that
IFNa production by a pDC is an important component of this priming signal.
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142

4.6 Results: H C V H H D transgenic m o u s e model
In all, these results suggest that pDC IFNa may be sufficient to provide

priming signals for CD8+ T cells in the absence of CD4s. The potential to trigger
endogenous antiviral cytokines in a manner that also enhances CD8+ T cell
immunity has important therapeutic implications for HCV in particular.
Although a small animal model for HCV in which these types of manipulations
can be performed has not yet been developed, HHD transgenic mice were
primed with cell associated HCV antigen to evaluate the role for pDCs in HLAA2.1-restricted HCV-specific T cell responses.

Immunization of HHD transgenic mice with apoptotic cells expressing full length HCV
antigen primes NS31073.1081-specific CD8+ T cells in a CD4-dependent manner

Although a few animal models exist to study HCV reactive T cell
responses225, immunity in the context of full length HCV has not been assessed.
Here, I setup to monitor HCV specific immunity in HHD transgenic mice
expressing monochains of human p2-microglobulin linked to the N-terminus of
the HLA-A2.1 chimeric heavy chain containing the ala2 domains of HLA-A2.1
and a3 cytoplasmic domains of H-2Db (provided by F. Lemonnier). These
transgenic mice were constructed in an H-2Ke/-De/- background and therefore
express no H-2 class la molecules. The expression of HLA-A2.1 allows for a
normally diversified TCR repertoire and the absence of MHCIa molecules
enables a better CTL response to HLA-A2.1 restricted epitopes226. Several HLAA2.1-restricted epitopes for HCV are known, but the relative importance of each
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for antigen processing227, immunity49, cross-reactivity228, or disease progression229
is not well understood.
In order to evaluate HCV specific T cell priming in vivo, a xenogeneic
osteosarcoma cell line expressing full length HCV under a tetracycline inducible
promoter (provided by B. Wolk and D. Moradpour) was employed to immunize
HHD transgenic mice. HCV specific immunity was evaluated using 4 well

characterized HLA-A2.1 epitopes: Core35.43, Core132.140, NS31073.1081, and NS31406
In order to evaluate the presence of HCV reactive T cells in the endogenous
repertoire, HHD transgenic mice were primed with a 1:1 mixture of Titermax
(Sigma) and the respective peptide (Fig. 4.13A). Similar to other studies, our
results showed antigen specific CD8+ T cell responses in the spleen and draining

lymph nodes to all of the indicated epitopes after 7 days. In contrast to peptide
priming, immunization with 5 x IO6 irradiated cells expressing full length HCV
primed NS31073.1081 reactive T cells most efficiently(Fig. 4.13B).
We considered the possibility that subcellular localization of cell
associated HCV played a role in epitope usage. Expression of HCV in cell
culture results in the formation of a "membranous web" that is tethered to the
endoplasmic reticulum (ER)230. In order to evaluate if this membranous web and
ER tethering were important for epitope selectivity, we employed a cell line
expressing NS3-4A, which associates with ER, or NS3 alone, which is diffusely
spread around the cytoplasm (Fig. 4.14A)230. Expression of equivalent levels of
NS3 protein in both cell lines was confirmed by FACS analysis. IFNy ELISPOT
two weeks post-immunization revealed equivalent NS31073.1081 responses

suggesting that cellular localization was not crucial for epitope selectivity (Fi
4.14B).
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Figure 4.13. Immunization of H H D transgenic mice with full length cell
associated H C V results in NS31073.1081 dominant C D 8 + T cell responses. A.
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with D C s pulsed with the indicated peptides as targets.
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C D 4 + T cells regulate priming versus tolerance of HCV-specific CD8s
In order to evaluate the role for CD4+ T cells in regulating the
immunologic outcome of HCV-specific CD8+ T cell responses to NS31073.1081 CD4depleted HHD mice were immunized with cell associated HCV antigen. Similar
to our findings for endogenous presentation in the H-Y system, CD4-depletion
reduced NS31073.1081 specific T cells responses as monitored by IFNy ELISPOT
(Fig.4.15). Tetramer analysis was also done to confirm these results. Using CD3
and CD8 antibodies to gate on the CD8+ T cell population, the percentage of
tetramer positive cells in the the CD8+ T cell population was calculated.

Consistent with the ELISPOT results, NS31073.1081 antigen specific T cells expand
when immunized in the presence, but not in the absence of CD4+ T cells.
Next, we evaluated the immunologic significance of the lack of CD8+ T
cell response in the absence of CD4+ T cells. In other words, is the lack of

response a result of ignorance or antigen specific tolerance? In order to do this
the HCV system, we boosted immunized mice to evaluate the functional state of
the CD8+ HCV-specific T cells. IFNy ELISPOT seven days after boost shows an
increase number of CD8+ NS31073.1081 reactive cells in mice primed and boosted
compared to boost alone or primed with a non-HCV control cell line (Fig. 4.16).
In contrast, CD4 depletion during priming resulted in a decrease in IFNy
producing NS31073.1081 reactive CD8+ T cells after boost. Mice immunized with
peptide alone were used as a positive control for tolerance induction76. These

results were also confirmed using HLA-A2.1 tetramers for NS31073.1081 (Fig. 4.16)

Consistent with the ELISPOT results, an increase in NS31073.1081 tetramer positiv
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Figure 4.16. C D 4 + T cell 'help' regulates priming versus tolerance of
N S 3 1073-1081 C D 8 + T cell responses. H H D transgenic mice with or without
C D 4 depletion (dep) were primed and boosted after two weeks with H C V
expressing cell lines ( H C V ) or n o n - H C V cell line controls (non-HCV). T cell
immunity to NS31073.1081 w a s monitored 7 days after boost by IFNy ELISPOT
and tetramer staining. Bars represent averages of three mice.
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C D 8 + T cells were seen in animals primed and boosted compared to boost alone
or primed with non-HCV control cell line. CD4 depletion during priming
inhibits the expansion of NS31073.1081 tetramer positive cells comparable to
immunization with peptide alone. Core^.^ specific tetramer staining is shown to
illustrate the dominance of the NS31073.1081 response.

CpG overcomes the requirement for CD4 'help' in NS31073.mi T cell priming
Finally, we evaluated if CpG could overcome the requirement for CD4
'help' for NS31073.1081-specific CD8+ T cell priming. Briefly, mice were either
untreated or CD4 depleted and immunized with either HCV expressing cell lines
alone or with CpG. Analysis of NS31073.1081-specific CD8+ T cell responses after
weeks by IFNy ELISPOT shows that CpG stimulation enables HCV-specific T cell
priming in the absence of CD4 'help' (Fig. 4.17).
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with or without i.v. CpG. NS31073.1081 T cell immunity was evaluated after 12
days by IFNy ELISPOT. Circles represent individual mice.
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4.7 Discussion
pDC IFNa/p substitutes for CD4+ T cell 'help' in CD8+ T cell priming

Despite the potent clinical efficacy of IFNa in the treatment of HCV, the effects
on HCV specific immunity have been contradictory213,231. IFNa can serve as a
'danger' signal in certain system to activate DCs184 or provide help directly to
CD8+ T cells207. In some systems, IFNa may even act directly on DCs to
overcome CD4+ T cell requirements for CTL priming185. However, the
experiments discussed in the last chapters suggest that spatial
compartmentalization of IFNa may be an important component in achieving this
immunological effect. Although pDCs are recognized as the main producers of

IFNa/p, their role in providing these signals at the DC / T cell interface is not
well defined. Here, using viral and non-viral triggers for pDC- and non-pDCderived IFNa, we evaluated the ability of pDC IFNa in providing priming
signals for CTLs in the absence of CD4 'help'.
Our results show that both MCMV and CpG can overcome the need for
CD4 'help' in generating Uty-specific IFNy producing CD8+ T cells (Fig. 4.8 and
4.9). Although MCMV and CpG trigger IFNa production with different kinetics
(Fig. 4.6), IFNa production by both stimuli requires pDCs. pDC depletion of
female mice before immunization abrogates the adjuvant effects of MCMV

suggesting that host pDCs are required for this effect (Fig. 4.8). Since donor DC
are the main stimulators of CD8+ T cell immunity (Fig. 4.4) and pDCs are not
efficient at cross-presenting antigen232, our data suggest that host pDCs
collaborate with immunizing male DCs to prime host CD8+ T cells (Fig. 4.18).
Although this model lacks the antigen specificity afforded by CD4 engagement
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of MHCILpeptide complexes, activated p D C s accumulate in the spleen
following activation (Fig. 4.7A). This migration may put them in prime location
to interact at the conventional DC / T cell interface, influencing priming and
tolerance.
The pDC-dependent CD8+ T cell priming requires IFNAR in the host (Fig.
4.11). This may suggest that IFNa is acting directly on the CD8+ T cell to
provide a third signal, similar to in vitro studies207; however, IFNAR is also
required for IFNa production in response to CpG stimulation (Fig. 4.6D) and
therefore effectively blocks potential effects on the immunizing WT DC as well.
Preliminary data suggests that IFNAR is also required on the immunizing male
splenocytes for CpG-dependent priming indicating that IFNa/p may also play an
important role on the DC at the DC / T cell interface (Fig. 4.18). Although mouse
pDCs may be capable of producing IL-12, this pDC-dependent priming effect is
independent of IL-12p40, which excludes a role for both IL-12 and IL-23 (Fig.

4.11). Notably, Uty-specific priming in this system does not require IL-12 and, as
such, these results cannot rule out a role for pDC produced IL-12 on CTL
priming in systems that are more sensitive to IL-12.
As such, there are two notable differences between the in vitro human and
in vivo mouse systems. First, IFNa is sufficient to allow for priming in the
absence of CD4+ T cell 'help' in the mouse whereas IFNa synergizes with CD40L
or TNF signaling to enhance priming in the human. It is possible that this

reflects species specific differences in IFNa signaling200. Alternatively, signal
provided by non-CD4+ T cells in vivo may synergize with IFNa/p to account for
its ability to promote priming. Second, while IL-12 is sufficient to rescue the
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Figure 4.18. p D C s collaborate with D C s at the D C / T cell interface to
provide IFNa/P-dependent 'helper' signals for C T L priming. p D C s enter
secondary lymph organs and the spleen from the blood across high
endothelial venules (HEV). p D C s m a y migrate into T cell zones and
collaborate with conventional D C s (cDC) for T cell priming via IFNa.
Notably, I F N a from the p D C s m a y act directly on the C D 8 + T cells or on the
D C s to activate S T A T 4 and promote T cell activation.
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inhibitory effects of IFNa on iDCs and enhanced IL-12 correlates with the
immune enhancing effects of IFNa on mDCs in human, pDC-dependent CD8+ T
cell activation in the H-Y model does not require IL-12/23. This may suggest
that the immune enhancing effects of IFNa/p signaling on DCs trigger redundant
pathways (e.g production of IL-27).
In light of the signaling switch in DCs, as well as antigen specific T cells208,
discussed in the previous chapter, it will be interesting to assess the role of
STAT1 and STAT4 in pDC-derived IFNa/p immune enhancing effects. Although
strain backgrounds prevented us from readily addressing these questions,
STAT4 may be a crucial regulator of the priming signals in both DCs and T cells
downstream of IFNa/p signaling.

pDC- versus non-pDC-derived IFNa in shaping CD8+ T cell immunity
Non-pDC cell types can also make IFNa depending on the viral
stimulus195. For example, conventional DCs can produce IFNa in response to
influenza ANSI206. Recent studies have revealed that while TLR7/9 stimulation
is crucial for IFNa production by pDCs, RIG-I regulates IFNa production in vivo
by conventional DCs in an MyD88 and TRIF-independent manner233. Although

influenza ANSI is also capable of stimulating pDCs via TLR7 in vitro, our results
in vivo suggest that a non-pDC is predominately responsible for IFNa production
(Fig. 4.12B).
In order to evaluate the effects of these distinct IFNa-producing cell

populations in regulating adaptive immunity, we directly evaluated the ability of
MCMV triggered IFNa versus influenza ANSI triggered IFNa to offer priming
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signals. Surprisingly, while M C M V triggered p D C IFNa supported Uty-specific
T cell priming, influenza ANSI triggered IFNa did not overcome the requirement
for CD4+ T cell 'help'(Fig. 4.12C). This result suggests that the type of cell
responsible for producing IFNa may be important in determining its effect on
immunity (Table 4.1). While pDCs migrate to the spleen following activation, the
IFNa producing cell during influenza ANSI infection may not reside at this
crucial location for effecting T cell priming. Two chemotactic factors, CXCR3
ligands and SDF-1 /CXCL12, play an important role in pDC migration to the T

cell areas via high endothelial venules234 and it will be interesting to evaluate
their role in pDC-dependent CD8+ T cell priming.
These findings highlight two important points. First, viruses such as HCV
may trigger IFNa production in a manner that does not effectively augment the
immune response against it. Second, with respect to therapeutic delivery of
IFNa, specific pDC agonists (e.g. TLR7 or TLR9 agonists) may more effectively
target IFNa production for promoting antiviral immunity.
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Table 4.1. Characteristics of I F N a production and effects by M C M V , C p G ,
and influenza A N S I

M C M V

C p G

Flu
A N S I

p D C

responsible

for s e r u m
I F N A R

p D C

p D C

N o

N o

Yes

Yes

N o

N / A

N o

N o

N / A

N o

Yes

Yes

N o

Yes

Yes

N o

I F N a

required

innate

Yes

I F N a

required

for s e r u m

Yes

for

immunity

required

for

adaptive
i m m u n i t y
A c t s as
for

adjuvant

priming

O v e r c o m e

C D 4

requirement
m o d e l

for

antigen
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H C V immunity in vivo
Although our impetus for investigating CD4-dependent CD8+ T cell immunity

rested on the role for CD4+ T cell 'help' in HCV-specific immunity, it is clear t
the H-Y model system may not be representative of HCV immunity. Ultimately,
a small animal model for HCV will be crucial for evaluating cellular
requirements in efficient cell-mediated immunity. In lieu of an infectious small
animal model, we were able to evaluate CD4-dependent HCV specific T cell
responses in a human HLA-A2.1 specific system. A better understanding of HCV
immunity in these mice will aid in the advancement of a mouse model for HCV.
Interestingly, our work shows a dominant CD8+ T cell response to the

NS31073.1081 epitope during immunization with full length, cell associated antige

(Fig. 4.13). This epitope cross-reacts with an influenza neuraminidase epitope 22

which may account for the high rate of NS31073.1081-reactive T cells in HCV-naive
individuals235. This epitope may also, however, play an important role in HCV

pathogenesis as the strength of the NS31073.1081 response correlates with associa
liver pathology during acute HCV infection229. Interestingly, one group reports

a high rate of non-synonomous mutations at the C-terminal end of the NS31073.1081
epitope in patients who progressed to chronic infection from a single source
outbreak236. This mutation impairs NS31073.1081 carboxyterminal processing and

thus antigen presentation. The selectivity for this epitope offers a target for t
virus to avoid detection of priming with cell associated, full length HCV.
Although this priming is likely due to cross-priming, the HCV cell line used
expresses low levels of human HLA-A2.1 and cross-priming will need to be
shown formally in a haplotype mismatched cell line. In any case, mutations in
the carboxyterminal end of the NS31073.1081 epitope may block endogenous
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presentation of this epitope by infected hepatocytes and consequently prevent

detection by NS31073.1081-specific T cells237. Finally, this epitope is located d
downstream of the protease domain and the contributions of replication fitness,
strength of cross-reactivity, and efficiency of antigen presentation in driving
escape mutation have not been evaluated. Futher work will be required to see if
this is true in vivo as well as in other HCV expression systems such as HCVcc.

Activation versus tolerance in HCV-specific models
In light of our in vivo findings of no overt DC defects during chronic HCV
infection, we proposed that another level of regulation might determine the
strength of CD8+ T cell immunity. Similar to our results in the H-Y system,
CD4+ T cell 'help' is required for efficient CD8+ T cell priming to NS31073.10gl
4.15). Notably, the role for HCV-specific CD4+ T cells has not been directly
evaluated. Specifically, it would be interesting to know if the efficacy of
vaccination against HCV antigens by cross-presentation depends on the
generation of strong MHCII epitopes227.
Furthermore, our data suggests that in the absence of CD4+ T cells,

functional tolerance of NS31073.1081 specific T cells ensues (Fig. 4.16). Currentl
tolerance is not a heavily favored model in HCV infection because T cell
responses can be seen in the liver of chronic patients many years following

infection41; however, it is possible that not all chronic HCV situations result f
a lack of effective CD8+ T cell immunity. Alternatively, although T cells may

remain present in patients, the epitope specificity of those T cell responses may

be crucial in determining clinical outcome229. This epitope selectivity may resul
from viral evolution41 or the effects of persistent antigen on T cell anergy238.
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Finally, the role of C D 4 'help' in H C V immunity m a y offer insight into
,48
progression and treatment strategy for HCV/HIV co-infection4

p D C s and C p G therapy for H C V immunity
In light our finding that pDCs are functionally competent in patients with
chronic HCV, the role of pDC IFNa serving in lieu of CD4+ T cell 'help' is
extremely attractive. In order to verify this finding in another antigen system

besides H-Y and, even better, an HCV specific system, we evaluated the ability of
CpG triggered pDCs to overcome CD4 depletion in NS31073.1081 specific T cell
priming. Similar to our findings in the HY system, CpG triggered pDCs enhance
HCV-specific CD8+ T cell priming (Fig. 4.17).
Notably, CpG motifs are currently in phase II trials for HCV and have
shown good antiviral effect in vivo. Although the effects of IFNa on HCVspecific immunity are unclear, it will be important to compare immunologic
response in IFNa versus CpG treated HCV patients. Moreover, the ability of
pDCs to substitute for CD4+ T cell 'help' may make CpG motifs and TLR7/9
therapy suitable for co-infected HIV/HCV patients with compromised CD4+ T
cell activity.
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C h a p t e r 5: D C s Coordinate H C V I m m u n i t y a n d Pathogenesis

HCV infects nearly 3% of the world's population and over 1 million
Americans. In some countries, the prevalence of HCV reactive antibodies is 15-

20%. Chronic HCV is a leading cause of cirrhosis and liver cancer. In addition to
the morbidity and mortality of these diseases, the disease burden in the 4th and
5th decades of life has significant socio-economic ramifications in some
communities. Clearly, more effective therapies and even vaccination would
substantially lower disease burden worldwide. But what are the crucial
characteristics of effective HCV immunity? Here, I will integrate my findings
into the larger literature of HCV immunity to gain insight into this central
question.

5.1 Re-examining the role for DCs and CD4+ T cell 'help' in generating
effective CD8+ T cell immunity to HCV
Several early studies provided evidence for the role of the CD8+ T cell
response in HCV immunity. In humans, the presence of strong HCV specific
CD8+ T cell immunity correlates with resolution40. Similarly, in chimpanzees,
CD8+ T cell immunity, in contrast to humoral responses, correlates with
protection against rechallenge34. This correlative data was directly tested by
CD8+ depletion. As expected, depletion of CD8+ T cells before re-infection
rendered the chimpanzees susceptible239. Although significant data support the
role for CD8+ T cells in HCV immunity, robust CD8+ T cell responses may also
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exist in chronic infection240 and the distinguishing characteristics of successful
immunity are not clear.
In order to evaluate the requirements for effective T cell priming during
HCV infection, many labs have focused on conventional DCs as the educators of
the CD8+ T cell responses. Early studies reported a generalized defect in
monocyte derived DC maturation, suggesting that defective maturation

prevented robust T cell priming159"161. This model, however, is inconsistent with
immune competence of chronically infected HCV patients. Furthermore, no
mechanism for the modulation of DC function (i.e. virus binding or infection)
could be identified to account for this global defect of monocytes. In contrast,

we241,242 and others243 have concluded that both monocyte derived and circulating
BDCA-1 conventional DCs are phenotypically and functionally normal in
chronically infected HCV individuals.
These findings offer two significant developments for studies of HCV
immunology. First, they suggest that another level of regulation exists to
influence the immunologic outcome of HCV-specific T cell priming (Fig. 5.1).
CD4+ T cell signals and differential cytokine production during HCV infection

are important candidates for this alternate level of regulation. Importantly, our
data are consistent with the possibility of HCV-induced modulation of DC
cytokine secretion; however, a mechanism for this remains to be identified.
Second, our findings lend credence to DC based immunotherapy for HCV.
These therapies may prove useful for enhancement of HCV specific immunity.
CD4+ T cell signals are a critical component of a successful CD8+ T cell
response41. This was directly evaluated in chimpanzees by CD4 depletion
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Epitope specificity of Effector Functions

Figure 5.1 Functional D C s regulate C D 8 + T cell immunity. In light of
normal D C function in chronic H C V , w e evaluated several alternate
mechanisms of regulating C D 8 + T cell priming. Although D C - S I G N
binds E2, direct infection of D C s has not been demonstrated. Crosspresentation of both viral particles or cell associated antigen is a
mechanism for generating H C V epitopes. Epitope selection m a y be
regulated by primary sequence mutations. C D 8 + T cell priming is
dependent on C D 4 help and plays a critical role in generating effective
immunity in vivo. Finally, the epitope specificity of C D 8 + T cells is an
important determinant of their efficacy.
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prior to rechallenge47. The results showed that C D 4 + T cell 'help' w a s necessary
for preventing escape mutations and allowing for resolution of infection.
Although these types of experiments cannot be done in humans, HCV /HIV coinfection provides a surrogate model for CD4 depletion. A recent study of coinfected patients showed that HCV CD8+ T cell responses correspond with
absolute CD4+ T cell count48. Furthermore, data from two patients infected from

a known source suggests that the diversity of the CD4+ T cell response correlates
with CD8+ T cell responses and resolution of infection49.
The status of HCV-specific CD8+ T cells in the absence of strong CD4+ T
cell 'help' is less well understood. In several animal models, CD4+ T cells are
required for the generation of effective CD8+ T cell memory68,244,245. Moreover,
we have shown that immunization with cell associated full length HCV in the
absence of CD4+ T cells induces HCV-specific non-responsiveness to rechallenge (see Fig. 4.16). Despite these data, T cell tolerance in HCV immunity
has not been widely favored due to the presence of CD8+ T cells in chronically
infected patients41. However, mutations in viral RNA makes HCV a rapidly
moving target and, although HCV responsive T cells can still be detected in
chronic HCV, the epitopes efficiently presented by APCs may be significantly
altered41. Moreover, the persistence of antigen during chronic infection may
induce functional anergy in a subset of HCV-specific T cells238. These data

suggest that while a crucial decision regarding T cell activation versus toleranc
is made during intial exposure, the generation of effective immunity depends on
the ability to prevent escape mutations and the adverse effects of persistent
antigen. Importantly, therapeutic intervention usually occurs after viral escape
and/or the effects of persistent antigen on selective antigen specific T cell
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responses. Thus, with better tetramers and larger cohorts of H C V donors, it will
be important to measure the relative importance of these processes on T cell
immunity to HCV through the course of infection. These data may provide
important insight into the important epitopes to target during immunotherapy
for chronic infection.

5. 2 Mechanism of antigen presentation in generating CD8+ T cell immunity
Although hepatocytes are generally recognized to be infected during HCV

infection, it is not clear if antigen presenting cells are directly infected141 (

Some studies suggest that DCs are infected in vivo2i6; however, these results are
not reproducible between patients. Furthermore, these findings are not based
on negative strand synthesis and therefore indicate the presence, but not
necessarily the replication, of HCV. Several studies have shown that HCV E2
glycoprotein binds to DCs via DC-SIGN94,95, providing a putative mechanism by
which HCV RNA is merely bound to surface of DCs. Although one report
suggests that DC-SIGN enables HCVpp infection247, the role for DC-SIGN in
HCVcc infection has not been substantiated (see Fig. 2.8). In lieu of mediating
direct infection, DC-SIGN binding may play an important role in virus
trafficking. This mechanism of "hitching a ride" may account for HIV trafficking
from mucosal surfaces to lymph nodes for T cell infection97. The importance of

this interaction in trafficking HCV from sites of mucosal or intravenous infectio
to hepatocytes has not been defined.
Although APCs can efficiently generate MHCII epitopes from exogenous
antigen, MHCI epitopes for the stimulation of CD8+ T cells are classically

generated from cytoplasmically processed antigen. The lack of direct infection of
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D C s would prevent classical loading of M H C I ; however, it w a s recently s h o w n
that DCs can cross-present antigen from viral particles for stimulation of HCV-

specific T cell lines180. We have confirmed the ability of full length cell assoc
HCV antigen to be cross-presented for stimulation of NS protein T cell immunity
in mice; however, presentation of HCV epitopes by uninfected DCs in humans or
chimpanzees has not yet been shown. This strategy also has the potential to
identify new HCV epitopes. Interestingly, cross-presentation of NS3 antigen in
the context of cytopathic bovine viral diarrheal virus (BVDV) infection was
found to generate robust NS3 T cell immunity, suggesting that cross-presentation
may offer unique advantages for vaccination strategies227.
In light of the alternate methods for antigen presentation, differential

antigen processing may be important in epitope generation (Fig. 5.1). In general,
peptide epitopes generated by proteasomes are loaded onto MHCI in the
endoplasmic reticulum. However, different cells process antigen differently. In
the influenza model, direct infection of DCs can generate strong immune
responses to both nucleoprotein (NP) and polymerase (PA) epitopes; however,
cross-presentation of influenza antigen results primarily in NP-specific
priming248. This epitope selectivity may have important consequences for the
efficacy of the adaptive immune response in mediating viral clearance. There is
precedent to suggest that viruses may use epitope preferences to mislead the
host. Although cross-presentation generates robust Derestricted M45 T cell
responses during MCMV infection, immune evasion protein ml52/gp40
specifically blocks epitope presentation and subsequent detection in infected

tissue237. In vivo mouse data for presentation of full length, cell associated HC
antigen suggest that NS31073.1081 is the dominant CD8+ T cell epitope.
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Interestingly, a high rate of non-synonomous mutation is seen at the C-terminal
end of this epitope which blocks proteasome processing and presentation236. In

light of the strong T cell immunity to NS31073.1081, mutation at the C-terminus o

this epitope might disrupt T cell stimulation. Alternatively, mutations at this s
may allow HCV to evade T cell immunity in the infected tissue, similar to
MCMV evasion described above237. With the availability of infectious HCVcc, it
will be important to determine MHCI epitopes generated by infected hepatocytes
versus DCs from infected patients by mass spectroscopy249. In conjunction with
concurrent tetramer data, these experiments will provide a more complete
picture of distinct regulation points in effective CD8+ T cell immunity: antigen
presentation by APCs, epitope specific T cell responses, and presentation of
antigen by infected hepatocyte targets.

5. 3 A role for DCs in the characteristic intrahepatic IFNo/P signature of HCV
infection
In contrast to other viral liver infections such as hepatitis B, HCV induces
robust expression of IFNa response genes in the liver during acute infection250.
IFNa is a potent antiviral cytokine that can act by both autocrine and paracrine
signaling mechanisms to induce the expression of proteins which protect against
viral infection: MxA, PKR, 2'-5' OAS, and ADAR (see Fig. 1.6). These antiviral

activities likely account for the potent therapeutic effects of pegylated-IFNa fo
HCV101.
Which cells are responsible for IFNa production during HCV infection?
Theoretically, all cells are capable of inducing IFNa production in response to
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viral infection. The strong data showing the infection of hepatocytes with H C V
in vivo U1, therefore, suggest that infected hepatocytes may be the most likely
producers of IFNa during acute infection. Several reports suggests that
hepatocytes are competent to respond to dsRNA via RIG-I and TLR3 signaling
pathways131,137. On the contrary, although IFNa response genes are significantly
upregulated in liver tissue, IFNa transcripts themselves are not found in liver

tissue. In response to this finding, it has been argued that IFNa transcripts are
present in PBMCs of acutely infected patients143. In contrast to hepatocyte
infection, HCV infection of PBMCs remains controversial. However, PBMCs
express numerous pattern recognition receptors e.g. toll receptors (TLRs), which
may make them uniquely suited to detect virus even in the absence of infection.
In particular, the natural interferon producing cells in the blood, plasmacytoid
DCs (pDCs), express TLR7 (receptor for ssRNA126) making them well suited to
produce IFNa in response to the HCV RNA. However, a mechanism for HCV
induction of IFNa has yet to be defined. In fact, infectious J6/JFH chimeric HCV

virus fails to trigger IFNa production in pDCs in vitro (Fig. 5.2) suggesting tha
another PBMC cell type may be involved in the IFNa response to infection;
however, the response of liver pDCs in vivo also needs to be assessed.
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Figure 5.2 J6/JFH chimeric H C V does not induce I F N a production by
h u m a n p D C s . B D C A - 2 and B D C A - 4 were used to identify and gate
p D C s by F A C S . Histograms show IFNa staining in p D C fraction
following 6 hr stimulation as indicated.
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Despite the lack of evidence for direct p D C activation by H C V , our

work242 as well as that of others162,174 has revealed lower percentages of pDCs p
PBMC in HCV-infected donors compared to healthy controls (see Fig. 2.6). It
remains unclear if this reflects decreased pDC production, migration to

extravascular sites such as lymph node or liver, or disappearance (albeit real or
artifactual) due to death or down regulation of characteristic pDC markers. The
latter occurs with phenotypic maturation of pDCs in response to viruses both in
vivo251 and in vitro (Fig. 5.3A). Although downregulation of BDCA-2 during pDC
maturation is coincident with migration, a transitional cell population may be
apparent in the circulating blood. For example, a BDCA-2 low population was
observed in PBMCs from 2 out of 22 HCV patients, but not in any healthy donors
(Fig. 5.3B). This BDCA-2 low population expressed CD123 and HLA-DR but
downregulated BDCA-4 (Fig. 5.3C). Consistent with a mature phenotype, this
BDCA-2 low population expressed high levels of CD83 and increased CD40.
This finding, however, was only present in select HCV+ patients and the
defining clinical characteristics could not be identified. Furthermore, exposure
J6/JFH chimeric HCV in vitro does not induce phenotypic maturation or enhance
survival. In vivo studies are required to evaluate the presence of pDCs in
infected liver or draining lymph nodes. An important caveat of this data is that
these findings are not necessarily HCV-specific (see Fig. 2.6) and may be
indicative of chronic infection172. Notably, endogenous as well as therapeutic
IFNa negatively regulates pDC number and IFNa production252; as such, it is
important for studies evaluating pDCs in chronic infections to document IFNa
serum levels as well as the time elapsed since termination of IFNa therapy.
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Figure 5.3. B D C A - 2 low population in chronic H C V upregulates
maturation markers. (Continued on the following page)
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Figure 5.3. B D C A - 2 low population in chronic H C V upregulates
maturation markers. A. B D C A - 2 and B D C A - 4 were used to identify
p D C s in P B M C cultures by F A C S . N u m b e r s indicate p D C percentage
per P B M C . Cells were exposed to influenza or not and analyzed at
indicated times after exposure. B. Enumeration of B D C A - 1 , B D C A - 2 ,
and B D C A - 2 low population as described in material methods. F A C S
plot shows data from H C V - donor 24263 and H C V + donor 24262. C.
Surface expression of indicated markers on B D C A - 2 low (gray line)
compared to B D C A - 2 high (black line) cell populations is represented by
histogram.
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Despite these reported abnormalities in cell numbers, p D C s from
chronically infected HCV donors are functionally competent to make IFNa/p in
response to TLR7/9 agonists. An initial report suggested that pDCs from HCV
infected donors showed impaired IFNa production in response to TLR9 specific
agonists; however, these results were based on IFNa levels from bulk PBMC
cultures and did not account for the decreased percentage of circulating pDCs
seen in chronic HCV infection162. More careful analysis accounting for the
decreased numbers of pDCs as well as FACS-based assays to monitor
intracellular IFNa production by pDCs revealed that the decrease in TLR9
triggered IFNa is a result of decreased pDC numbers and not reflective of a
functional defect in pDC IFNa production (see Fig. 2.7)242,243. These findings
suggest that HCV does not specifically interfere with pDC production of IFNa,
supporting a potentital role for TLR7/9 agonist therapy for HCV.
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Conventional D C s can also produce significant amounts of IFNa206. Using
influenza as a stimulus, we showed that iDCs produce IFNa equivalent to pDCs
stimulated with CpG (Fig. 5.4A). 2-aminopurine inhibits this IFNa production
suggesting the importance PKR or other kinase activity in this response (Fig.
5.4B). Interestingly, DC maturation shuts down this IFNa production (Fig. 5.4B).

We hypothesized that this finding reflects an intrinsic inability of mDCs to make
IFNa due to their decreased need to detect pathogens (and consequent
downregulation of TLRs (Fig. 5.4C)); however, infection with influenza ANSI
revealed the capacity of mDCs to produce IFNa (Fig. 5.4D). This finding needs

to be evaluated by intracellular cytokine staining to rule out the possibility of
contaminating iDCs accounting for the interferon production. This finding
suggests that viruses may actively inhibit IFNa production in mDCs. The ability
of HCV to trigger conventional DC IFNa production in vivo or in vitro has not
been evaluated.
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Figure 5.4. Influenza N S 1 protein antagonizes m D C I F N a production
via non-TLR dependent mechanism. (Continued on the following page)

175

_

800

s
"56
Cm

600

I
Ph

400
200

iDC

iDC

mDC

Flu

mDC

mDC

Flu

Flu A N S I

Flu
ANSI

Figure 5.4. Influenza N S 1 protein antagonizes m D C I F N a production
via non-TLR dependent mechanism. A. p D C s or iDCs at 106/mL were
stimulated with 3 m g / m L of C p G 2216 or 50 H A U influenza (Flu) in the
presence of 2-aminopurine (2-AP) or acetic acid solvent (AA). I F N a in
24 hour supernatants w a s quantified by ELISA. B > iDCs or m D C s at
106/mL were stimulated with 50 H A U influenza (Flu) and cultured in
media alone or media with maturation stimuli T N F a and PGE-2 (T+P)
for the indicated amount of time. I F N a w a s quantified by ELISA. C.
Surface staining of iDCs and m D C s for T L R 3 and CD83. D. IFNa in iDC
and m D C supernatants containing 106 cells/mL stimulated for 24 hours
with media alone, 50 H A U influenza (Flu), or 50 H A U influenza A N S I
(Flu A N S I ) monitored by ELISA.
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Despite the clinical efficacy of IFNa and the sensitivity of H C V to I F N a in
vitro, it is surprising that induction of IFNa response genes does not correlate
with resolution of acute HCV infection139. Notably, several mechanisms by
which HCV proteins antagonize IFNa signaling and production in infected cells
have been elucidated133,134 (Fig. 5.5). The NS3-4A protease plays a key role in

disrupting IRF-3 phosphorylation135 by targeting the RIG-I adaptor, Cardif136,253
and TLR3 associated TRIF adaptor protein137. These antagonistic functions may
limit IFNa's anti-viral effect during acute infection. Another study has
suggested that the dose of infection may be an important factor in determining
the nature of the protective response37. In other words, innate immunity and
IFNa may play a more important role in low dose exposures. Alternatively,
HCV, as well as other pathogens, may take an active role in manipulating the
host's IFNa/p response to evade adaptive immunity and promote viral
persistence.
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Figure 5.5. Regulation of I F N a production and induction of I F N a
response genes during H C V infection. Despite the robust induction of
IFNa response genes in liver tissue samples, H C V has numerous
mechanisms to inhibit both effector function and production of IFNa.
The nature of the IFNa producing cell during acute H C V infection
remains unidentified as does the mechanism by which it detects H C V .
A s proposed in the figure, RIG-I and T L R 3 mechanisms m a y trigger
I F N a production directly by hepatocytes. Although a decrease
circulating p D C numbers has been documented, it is not clear which
P B M C cell type produces IFNa during acute infection.
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5.4 IFNa/P's double-edged sword: strategies for immunoevasion and immunity
The actions of IFNa/p on immune regulation are pleiotropic140. The
counter-inflammatory effects of IFNa/p play important role in controlling nonspecific activation during times of hyper-activity. During viral infection, for
example, IFNa/p suppresses bystander T cell activation209 as well as excessive
production of IL-12 186 via ST ATI dependent signaling140,208. Moreover, we have
shown that the inhibition of IL-12 production by ST ATI signaling in iDCs blocks
CD8+ T cell activation by cross-presentation, thereby providing another level of
regulation against non-specific activation during viral infection (Fig. 5.6).
These counter-inflammatory actions provide crucial targets for invading
pathogens. L. monocytogenes, for example, uses the IFNa/p response to promote
lymphocyte apoptosis254 and inhibit IL-12 production210. As such, IFNAR-/- mice
are significantly more resistant to high dose challenge. Viruses, such as HCV,
may also take advantage of these counter-inflammatory targets. Although HCV

has several mechanisms to inhibit IFNa/p signaling in infected cells, high levels
of IFNa/p are present in hepatic tissue. Thus, in the absence of DC infection,
IFNa/p will act on the DCs as they capture antigen in the liver. The importance
of CD4+ T cell 'help' in generating strong HCV-specific CTLs may enable IFNa/p
in the tissue to play an important role in preventing CD8+ T cell activation by
cross-presenting DCs. Polymorphisms in IL12B promoters could contribute to
the complexity of IFNa/p regulation of IL-12 production, resulting in wide
variation in clinical outcomes255.
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Figure 5.6. Spatial compartmentalization of I F N a reflects both therapeutic
and viral strategies of modulating immunologic outcome. A. I F N a in
peripheral tissue during an infection or inflammatory response can be
produced by infected cells, p D C s , or cDCs. Activation of S T A T 1 dependent
signaling in cDCs decreases consquent IL-12 production and T cell priming.
This mechanism m a y play an important role in viral infections that trigger
non-pDC-produced I F N a in tissue such as H C V , inflammatory situations
with p D C infiltrates, or therapeutic Betaseron® for multiple sclerosis. B. In
contrast, IFNa in lymph nodes m a y facilitate immunity. Activation and
migration of p D C s or c D C s to the D C / T cell interface places them in prime
location to affect the immunologic outcome. IFNa/p might act on the D C or
the C D 8 + T cell via STAT4-dependent signaling.
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In addition to its counter-inflammatory effects, IFNa/p also plays an
important role in enhancing immune responses. Although IFNa/p inhibits IFNy

production by NK cells and naive T cells during viral infection181, it is require
trigger NK cell cytotoxicity and stimulate proliferation of certain T cell

subsets182,183. Similarly in DCs, although our data show that the inhibition of I

12 by IFNa/p blocks T cell activation, other reports suggest that type I IFNs may
serve as a 'danger' to facilitate DC activation184 and 'license' DCs to crossprime185. In some conditions, IFNa/p may even synergize with TLR ligands to
enhance IL-12 production by DCs198.
We have identified a signaling switch in DCs coincident with maturation
that modulates the effect of this pleiotropic cytokine acting through a single

IFNa/p receptor (Fig. 5.6). In contrast to IL-12 inhibition by STAT1 signaling in
iDCs, exposure of mDCs to IFNa/p results in signaling via STAT4, enhanced
production of IL-12p70, and subsequent T cell activation. This data provides
evidence for a maturation-induced molecular switch in signaling pathways,
which accounts for the opposing effects of type I IFNs on antigen crosspresentation. This alteration in signaling networks offers a novel mechanism by
which DCs modulate the integration of signals from the surrounding

environment. This switch is reflective of similar intracellular regulation in bot
NK and T cells181,199. Recent data suggest that antigen specific CD8+ T cells

regulate total STAT1 levels, thereby reducing their sensitivity to IFNa/P's anti-

proliferative effect208. In sum, the cell-specific regulation of signaling networ
enables multiple, yet specific, effects of IFNa/p in coordinating immunity.
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5.5 IFNa7P compartmentalization in disease and immunity
The migration of pDCs to secondary lymph organs upon activation offers
a clear mechanism for IFNa/P's immune enhancing effects. IFNa/p production

during most viral infections is not restricted to the tissue and may also activat
pDCs to produce IFNa. Our experiments suggest that pDC-derived IFNa at the

DC / T cell interface can overcome the inhibitory effect of IFNa 'early' (see Fig
3.13). This finding supports the hypothesis that inflammatory cytokines in the
periphery may not be sufficient and that TLR-dependent detection and

movement of blood cells is crucial to orchestrating an effective CTL response. In
contrast, a recent study suggests that inflammatory cytokines triggered by CpG
are insufficient to allow for activation of transgenic CD4+ T cells256. These
findings may reflect differences in activation of transgenic CD4+ T cells versus
endogenous CD8+ T cells. Alternatively, the delivery of CpGs in the footpad
may not be sufficient to trigger pDC migration and IFNa production in the
lymph node at the DC / T cell interface. Another recent study suggests that
pDCs are critical for generating herpes simplex virus (HSV)-specific CTLs in

response to viral challenge223. This finding, however, may be specific for HSV, a
pDC depletion does not affect the generation of M45 epitope-specific CD8+ T cell
priming in response to MCMV infection(see Fig. 4.8). However, MCMV or CpG
activated pDCs can substitute for CD4+ T cell 'help' in priming CD8+ T cells
against H-Y model antigens. Thus, in the absence of robust CD4+ T cell
responses (e.g. in HIV-AIDS), pDCs may play an important role in T cell
priming. This pDC effect is independent of IL-12, but dependent on IFNAR
suggesting that IFNa production is required at the DC / T cell interface. These
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findings show that p D C s can offer priming signals to C D 8 + T cells and provide a
functional rationale for their migration to lymph nodes during viral infection.
As previously mentioned, pDCs are not the only cells capable of making
IFNa/p. Infected tissue as well as conventional DCs are able to produce IFNa/p.

Naturally, the IFNa/p produced by infected tissue is restricted to the local area
infection. Although DCs may migrate to lymph nodes like pDCs, maturation is
coincident with decreased IFNa/p production (Fig. 5.4). This may represent
active interference by viral proteins to prevent the immune enhancing effects of
IFNa/p production at the DC / T cell interface. With regard to vaccine
development, viral vectors lacking viral proteins that disrupt IFNa production
by mDCs (i.e. influenza ANSI) may enhance immunogenicity.
Compartmentalization of IFNa/p production during viral infection may
represent a distinct signature of the host-pathogen interaction. Herpesviruses,
such as HSV and MCMV, are potent activators of pDC-derived IFNa/p188. The
activation of pDCs by herpesviruses such as HSV and MCMV may be tightly
linked to the importance of cross-priming for robust T cell immunity during
infection257. In contrast, influenza ANSI triggers IFNa/p production by a nonpDC and can generate an immune response via direct infection of APCs248.
Notably, the production of IFNa/p during influenza ANSI infection does not
substitute for CD4+ T cell 'help' during H-Y priming. LCMV also induces
production of IFNa by a non-pDC195. Although LCMV-specific CD8+ T cell
priming was classically defined as CD4-independent, recent data suggest that
CD4+ T cells are important for secondary expansion68. It will be interesting to
see if pDC IFNa/p affects secondary expansion in this model.
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H C V m a y also induce spatial compartmentalization of IFNa/p. Despite
the functional responsiveness to TLR9 agonists242 ex vivo, no direct evidence
shows HCV activation of pDC-derived IFNa; nonetheless, IFNa/p response
genes are induced in hepatic biopsy tissue139. This spatial compartmentalization
during HCV pathogenesis may make HCV uniquely suited to take advantage of
the inhibitory effects of IFNa/p on CD8+ T cell activation by cross-presenting
DCs.

5.6 pDC-based therapy for HCV
Given the correlation between T cell immunity and clinical response, it
was hypothesized that IFNa treatment would enhance HCV-specific T cell
immunity. A recent report, however, suggests that this is not necessarily the
case213. Despite the sustained virologic response (SVR), HCV-specific T cell
immunity was not enhanced. Several possibilities may account for these
findings. First, a simple decrease in antigen load may have led to a decrease in
cell response. Second, as described above, the inhibitory effects of IFNa on DCs
may dominate during systemic delivery to decrease T cell activation. Third,
treatment may selectivity enhance T cells with an antigen specificity not

represented in the functional assays used. As such, it will be important to follo
these T cells responses, especially CD8+ T cell response, after SVR to a variety
epitopes expressed by the particular virus that infected the patient.
Targeted activation of pDCs for HCV therapy may offer a more effective
strategy for enhancing the immune response. Our results evaluating HCV
specific immune responses in mice suggest that pDC-derived IFNa/p enhances T
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cell immunity. Although decreases in p D C number have been reported during
chronic HCV infection by us242 and others162,174, these pDCs still produce
significant amounts of IFNa/p upon stimulation. CpG trials by Coley
Pharmaceutical Group report good anti-viral activity suggesting that the CpG
motifs are effective in triggering IFNa in vivo. TLR7/9 agonist therapy may be
an important therapeutic strategy to promote CD8+ T cell immunity in patients
with compromised CD4+ T cell responses (i.e. HIV/HCV co-infected patients).

In all, host-virus interactions play a key role in dictating the
immunological outcome of HCV infection. Although we are still in the early

stages of understanding these interactions in vivo, the role of IFNa/p in respons
to HCV infection offers a salient example of the complexity with which HCV
modulates the immunologic outcome. Better tools for studying human
immunology and the development of a small animal model for HCV will add
tremendous insight into the mechanisms involved in the interaction of HCV with
its host, as well as novel mechanisms of immune evasion required for viral

persistence. A better understanding of the crucial aspects of this interaction wi
put us on more solid ground for designing therapeutic interventions to prevent
and possibly cure HCV infection.
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A p p e n d i x 1: Learning f r o m o u r s u c c e s s e s — Y e l l o w fever interacts
w i t h D C s to generate robust C D 8 + T cell i m m u n i t y

When looking to achieve a specific aim in almost all endeavors, it is helpful to
know what worked in the past. Accordingly, HCV research in general and my

thesis work in particular takes advantage of both natural resolvers and sustained
virologic responders to gain insight into successful immunity, disease
pathogenesis, and rational therapeutic design for HCV. Although we frequently
learn many things from these situations, these successes are sometimes not
widely studied. For example, the vaccine for yellow fever, developed in part

here at Rockefeller University, is an extremely effective vaccine that has been i
use for over 60 years to immunized over 400 million people; however, the
mechanisms associated with the robust immunity it generates are poorly
defined. During my thesis work, I had the opportunity to address some of these
questions in collaboration with Giovanna Barba-Spaeth in the Rice lab. It is my
hope that a better understanding of the effective components of the yellow fever
vaccine will bring us closer to developing an HCV vaccine.
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Al.l Abstract
The yellow fever (YF) 17D vaccine is one of the most successful live attenuated
vaccines available which confers life-long immunity to pathogenic YF, a
flavivirus related to HCV. A single immunization of YF17D induces both YF
specific T cell responses and neutralizing antibodies that can be detected for
many years after vaccination. Surprisingly, the mechanism for this robust and
long-lasting immunity has not been widely studied. Several recent reports have
shown flavivirus interaction with dendritic cells (DCs); however, the mechanism
of YF17D interaction with DCs and the significance of this interaction in
generating T cell immunity have not been explored. Here, we show that YF17D
can infect immature and mature human DCs. Viral entry is Ca2+-dependent, but
independent of DC-SIGN as well as multiple integrins expressed on the DC
surface. Similar to infection of cell lines in vitro, YF infection of iDCs is
cytopathic. Although infection itself does not induce DC maturation in vitro,
TNFa-induced maturation protects DCs from YF-induced cytopathogenicity.
Furthermore, we show that DCs infected with YF17D or YF17D carrying a
recombinant epitope can process and present antigens for CD8+ T cell
stimulation. This work offers insight into the immunologic mechanisms
associated with the highly effective YF17D vaccine that may guide effective
vaccine design.
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A1.2 Introduction
"He gave to man control over that dreadful scourge, yellow fever."
President Eliot, Harvard University
Upon conferring master of arts to Dr. Walter Reed

Yellow fever had tremendous public health impact on Central and Northern
America from the 1600's until early 1900's infecting over 300,000 people with a
mortality of over 40%. It was named "yellow" fever for the characteristic
jaundice it produced in infected individuals. In his pioneering work presiding
over the Yellow fever Board in Cuba in 1900, Major Walter Reed and his
colleagues proved Carlos Juan Finlay's theory, that the mosquito, Aedes aegypti,
was the vector for this transmissible agent258. The following year, Reed's

colleague, Dr. James Caroll, showed that yellow fever agent was filterable259. YF
is classified in the same family as HCV, Flaviviridae, based on sequence and
physical similarities.
In 1930's, Max Theiler's seminal work on YF grew out of his observations

that propagation of the virus in mice produced an attenuated virus that was less
infectious in rheseus macques. After his move to the Rockefeller Foundation
(renamed Rockefeller University), Theiler along with Hugh Smith produced an
attenuated virus in chicken embryos that conferred protection to pathogenic
infection260. In 1951, Theiler was awarded the Nobel Prize for his discovery of
live attenuated yellow fever vaccine.
The yellow fever vaccine strain 17D (YF17D) is a live attenuated vaccine
that has been used for over 60 years in more than 400 million people for
vaccination against yellow fever virus with a remarkable record of safety and
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efficacy261. The vaccine strain Y F 1 7 D w a s generated from the wild-type strain

Asibi and differs from Asibi by only 32 amino acids, 12 of which are clustered in
the envelope protein262. Viscerotropism of the parental Asibi is markedly
reduced in YF17D but the basis of the attenuation remains unknown.
Furthermore, the YF17D receptor and mechanism of entry are not known.
YF17D vaccination generates both neutralizing antibodies and T cell

responses that persist for many years 263,264. Given its safety and efficacy, YF1
has been engineered as vaccine vector for antigens of other flaviviruses such as
dengue, Japanese encephalitis and West Nile viruses. Some of these chimeric

viruses are in phase II clinical trials265. YF17D can also be engineered to deliv
epitopes from unrelated pathogens and it is able to induce protective immunity

against heterologous agents266,267. The antibody response most likely accounts fo
the effectiveness of the vaccine; however, a role for cell-mediated immunity in
generating an effective immune response has also been suggested264. Only
recently have YF-specific human CD8+ T cell response been assayed268, but the
immunologic mechanisms associated with YF-specific CD8+ T cell priming are
still unknown.
As discussed in the introduction, DCs are potent antigen presenting cells
that play a crucial role in regulating the adaptive immune response52. DCs may
interact with pathogens in peripheral tissue via direct infection or via
phagocytosis of either infected cells or viral particles. Upon exposure to
inflammatory signals or certain pathogens, DCs undergo a programmed
phenotypic maturation program coincident with CCR7 upregulation and
migration to the lymph node for engagement and activation of T cells. In
addition, DC maturation confers resistance to cytopathogenicity of some viral
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infections, facilitating T cell priming m. DC-SIGN, a D C specific I C A M - 3
grabbing non-integrin that is present most robustly on immature dendritic cell
(iDCs), mediates entry of dengue virus into DCs92,93 and binding of the HCV
envelope protein269.
In this chapter, I explore the interaction of YF17D with human DCs. We

investigate the ability of YF17D to infect DCs, the requirements for viral entry,
and the cytopathic effect of YF17D in DCs. Furthermore, we evaluate the
immunologic determinants of DC infection by monitoring T cell responses to
endogenous and model antigens from YF17D vectors. This work provides new
insight into the immunologic mechanisms associated with the highly effective YF
vaccine and may provide clues relevant to effective vaccine design.

A1.3 Materials and Methods
Isolation and Preparation of cells

PBMCs, DCs, and T cells were prepared as previously described168. PBMCs were
isolated from whole blood by sedimentation over Ficoll-Hypaque (Amersham
Pharmacia Biotech, NJ). T cell enriched and T cell depleted fractions were
prepared by adherence to plastic in 1% single donor plasma. iDCs were prepared

from the T cell depleted fraction by culturing cells in the presence of 1000 U/ml
GM-CSF (Berlex, Seattle, WA) and 500-1000 U/ml IL-4 (R&D Systems,
Minneapolis, MN) for 6 days 170. To generate mature DCs, cultures were
stimulated on day 6 with 50 ng/ml TNFa (Alexis Biochemicals) and lOmM PGE-

2 (Sigma) for 36-48 hr 171. Patient material was obtained as per protocol approve
by the IRB The Rockefeller University Hospital (JKR-0397), and all patients gave
written informed consent.
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Preparation of virus stocks
Yellow fever 17D (YF17D) viral stocks were derived from pACNR/FLYF
plasmid containing the full length infectious YF17D genome under a SP6
promoter270. In vitro-generated RNA transcripts were electroporated in SW13
cells as previously described 271. Virus stocks were harvested at 48 hrs post-

transfection with typical yields of 107-108 PFU /ml as determined by plaque assay
on SW13. Single use aliquots were stored frozen at -80°C until use. YF17D/M1
was constructed by inserting the influenza HLA-A2.1 CTL epitope of matrix
protein (GILGFVFTL)272 between yellow fever NS2B and NS3 proteins. Two
specific oligonucleotides containing the Ml epitope sequence (forward 5'aggggagcgcgcagaagtggaattttaggattcgtgttcacgctcggtcaccggagaagt-3' and reverse
5'-acttctccggtgaccgagcgtgaacacgaatcctaaaattccacttctgcgcgctcccct-3') and two
YF17D-specific primers were used to generate two PCR fragments containing the
influenza Ml epitope and a portion of the NS2B or NS3 gene, respectively. One
of 50pil of each PCR reaction was mixed together and used as template for PCR
with YF17D-specific primers lying in NS2B and in NS3. The final product was
digested with BssHII and BstEII and cloned in YF17D2B/3 described
elsewhere267. The recombinant virus was recovered 48 hrs post-transfection of
SW13 cells with infectious RNA and tested for stability by PCR and sequence

analysis of the region overlapping the insertion. UV-inactivation was carried out
with a GS Gene-Linker UV chamber (Bio-Rad) using the sterilizing program.
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Infection of Cells

DCs were washed in RPMI and infected for 1 hr at 37°C using the indicated
PFUs. UV-inactivated virus was used as a negative control. The infection was
quenched with 5% pooled human serum and washed twice to remove excess
virus. For EDTA/EGTA blocking, DCs were washed twice in PBS without ,2+
Ca2
and Mg2+ and lOmM EDTA or EGTA was added before infection. For antibody
blocking, DCs were washed in RPMI and resuspended in 1% FBS/PBS. DCs
were incubated with 10^g/mL of antibody (DC-SIGN (612) or avP3 (Chemicon))
or 100^g/mL RGD tripeptides (Sigma) for 15 minutes at room temperature prior
to infection. Following 1 hr infection, DCs were resuspended in conditioned
media with or without TNFa / PGE-2 maturation stimulus as indicated and
incubated 24 hrs before monitoring for infection.

Immunostaining for FACS Analysis
Surface staining was done in serum containing media at 4°C. Anti-CD14, CD25,
CD40, CD83, CD86, HLA-DR, and isotype control were obtained from BD
Biosciences. Cytoperm / CytoFix Kit from BD Biosciences was used for fixation
and permeabilization. MAb 1A5 is a mouse monoclonal antibody against the
nonstructural protein NS1273 and C12 is a rabbit polyclonal antisera that
recognize the nonstructural proteins NS4A and NS4B 274. Secondary antibodies
used were from Jackson (PE) or molecular probes (APC).
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Plaque Assay
For plaque titration serial 10-fold dilutions were used to infect monolayers of
SW13 for 1 hr at 37°C. After infection cells were overlayed with 0.6% agarosecontaining medium and plaques were allowed to develop at 37°C for 4 days.
Plaques were fixed in 7% formaldehyde for 1 hr and stained with crystal violet
(1.25%in20%EtOH)271.

Detection of influenza-specific T cells by ELISPOT
DCs and T cells were plated in 96-well Millipore plates coated with 5}xg/ml of
anti-IFNy mAb (Mabtech, Mab-1-D1K). Cultures were incubated for 24-36 hrs at
37°C, washed with mild detergent, and incubated with l[xg/ml biotin-conjugated
anti-IFNy mAb (Mabtech, Mab 7BG-1). Spots were visualized using Vectastain
Elite Kit (Vector Laboratories) and AEC substrate. Evaluation was performed in
a blinded fashion by an independent service (Zellnet Consulting, Inc., NY) using
an automated ELISPOT reader (Carl Zeiss, Inc., NY). Spots represent IFNy

production by single cells and are reported as spot forming cells (SFCs)/106 cell
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A1.4 Results
YF17D infects immature and mature DCs
To test the hypothesis that the immune response induced by YF17D vaccination
is generated by direct infection of DCs, we exposed both immature and mature
human monocyte-derived DCs with characteristic surface phenotype to YF17D
virus. FACS analysis for intracellular nonstructural protein NS1 showed robust
expression in both immature DCs (iDCs) and mature DCs (mDCs) infected at 2

or 20 PFU/cell (Fig. A1.1A). Detection of nonstructural viral proteins not present
within the virion indicates productive infection. Infection was confirmed using
an antibody to nonstructural proteins NS4AB (Fig. A1.1B). In addition, virus
production in both the iDC and mDC cultures was monitored by plaque assay.

Results showed a 3-log increase in infectious particles within 24 hrs that peaks
hrs post-infection confirming productive infection (Fig. A1.1C). No significant
difference in infectious particle production was seen between iDC and mDC
cultures. To exclude antibody-mediated enhancement of YF17D DC infection,
DCs were generated in plasma from non-immunized donors and in control
experiments, blocking antibodies against the Fc-receptor (FcR) did not block
YF17D infection (data not shown). These data demonstrate that YF17D can infect
and productively replicate in human DCs, and infection occurs irrespective of
their maturation state.
Other cell types were not as susceptible to YF infection. High-level virus
production was not seen in T cell, B cell or monocyte enriched PBMC (Fig.
A1.1D). In addition, infection of B cell lines (MC116, RAMOS, and Raji) did not
result in productive infection (data not shown).
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Figure Al.l. Immature and mature D C s are productively infected
by YF17D. A. Intracellular F A C S analysis of N S 1 expression in iDCs
and m D C s infected with 2 or 20 PFU/cell 48 hrs post-infection. B.
Intracellular staining of N S 4 expression in iDC infected with 2
PFU/cell. C. Virus production by iDC and m D C cultures measured
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and monocyte enriched P B M C fractions compared with iDCs.

195

IO4

In order to test if resident skin D C s exposed to Y F during natural
transmission by mosquito or subcutaneous vaccination are infected by YF,
langerhan cells (LCs) and dermal DCs (DDCs) were generated from CD34+
hematopoetic progenitor cells and exposed to YF17D275. FACS analysis for
NS4AB revealed that YF17D exhibited a significant preference for CD34+ derived
DDCs compared to LCs (Fig. A1.2).

DC infection is Ca2+ dependent
The cellular receptor involved in YF17D infection is unknown. In order to assess
a possible requirement for divalent cations, iDCs were pre-treated with lOmM
EDTA and then exposed to YF17D for 1 hr to evaluate their role in infection.
NS4AB expression at 24 hr was completely blocked by pre-treatment of DCs with
EDTA (Fig. A1.3A) whereas EDTA pre-treated DCs were still competent for
infection with influenza (Fig. A1.3B). EGTA treatment also blocked infection
indicating a Ca2+-dependent mechanism (Fig. A1.3A). Consistent with this
finding, addition of Ca2+, but not Mg2+, was able to overcome the EDTA block
(Fig. A1.3A).
In light of this result, we tested specific integrin blocking antibodies

including pi7 p3, avp3, p5, avp5, avp5 as well as RGD peptides to evaluate the rol
specific integrins in viral entry. Antibodies and peptides were used at
concentrations reported to be sufficient for blocking West Nile virus98. None of

the integrin blocking antibodies significantly inhibited infection as monitored b
NS4AB expression 24 hrs post-infection (Fig. A1.3C and data not shown). The

lack of inhibition by RGD peptides is consistent with previous reports suggesting
: 98,276'
YF17D infection is independent from the RGD motif
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Figure A1.2. Dermal D C s but not LCs are infected by YF17D.
Monocyte derived D C s , C D 3 4 + derived D D C s and LCs were exposed
to 2 PFU/cell Y F 1 7 D and stained for F A C S analysis after 48 hrs with
maturation stimuli. Cells were gated based on side scatter (SSC) and
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that stain positive for NS4.
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In addition, blocking antibodies against DC-SIGN93 did not inhibit Y F 1 7 D
infection (Fig. A1.3C). This finding is consistent with our data showing
equivalent virus production in iDCs and mDCs which significantly differ in DCSIGN expression (high in iDC, low in mDC) (Fig. A1.1C) as well as a recent
report showing the inability of DC-SIGN to permit infection in THP-1 cells92.
Although YF17D infection of DCs is Ca2+ dependent, the receptor for YF17D
remains elusive.

YF17D infection does not alter DC maturation in vitro
Several reports indicate that viral infection of DCs promotes or inhibits
maturation84"86. In order to evaluate DC maturation as a result of YF17D
infection, surface expression levels of CD83, CD86, and MHCII were assayed 36
hrs post-infection. Interestingly, infection alone did not induce robust DC
maturation. Although slight upregulation of CD86 and MHCII was observed
(data not shown), conventional maturation markers such as CD83 were not
expressed (Fig. A1.4A). However, in contrast to inhibition of maturation by

several infectious pathogens 85,86, YF17D infection did not inhibit TNFa-mediated
DC maturation (Fig. A1.4B).
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Figure A1.4 Y F 1 7 D infection does not induce or inhibit D C
maturation. A. iDCs infected with 10 P F U /cell were analyzed for
C D 8 3 surface expression. C D 8 3 expression of Y F 1 7 D infected
population (compared to m o c k infected) w a s analyzed 36 hrs postinfection. B. iDCs were infected with 10 PFU/cell and exposed to
T N F a / PGE-2 maturation cocktail. C D 8 3 expression of YF-infected
population (compared to m o c k infected) w a s analyzed after 36 hrs.
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Maturation protects D C s from YF17D-induced apoptosis
Since YF17D has been shown to be cytopathic in mammalian cells, we evaluated
potential cytopathogenicity in human DCs using a FACS-based assay for
monitoring apoptotic cell death. Similar to infection by several other viruses,
YF17D induces cleavage of caspase-3 in iDCs and triggers cell death. In a
representative individual, we show 37% (2 PFU/cell) and 54% (10 PFU/cell)
caspatag™-positive iDCs at 48 hrs post-infection (Fig. A1.5A). These values were

similar to the ones obtained in the SW13 cell line (29% at 2 PFU / cell and 69% a
10 PFU / cell). Interestingly, when we exposed infected iDCs to inflammatory
stimuli capable of inducing maturation, there was a significant reduction in the
YF17D-induced cytopathogenicity—9% (2 PFU/cell) and 13% (10 PFU/ cell) of
the total cells had activated caspase-3 48 hrs post-infection (Fig. A1.5A).
In order to confirm that iDC cytopathogenicity was YF17D-specific and
that caspatag™-negative mDCs were indeed YF17D-infected, we stained the
infected iDCs for CD83, YF NS4AB, and activated caspase-3. In a data set
representative of 3 similar experiments, gating on the YF-infected CD83" cells
showed 21% caspase activation compared to 6% in the YF17D-negative
population (Fig. A1.5B). In contrast, mature, YF17D-infected DCs (CD83+ / NS4+)
showed only 3% caspase activation (Fig. A1.5B). Plaque assays performed on the
supernatants from both cultures confirmed comparable levels of virus
production (data not shown). Based on this data, we conclude that the resistance
to YF17D-induced cytopathogenicity is dependent on DC maturation.
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A . Caspase activation is m e a s u r e d using C a s p a t a g ™ - F I T C in S W 1 3 ,
iDCs, or i D C s + T N F a , exposed to the indicated P F U of Y F 1 7 D virus
at 48 hrs. Tables indicate the percent of cells that w e r e caspatag™
positive. B. Y F 1 7 D infected i D C s or i D C s + T N F a w e r e identified b y
intracellular staining with N S 4 . C D 8 3 staining w a s used to
distinguish i D C vs. m D C . Caspase activation of the indicated cell
populations are indicated b y histogram a n d the percent C a s p a t a g ™
positive indicated.
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Infection of D C s allows for processing and presentation of endogenous and model
antigens
In light of the direct infection of DCs and the resistance to YF17D-induced cell
death upon maturation, we evaluated the ability of mDCs to process and present
endogenous antigens produced by YF17D. mDCs generated from subjects
vaccinated with YF17D were infected and used to stimulate autologous CD8+
and CD4+ T cells. IFNy ELISPOT results showed that infected DCs were able to
process and present YF17D antigen for antigen specific CD8+ and CD4+ T cell
stimulation (Fig. A1.6A). No T cell response was detected in non-immune
donors. Influenza was used as a positive control to show T cell responses in both
immune and non-immune donors.
Due to the efficacy of the YF17D vaccine, many groups have proposed its
use as a vaccine vector for generating CD8+ T cell immunity. We propose that

these vectors may directly infect DCs allowing for processing and presentation of
CD8+ T cell epitopes. We tested this hypothesis by constructing a YF17D vector
carrying the immunodominant HLA-A2.1 Ml CTL epitope from influenza matrix
protein. The Ml CTL epitope was inserted between NS2B and NS3 protein (Fig.

A1.6B). This site has been shown previously to tolerate small insertion of foreign
sequences266 mDCs from naive donors were infected with YF17D or chimeric
YF17D-M1 virus at 2 PFU/cell as described above and used to stimulate
autologous CD8+ T cells. IFNy ELISPOT results showed that YF17D-M1 infected
DCs stimulate robust Ml-specific CD8+ T cell responses similar to Ml-peptide
pulsed or influenza-infected DCs (Fig. A1.6C) while DCs infected with YF17D
alone did not stimulate IFNy secretion in the non-immune donor. Importantly,
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w a s measured by IFNy ELISPOT, as mentioned above.
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this is the first demonstration of a Y F 1 7 D 2B/3 chimeric virus presenting an
HLA-A2.1 CTL epitope for T cell stimulation, offering proof of principle for a
possible vaccine approach.

Al. 5 Discussion
YF17D infects DCs in Ca2+dependent fashion
Recent reports have identified the receptors for related flaviviruses West Nile

virus and dengue virus as avp3 and DC-SIGN, respectively92'9398. In addition, the
presence of an RGD motif in the ectodomain of the YF17D envelope protein
suggests a mechanism for interaction with integrins276. Both integrins and DC-

SIGN require divalent cations for structural and functional integrity. Consistent
with these findings, our data suggest that YF infection is Ca2+-dependent (Fig.

A1.3); however, direct investigation of the role of avp3 as well as numerous other
integrins using blocking antibodies failed to inhibit infection. Cyclo-RGD
peptides also do not competitively block YF infection which is consistent with
data suggesting that RGD motif in the envelope domain is not required for viral
spread; however, this does not formally rule out the RGD motif from playing a

role. The RGD motif in the envelope protein does not exist in YF Asibi262'276—thi
motif was acquired as a result of mutation during passage in chicken embryos.

The characterization of YF Asibi interaction with DCs may offer insight into the
role of this motif and integrins in DC infection.
Furthermore, our results, as well as other's92, suggest that, in contrast to
dengue, YF17D infection of DCs is not mediated by DC-SIGN. One explanation

for this difference may be the differential glycosylation of the envelope protein
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In contrast to dengue virus envelope protein which contains one or two N-linked
gly cans, the envelope protein of YF17D-204 used in these experiments is not
glycosylated277. Although other YF17D substrains (YF17DD and YF17D-213)
may be glycosylated, our data indicate that DC-SIGN interaction is not necessary
for infection and that YF17D interacts with DCs via mechanisms distinct from
related flaviviruses.

DC maturation prevents YF-induced cytopathogenicity
Many viruses have been suggested to play an active role in immune
evasion via inhibition of DC maturation. Our data, however, suggest that YF17D
does not inhibit maturation (Fig. A1.4). These results suggest therefore, that in
the context of YF17D vaccination, release of inflammatory cytokines in
peripheral tissue may play an important role in triggering DC maturation; this
will allow for DC migration to the lymph node and subsequent T cell
engagement and priming (Fig. A1.7). Consistent with this model, an increase in
TNFa has been detected in subjects vaccinated with YF17D278.
The ability to undergo functional maturation plays an important role in
preventing YF-induced cytopathogenicity. This resistance to cytopathogenicity
could play an important role in allowing infected DCs to remain alive for

trafficking to lymph node and priming of T cell responses. It will be interesting
to evaluate the effect of pathogenic YF Asibi on DC maturation and
cytophathogenicity.
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Maturation Enables Survival and
Migration to L y m p h N o d e
Ca2+ -dependent
Infection

Inflammatory
Signals

Yellow
Fever

Figure A1.7. Schematic for D C / Y F interaction in generating T cell
immunity. In the periphery, iDCs m a y interact with various.
Calcium-dependent infection of D C s does not itself mature the D C s ;
however, infection does not block normal maturation by other
inflammatory signals. Maturation prevents the cytopathic effects of
YF, enabling migration to the lymph node and priming of T cells.
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Infected mature D C s present antigen for T cell activation
The ability of maturation to protect DCs infected in the periphery from
apoptosis enables antigen loaded DCs to traffic to lymph nodes for T cell
engagement. In vitro analysis indicates that these DCs are fully capable to
present antigen for CD8+ and CD4+ T cell activation (Fig. A1.6). Although the
mechanism of processing and presentation of endogenous CD4 epitopes remains
poorly characterized, the YF17D epitopes presented may be derived from the
small percentage of dying infected cells or by alternative mechanisms of
processing 279. Similarly, infected DCs can process and present heterologous
epitopes from chimeric viruses indicating that that DC infection may be a potent
mechanism for robust immunity seen in vivo. These data indicate that YF17D
vector is capable of delivering endogenous and recombinant epitopes to the
surface of the DC enabling specific T cell activation. In the presence of a
maturation stimulus produced in infected tissue, we therefore propose that Ca2+dependent direct infection of human DCs may offer a mechanism for the robust
and long-lasting immunity associated with the YF17D vaccine.

More questions remain for YF
It is surprising that even at after 100 years since the discovery of YF, the
mechanisms associated with its pathogenesis and immunity are not well
understood. In light of the interactions of other flaviviruses with DCs, we
designed these experiments to explore the interaction of YF17D with DCs.
Although infection of DCs is robust, selective, and Ca2+-dependent, the
receptor(s) affording these characteristics remain elusive. A better
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understanding of the surface proteins involved in this infection m a y identify
target molecules on DCs for vaccine delivery. Interestingly, the majority of
amino acid changes between YF17D and pathogenic YF Asibi exist in the
envelope protein262. Thus, a better understanding of the molecules involved in
infection may offer insight into tropism differences between YF17D and Asibi
that result in immunity versus disease.
Mouse models are of limited significance since mice are not a true host for
YF. As such, it is crucial to evaluate these questions in human models. Of

particular note, is the nature of the infection of YF in the skin (during natural
transmission by the mosquito) as well as in the subcutaneous tissue (during
immunization). While we have made an attempt to evaluate the infectivity of
DDCs and LCs using CD34+ derived cells (Fig. A1.2), these experiments need to
be performed in skin ex vivo to understand YF interaction with resident skin DCs
in both immunity and disease.
Finally, the efficacy of YF as a vaccine vector needs further clarification.
Although we have shown proof of principle that human DCs can process and
present the minimal Ml epitope inserted into the the NS2B/3 site, the

components of this process have yet to be defined. The role of the viral protease
host proteasome, length of flanking regions, and site of insertion in mediating
efficient presentation by DCs will offer tremendous insight into vaccine vector
design.
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A p p e n d i x 2: T h e D C database

As mentioned in chapter 3, transcriptional changes associated with maturation
and IFNa/p treatment were monitored by affymetrix analysis using human
U133A microarrays. The amount data obtained in these experiments is
enormous and we are still only beginning to harness this resource. In order to
manage such a large amount of data, I adapted a database provide by our

collaborator Dr. Nir Hacohen at MIT to facilitate searching and navigation of the
data. Our initial work with the database has offered us important insight into
DCs regulation of IFNa/p signaling (Chapter 3) as well as novel regulation of
indoleamine 2,3-deoxygenase activity in DCs280.

Preparing the database
Biotinylated cRNA for hybridization was prepared as per Affymetrix Manual
(see Chapter 2, Materials and Methods) and loaded onto the U133A microarray.

This array analyzes expression of 18,400 transcripts and variants, 14,000 of whic
are well characterized genes. Each array is chemically loaded with over 22,000
probe sets. Each probe is a 25-mer chosen to allow selectivity for the gene of
interest. For each gene probe a 'mismatch probe' exist with a single base pair
mismatch in the middle of the 25-mer. This allows for a quantitative index of

signal to noise. MAS5.0 analysis software calculates the p-value for the intensit

signal of the specific probe versus that of the mismatch probe. p<0.05 is used to
determine if the gene expression is present (P) above the noise or absent (A)
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below the level of detection. Notably, background depends on the specific probe
so the absolute level of signal intensity only indicates relative expression.
The data generated following MAS5.0 analysis was exported to Excel and
the comparisons of interest were created. For example, comparison of mDC
signal to iDC signal intensity was generated for the whole list of genes. Both
forward (mDC / iDC) and reverse (iDC / mDC) ratios were created to facilitate
searching. These data were then imported into Filemaker pro according to the
specific donor preparation. Data from individual donors were linked for
multiple donor comparisons using the Affymetrix ID numbers. A master
template was created with search criteria for various comparisons used in our
analysis (Fig. A2.1). Searches can be performed based on gene name/symbols,
comparison ratios (using >, <, or = functions), absolute value (using >, <, or —
functions), and/or absent/present calls (using "a" or "p," respectively). Another
template was created to allow for quick scanning of search results (Fig. A2.2).
This list displays gene symbol, genename, and absolute signal values. Of note,
not all the probes have been associated with defined genes and may therefore
appear without a gene name. As the gene names become available, the database
can be update with new lists linked to the Affy ID.

214

Gene N a m e and Symbol
Link to NLM
for full gene
details
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p-value statistic calculated by
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Figure A2.1.
D C Database. Affymetrix data from individual donors
(indicated by color). The top panel indicates gene symbol, name, and
Affy ID. Searches m a y be performed for any of the fields. The
middle panel shows comparison ratios of samples indicated in the
left hand column. Both forward and reverse ratios are shown.
Searches can be performed using >, <, or = functions in these fields.
The bottom panel shows absolute signal value, A / P calls, and pvalue calculated by MAS5.0 software of the samples in the left hand
column. Absolute signal can be searched with >, < or = functions and
A / P call with text A or P.
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Figure A2.2. Genes upregulated u p o n T N F o / P G E - 2 maturation.
The top 45 genes with the highest comparison ratios of m D C / i D C
over multiple runs are displayed in a table in filemaker database.
This arrangement allow quick scanning of gene names (pink and
green), absolute signal for i D C (beige) and m D C (tan), and gene
regulation during C D 4 0 L engagement (orange).
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Transcriptional Profiles of iDCs verus m D C s : the gift that keeps giving
One important analysis performed is the set of genes regulated during DC
maturation (Fig. A2.2 and A2.3). The majority of genes do not change by greater
than 2-fold during maturation providing an important internal control.
However, a significant number of genes are either up or down regulated during
maturation. Many of these transcriptional changes are consistent with known
phenotypic and functional changes associated with maturation (Fig. A2.3). For
example, iDCs express high levels of TLRs and antigen capture receptors to
allow them to respond to PAMPs and capture antigen for initiating an immune
response. Upon maturation, chemokine receptor (CCR) 7 is upregulated
allowing migration to the lymph node. mDCs also upregulate important
cytokines such as IL-12 and characteristic maturation marker such as CD83.
The transcriptional profiles associated with maturation have been very
important for our analysis. These data were mined extensively to provide a
candidate list of genes responsible for the dual effects of IFNa/p described in
chapter 3. Furthermore, we have made an effort to characterize the role of
several interesting genes whose role in DC maturation is not well understood.
Deborah Braun, a post-doc in Matthew Albert's lab, tackled the question of
indoleamine 2,3-dioxygenase (IDO) upregulation in mDCs. IDO is an enzyme
involved in tryptophan catabolism and is implicated in T cell tolerance281. Her
work showed that while PGE-2 induces the expression of IDO mRNA, a second
signal by TNF-R or TLR engagement is required to induce IDO activity (Fig.
A2.4)280.
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Figure A2.3. Genetic Signature of immature and mature D C s .
Absolute signal intensities of iDCs versus m D C s are displayed as a
dot plot. Red lines indicate a lOx change, blue lines 5x change, and
black lines a 2x change in comparison ratios. The numbers in
parentheseses indicate the number of genes associated with the fold
change. Specific genes are indicated.
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Figure A2.4. T w o step regulation of indoleamine 2,3-dioxygenase
(IDO) induction during D C maturation. PGE-2 acting through
receptor EP-2 activates I D O transcription. However, a second signal
from a T L R or T N F - R is required for protein expression and
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The database allows us to continue to push our functional findings to molecular
mechanism in a relatively systematic fashion. For example, several genes have

been identified as potential candidates in the regulation of IFNa/|3 signaling in
DCs based on the expression profile and likely interactions with STAT signaling
molecules. We are currently evaluating various technologies such as retroviral
shRNA to identify the importance of these genes in our functional assays. As we
learn more about the interconnectedness of these signaling pathways, I believe
that the database will continue to be a very important tool in aiding these
discoveries.
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A p p e n d i x 3: C R I - 0 5 0 5

During my thesis work, I had the unique opportunity to write and participate in

a clinical protocol in collaboration with Andy Talal. As I mentioned in chapter 2

our desire to define the function of circulating DCs required larger quantities o
PBMCs. As such, we wrote clinical protocol CRI-0505 in order to use
leukapheresis to obtain large amounts of PBMCs. This experience was important
for me for two reasons.
First, as an MD/PhD student, it gave me my first experience with

translational research. This type of research is not easy. The following document
shows the preparation that goes into coordinating this type of study. Research
on human samples involves numerous concerns and must be extensively
reviewed both scientifically and ethically. Once the protocol is approved,
technical difficulties exist in physically obtaining samples. Sometimes patients
cannot give detailed histories; sometimes you get a smaller sample than you
would like; sometimes appropriate controls are not available; and sometimes you
get no sample at all. However, for many diseases in which animal models are
not available, we must perform the highest quality science with human samples
in order to gain insight into human diseases. Despite these difficulties, I was

extremely fortunate to have the opportunity to do this work in collaboration with
the staff at the Rockefeller University Hospital (RUH). The infrastructure setup
at RUH removes a significant amount of administrative and technical problems
associated with human research. I am very grateful for the professional and
courtesy help of all the staff, nurses, and doctors at RUH.
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Secondly, this work served as a constant reminder of w h y I do this
research—to help the people affected by HCV. I was involved in coordinating
each leukapheresis and had the opportunity to explain to most of the donors the
goals of our research. I am very grateful for their generous contributions.
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Abstract, Rationale of Study, Research Plan and Procedures.
a) Abstract
Hepatitis C virus ( H C V ) infects approximately 200 million people
worldwide. Current estimates indicate that 3 0 % of infected individuals
spontaneously resolve the infection. Both resolution and protection correlate
with the presence of HCV-specific T cell responses. In the 7 0 % of individuals
that progress to chronic H C V infection, pegylated interferon alfa (IFNa) and
ribavirin enables - 5 0 % of individuals to sustain virologic responses after
treatment is discontinued. The role for HCV-specific T cell responses and
IFNa highlight the importance of understanding D C function during H C V
infection as myeloid D C s are required for priming T cells in vivo and
plasmacytoid D C s (pDCs) are the principle cell type responsible for
endogenous IFNa production. In this study, w e characterize the phenotype
and function of these D C s in vivo. Furthermore, w e evaluate mechanism of
H C V antigen presentation by D C s as well as adaptive and innate signals
which regulate the immunologic outcome of antigen presentation (T cell
activation, tolerance, or ignorance). This study will offer insight into the
pathogenesis of H C V and effective immunotherapy strategies.
b) Overview
Hepatitis C virus ( H C V ) infects more than 100 million people worldwide
posing a significant public health risk. Approximately 3 0 % of people
infected with H C V resolve infection while 7 0 % progress to chronic
infection. M a n y studies have explored the mechanisms by which the virus
is able to circumvent both humoral and cell-mediated i m m u n e responses.
Although an HCV-specific humoral response is commonly seen in H C V infected chimpanzees and h u m a n s , HCV-specific antibodies are not
capable of conferring protection34. Instead, protection in chimpanzees has
been s h o w n to correspond with expanded populations of HCV-reactive
CD8+ T cell responses. Similarly in humans, tetramer analysis of CD8+ T
cells from successful resolvers indicates the presence of HCV-specific
CD8+ T cells, which are absent in chronically infected patients40. To better
define these distinct immunologic outcomes, and gain insight into the
pathogenesis of chronic H C V infection, w e propose to explore the role of
dendritic cells (DCs) in H C V infected patients across the spectrum of
disease.
b) Hypothesis
i. Circulating populations of dendritic cell in HCV patients are
phenotypically and functionally normal.
ii.
H C V encoded proteins modulate D C function through direct
interaction with surface receptors (e.g. C D 8 1 or DC-SIGN) or through
engagement of intracellular signaling proteins (e.g. PKR), thus
resulting in the selective inactivation of HCV-reactive CD8+ T cells.
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c) A i m s
i.

ii.

To enumerate and characterize circulating populations of D C s in
patients with H C V . This will be performed on fresh blood or P B M C s
isolated from a leukapheresis sample. W e will focus our attention on
the rare CDllc+ myeloid D C and the CD123+ plasmacytoidal D C
(approximately 0.2 - 0.5% of the P B M C fraction), as w e believe the
study of such cells will provide better insight into D C function in the
native state.
To identify HCV-mediated points of dysregulation whereby
dendritic cell / T cell interactions result in the selective tolerization of
HCV-reactive T cells.

Aim 1. To investigate phenotypic and functional characteristics of circulating DCs.
Using Miltenyi Bead technology, w e will isolate CDllc+ myeloid and
CD123+ plasmacytoidal DCs. Briefly, using the Miltenyi microbeads, cells
can be separated from complex cell mixtures to very high purity within
minutes. They are specifically labeled with super-paramagnetic M A C S
MicroBeads. After magnetic labeling, the cells are passed through a
separation column that is placed in a strong permanent magnet. The column
matrix serves to create a high-gradient magnetic field. The magnetically
labeled cells are retained in the column while non-labeled cells pass through.
After removal of the column from the magnetic field, the magnetically
retained cells are eluted. Both labeled and non-labeled fractions can be
completely recovered. Using this approach it will be possible to isolate the
respective D C populations to > 9 5 % purity.
We will employ antibodies specific for the BDCA-2 antigen for the
isolation of CDllcCD123+ plasmacytoid dendritic cells in blood15*151. B D C A 2+ D C s show a plasmacytoid morphology, express the pre-T cell receptor achain and are C D 4 5 R A + , CD14- and CD2-. They express neither myeloid
lineage markers like C D 1 3 and CD33, nor Fc receptors like CD32, C D 6 4 or
FceRI, and are negative for B D C A - 3 and C D l c (BDCA-1).
Use of the antibody specific for CDlc will be used for isolation of
circulating myeloid DCs. CDlc is specifically expressed on dendritic cells
which are CDHc1"8*1 CD123low and they represent the major subset of
myeloid dendritic cells in blood150. CDlc+ dendritic cells show a monocytoid
morphology and express myeloid markers such as C D 1 3 and C D 3 3 as well
as Fc receptors such as CD32, C D 6 4 and FceRI. Furthermore, they were
determined to be CD4+, Lin, CD2+ and C D 4 5 R O A In blood, in addition to
dendritic cells, a subset of B cells also expresses CDlc. For this reason, w e
will first deplete the P B M C fraction using C D 1 9 for negative selection,
followed by isolation of the CDllc+ myeloid DCs.
Cells will be analyzed phenotypically by flow cytometry; their ability
to undergo normal maturation will be assessed by placing them in culture
for 24-36 hrs; and their ability to prime allogeneic T lymphocytes will be
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assessed. Additional studies will include analysis of cells for negative and
positive strand H C V R N A ; and quantification of IFN-a released in the
respective cell populations in response to H C V patient versus control
plasma.
This study is designed for the collection of large numbers of PBMCs, thus
allowing us to study circulating populations of D C s — C D l l c + myeloid
D C and C D 1 2 3 + plasmacytoidal D C s . Note, these populations constitute
<0.5% of the P B M C s ; therefore to perform functional studies, >250cc of
blood are required. This has been difficult to obtain by blood draw and as
proposed below, leukapheresis will yield enough material to run replicate
studies.
If our hypothesis is incorrect and there is indeed a defect in a subset of
dendritic cells that distinguishes patients w h o resolve vs. those that progress
with chronic H C V infection, w e will re-focus our efforts to characterize this
finding.
Aim 2. To monitor the presence of HCV-specific memory T cells with DCs crosspresenting cell associated H C V proteins.
Tetramer analysis has identified HCV-specific T cells in patients w h o
successfully resolve the virus. While useful reagents, this method for T cell
characterization is limited to those patients with c o m m o n M H C alleles
and viral epitopes that have been defines as strong binders of the
respective M H C molecule. A s M H C molecules are highly polymorphic
and the H C V genome is itself variable across patient populations, w e
propose to use antigen cross-presentation assays for the screening of
HCV-reactive T cells. In these experiments, w e will use an osteosarcoma
cell line with tetracycline-repressible H C V protein expression. These cells
express full length H C V , genotype lb. W e will monitor the presentation of
H C V antigen by patient D C s , whereby antigen is derived from
internalized apoptotic osteosarcoma cells. The activation of patient T cells
will be monitored using IFN-y ELISPOT assays. A s a positive control
antigen in these cross-presentation studies, the osteosarcoma cell line will
be infected with influenza virus allowing us to monitor influenza reactive
cells present in the patient population.
Cross-presentation of antigen derived from HCV-expressing cell lines. W e have
previously analyzed the response of HCV-expressing tumor cell lines to
apoptotic-inducing stimuli. W e have also assessed the phagocytosis of the
apoptotic cell lines by D C s and demonstrated their ability to transfer
antigen for the loading of M H C I/peptide complexes and the activation of
influenza-reactive CD8+ T cells. These assays have been estalished in
normal control individuals. With large quantities of P B M C s from H C V
patients, w e n o w propose to look at responders versus non-responders,
comparing the frequency of HCV-specific T lymphocytes. W e hypothesize
that there will be a qualitative difference in T cell reactivity, present in
patients w h o resolved H C V and absent in those w h o progress to chronic
infection. A s previously described193,282, apoptotic cells will be exposed to
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D C s and cultured with patient T cells to evaluate the responsiveness to
H C V antigen. Assays for monitoring T cell activity will include ELISPOT
and intracellular cytokine stimulation assays.
Regarding the use of the osteosarcoma cell line, our previous results have
demonstrated that there is n o baseline allo-reactivity in normal
individuals. A s a result, these cells m a y be used as a vehicle for the
delivery of viral antigen.
In addition to characterizing CD8+ T cells responses, w e will also screen
for the presence of HCV-reactive CD4+ T cells. Insight into the helper T
cell i m m u n e repertoire will aid in the testing of our hypotheses regarding
cell-mediated HCV-specific T cell tolerance. Positive controls for the CD4+
T cell assays will include reactivity to H C V peptides. W e will also employ
influenza antigen as a non-modulated antigen control for both the CD4+
and CD8+ T cell i m m u n e assays.
d) Primary outcomes
Demonstration of phenotypic and functionally normal D C s in the circulation
of H C V patients as detailed above. Briefly, > 9 5 % of the isolated circulating
D C s will take on a CD83+ H L A - D R m mature phenotype after 24-36 hours in
culture. These cells will be able to stimulate an allogeneic T cell response
with >100,000 counts per minute at a ratio of 100 T cells : 1 D C , as measured
in a thymidine incorporation assay.
e) Secondary outcomes
A secondary outcome of this study will be the identification of
HCV-reactive T cells in patients w h o have resolved their H C V infection. A
positive T cell response will be defined as >50 SFCs / IO6 CD8+ T cells.

f) Study design
This is an observational study. Subjects with chronic or resolved H C V
infection as defined below are eligible. In this study, w e will enroll a total
of 10 patients with chronic H C V and 10 patients w h o resolved infection.
All patients will be leukapheresed for purposes of harvesting white blood
cells and plasma for immunologic study. Prior to the leukapheresis,
patients will be enrolled by a study investigator or a clinical collaborator;
two red-top tubes will be collected at that time for pre-screening of
patients for H B V , H I V and syphilis.
W e will obtain peripheral blood by leukaperesis, but venipuncture will be
offered as an alternative to this procedure.
Initial screening of patients will occur at either The Rockefeller University
Hospital or by the collaborating physician. All leukapheresis procedures
will take place at The R U H .
i) Identification of Patients
Patients will be identified by collaborating physicians.
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ii) Leukapheresis and Blood collections
All patients will be leukapheresed at The Rockefeller University Hospital.
Samples will be stored at room temperature.
iii) Schedule of events
Screening. Screening will be completed within 10 days, but no greater
than 30 days, and at least 24 hours prior, to study entry.
Medical History: The Principal Investigator's designee will perform a
pertinent medical history. A detailed medical history will be provided by
the collaborating physician.
Complete Physical Examination: The Principal Investigator's designee
will perform a complete physical exam at the indicated times.
If any laboratory result is outside the reference range and is considered to
be clinically relevant by the designee of the PI, the test will be repeated at
appropriate time intervals until it returns to baseline or becomes a
clinically insignificant finding.
Complete Blood Count: including differential white blood cell count,
absolute neutrophil count, hemoglobin and platelet count.
Hematologic Tests: PT/PTT.
Blood Chemistries: Calcium, prior to leukapheresis.
Viral screens: Hepatitis B surface antigen, H I V antibodies, Syphilis screen.
H L A haplotype: complete H L A haplotype is obtained as part of the
patient database, but is not used as a clinical screening parameter. Results
of H L A haplotyping do not need to be available prior to leukapheresis at
week 0.

g) Statistical model
The primary variables will be the enumeration of D C subsets and
determination of myeloid and plasmacytoid D C phenotype and function. In
preliminary data, two tailed non-parametric comparisons (Mann-Whitney
test) were used to calculate p values for differences in myeloid and
plasmacytoid D C enumeration, as well as total IFNa production by P B M C s ,
as this method allows for data with a non-Gaussian distribution, p values for
data normalized on a per cell basis (e.g. IFNa production per plasmacytoid
D C ) was evaluated with a two-tailed parametric comparison (unpaired t
test, Welch corrected).
Statistical significance will be set using 9 5 % confidence intervals (p value
0.05). Based on preliminary standard deviations for n=17 chronic H C V
patients (myeloid D C S D = 0.40 and plasmacytoid D C S D = 0.17), 20 patients
will give us 9 5 % power to detect a difference in means of 0.47 for myeloid
D C s and 0.20 for plasmacytoid DCs. A s with preliminary data from myeloid
DCs, it is possible to obtain "statistically significant" results with very low
power. Failure to reject the null hypothesis will be complemented with
equivalence testing to evaluate the lack of difference between H C V and
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normal populations. Briefly, if addtition of one standard deviation
statistically increases the H C V population relative to normal controls while
subtraction of one standard deviation statistically decreases it, equivalence
will be concluded provided the power is significant.

10. Subjects of Study:
Study group: Subjects for study will be chosen on the basis of a definitive
diagnosis of prior or ongoing H C V infection as based on seropositivity and/or
viral load. These patients are expected to fall into three distinct groups based on
the natural course of disease: complete resolvers, with no plasma H C V titers;
sustained responders, whose H C Vtiterdrops below the level of detection for
>6months post-IFN-a and ribavirin therapy; and chronically infected, patients
w h o have persistent high-titer plasma H C V . For purposes of this study w e
combine groups 1 and 2 as both populations have cleared infection and
presumably harbor HCV-specific T lymphocytes40. All H C V patients will
receive leukapheresis or whole blood donation (360cc).
Inclusion/exclusion criteria
Screening to determine eligibility (with the exception of H L A haplotyping) will
be completed within 10 days and not less than 24 hours prior to study entry.
—Disease Characteristics—
1. Confirmed H C V infection based on serologic studies and /or plasma H C V
titers
—Prior /Concurrent Therapy—
1. Recovered from toxicity of any prior therapy
2. Biologic therapy:
N o concurrent immunotherapy
Greater than 6 months post IFN-a and Ribavirin therapy
3. Chemotherapy:
At least one year post-chemotherapy for other medical condition.
4. Endocrine evaluation/therapy:
At least 4 weeks since corticosteroid treatment
5. Radiotherapy:
At least 4 weeks since radiotherapy
N o concurrent radiotherapy
6. Surgery:
Prior surgery allowed
—Patient Characteristics—
1.
Age: 18 and over, able to give written informed consent.
2.
Performance status: Karnofsky 70-100%
3.
Life expectancy: At least 12 months

229

4.

5.
6.
7.
8.

Hematopoietic:
W B C greater than 3,800
Absolute lymphocytes greater than 1,500
Platelets greater than 120,000
H b at least 9.5 g/dl
INR<1.5
Hepatic:
N o patients with decompensated cirrhosis.
Cardiovascular:
N o N Y H A class III/IV status
Pulmonary:
N o severe debilitating pulmonary disease
Other:
N o active infection requiring antibiotics
Not HIV, syphilis, or hepatitis B; anti-HIV and H b s A g antibody
negative obtained within 90 days prior to study entry
N o serious uncontrolled medical illness
N o currently active second malignancy other than non-melanoma skin
cancer (note: a patient is N O T considered to have currently active
malignancy if they have completed therapy and are n o w
considered by their physician to be at less than 3 0 % risk for
relapse)
N o history of vasculitis, including but not limited to systemic
necrotizing
vasculitides (polyarteritis nodosa
group),
hypersensitivity vasculitis, Wegener's granulomatosis.
N o receipt of i m m u n e modulators or suppressors within 30 days
prior to study entry, including but not limited to interferons
and thalidomide. N o active requirement for corticosteroids;
prior use is acceptable.
N o psychiatric illness or social condition that, in the opinion of the
investigator, would interfere with adherence to study
requirements.
N o alcohol or drug use or dependence that, in the opinion of the
investigator, would interfere with adherence to study
requirements.

No patient will be excluded who wants to enter this study, except for the
reasons detailed above. All w o m e n and minority patients will be encouraged to
participate. All referrals will be accepted after screening and w h e n appropriate,
entered into the study.

Control Group: Normative data will be obtained from individuals without
Hepatitis C or other k n o w n disease. Initially, buffy coat material obtained from
anonymous normal donors will serve as a control population. These samples
will be purchased from the The N e w York Blood Center. Depending on the
results for A i m #1, w e m a y wish to include H B V or H I V / H C V co-infected
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individuals in this study. At that time, an addendum to the current protocol will
be submitted.

11. Recruitment and Consent Procedures:
All H C V patients that are not otherwise medically excluded, will be eligible for
entry into the study. Recruitment will be performed in an office or hospital
setting with patient and family present; recruiters include Drs. A n d r e w Talal,
Ira Jacobson, Matthew Albert and Charles Rice. Consent will be obtained by
Drs. A n d r e w Talal, Ira Jacobson Matthew Albert, Randy L o n g m a n or
collaborating physicians. Information regarding the current expected prognosis
of H C V infection will be offered exclusively by the treating physician. Grounds
for exclusion from study will be solely medical.

12. Risks and Alternative Methods:
Risks associated with enrollment into this study include the discomfort
associated with phlebotomy and leukapheresis. Bruising at the site where the
needles are inserted m a y occur, particularly post-leukapheresis. All of these
procedures, in which needles are inserted into the body, have a minor risk of
introducing an infection, or causing bleeding in the area if needle insertion.
Leukapheresis is a means of drawing blood meant to save the subject large
amounts of blood draws. In leukapheresis, a procedure very m u c h like blood
donation for the subject, one needle is placed in each arm, and blood is collected
in the blood bank. Unlike blood donation, however, the patient's o w n red blood
cells (one component of the blood) are returned to the patient, in an effort to
prevent anemia sometimes associated with blood donation. Only a fraction of
the patient's serum and the white blood cells are kept for clinical study; the
white blood cells are replaced completely by the patient within a short period of
time through trafficking of cells out of the lymph nodes and spleen (minutes).
At no time during or after the leukopheresis is the patient
immunocompromised28*284.
The risks involve the use of an invasive needle, which m a y lead to bruising of
the arms where the needle is placed. There is a minor risk of bleeding from
anticoagulants given during the procedure; this anticoagulant (citrate) is
broken d o w n by the body within one minute, any bleeding will be stopped
by terminating the leukapheresis. The use of the citrate anticoagulant m a y
result in hypocalcemia. This is readily detected as the patients lips will begin
to tingle. Turns™ will be administered prophylactically and additional
Turns™ will be given as per needed. Rarely, patients m a y faint (suffer
hypotension due to a vasovagal reaction) during leukapheresis; for this
reason patients lie d o w n during the procedure and are accompanied at all
times by medical staff. The leukapheresis will be temporarily stopped and it
the patient continues to feel faint, the procedure will be ended prematurely.
Patients sometimes feel chilled during leukapheresis; if they do, they will be
given blankets to keep warm.
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Alternative methods: A n alternative to leukapheresis is a standard blood draw.
To obtain a sufficient number of cells for study, approximately 360cc of blood
would need to be d r a w n (3/4 unit of blood in a standard blood donation;
note however that in some patients, only 30-50cc total blood will be drawn).
Leukapheresis is essentially the same for the patient, but has the advantages
of providing more cells for study while not depleting the patient of their o w n
red blood cells. Thus wherever possible, leukapheresis will be preferred over
standard blood drawing to obtain cells for study w h e n large numbers of cells
are required.
13. Data and Safety Monitoring Plan:
a. Level of Risk: This project entails moderate risk to subjects.
Monitoring will be conducted by the Principal Investigator (PI), a
credentialed co-investigator, and the Rockefeller University
Institutional Review Board (IRB), through annual reports of progress
and by immediate notification of adverse events by the PI to the IRB,
the G A C , and any federal regulatory agency (e.g. F D A ) w h e n
appropriate or required.
b. Data and Safety Monitoring Board: This protocol comprises the
collection of patient samples, does not expose participants to
substantial risk, does not involve blinding, and does not involve
vulnerable populations. It will therefore not need a Data and Safety
Monitoring Board. Monitoring will be conducted by the PI and the
monitoring group (see below, 14.e.) and the Rockefeller University
IRB, through annual reports of progress.
c. Safety review plan: Routine and safety lab tests will be reviewed in
real time by the PI and/or co-investigators, as they are returned from
the laboratory. A b n o r m a l results will be evaluated for clinical
significance and so documented. Clinically significant abnormalities
will be followed u p by the investigator or referred for care as
appropriate. The only "safety data" that will be collected are the C B C ,
calcium and P T / P T T prior to leukapheresis. These results will be
reviewed immediately u p o n receipt by the physician of record.
Patients will not be leukapheresed if any of these tests are outside
normal limits. Additionally, the nurse w h o is performing the
leukapheresis will be given study personnel contact information so
that any unexpected symptoms m a y be reported to the study clinicians
as they occur. The c o m m o n toxicity criteria version 2.0 will be used as
guidelines
to monitor
toxicities a n d
adverse
events
(http://ctep.inof.nih.gov). Adverse events will be reviewed in real
time and documented in the medical record of each patient, and then
entered into a separate A E log for that patient. On-line adverse event
reports generated by the G C R C nursing staff will also be reviewed as
they are received and any not already entered in the log will be added.
This A E log will be used for tabulation of adverse events in the annual
report to the IRB.
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d. Serious Adverse Events (SAE): A serious adverse event or reaction is
any untoward medical occurrence that at any dose results in death, is
life-threatening, requires in-patient hopitalization or prolongation of
existing hospitalization, results in persistent or significant
disability/incapacity, or is a congenital anomaly/birth defect. All
serious adverse events will be conveyed to the PI immediately by the
G C R C nursing staff or a study team member. Medical intervention will
be initiated as appropriate and the patient referred for further care as
necessary. All unanticipated A E s of N C I grade 3 or higher occurring
during inpatient stay or within 10 days of discharge will be reported to
the Rockefeller University IRB and the G C R C Clinical Research Officer
within 48 hours. All adverse events tabulated from the A E log
(including severity and attribution), as well as total enrollment,
demographics of enrollment, reasons for attrition, significant protocol
violations, current status of subjects (completed, ongoing, dropout),
and any available research data will be reported in the annual progress
report to the IRB. The PI will maintain documentation of adverse event
(AE) reports, all source documents, research records, and IRB
documents.
e. Data m a n a g e m e n t and Patient Confidentiality: Data will be collected
in a password-protected dedicated computer file and labeled with a
patient ID number only. A standard form for the input of patient data
will be used for all patient clinical data and to store the results of
antibody assays, gene expression studies, and T cell assays. Laboratory
data will be collected into bound laboratory notebooks. This data will
then be transcribed into an electronic database. This database will
electronically date and time stamp entries and will maintain an audit
trail. This database will be backed u p daily by the Laboratory
Administrator. Data records will be reviewed at regular intervals in
accordance with the monitoring plan to ensure that data is recorded
accurately and properly.
f. Study monitoring: The monitoring group will meet every two months
to review the Q A data. The monitoring group will consist of Dr. Rice,
Dr. Albert and Dr. Talal. Medical records of u p to three patients will be
randomly selected and reviewed for completeness of documentation
and to confirm informed consent, eligibility, enrollment note, accurate
transcription in to the A E log, and the proper conduct of the protocol.
Research laboratory results of u p to three patients will be randomly
selected and reviewed for S O P compliance. Occurrence of these record
and data reviews will be noted in a monitoring log. The monitoring
group will also review the A E log for completeness (grading, expected
or unexpected, attribution, outcome), and will review for appropriate
reporting to the IRB.
g. C L I A laboratory certification: Laboratory tests performed as part of
this study are not C L I A or C L E P certified. Therefore, no laboratory
tests run in the laboratory as part of this research protocol will be
communicated to the patient, given to referring physicians, or
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influence decisions about the research participants' treatment.
14. Procedures to Minimize Risks:
Leukapheresis or venipuncture will be performed by professional licensed staff
at The Rockefeller Hospital or by certified phlebotomy laboratories.

15. Potential Benefits:
There is no direct benefit to participants in this study. The potential benefits are
the identification of the i m m u n e defect in patients with chronic H C V infection
that is in part responsible for the inability to clear the virus. This study might
ultimately be useful in identifying surrogate markers for effective anti-viral
protocols.
16. Risk to Benefit Ratio:
The balance of the risks versus benefits involved in participation are judged by
the investigators to be clearly in favor of the benefits derived from participation.
The risks are judged overall to be moderate, but are not anticipated to include
serious adverse reactions. This is an observational research study, and the
potential benefit of this study is entirely unknown. If the hypothesis proves to
be correct, this study will be offer the opportunity to derived n e w insight into
the development of anti-viral protocols aimed at achieving cures in chronic
H C V patients.
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17. Compensations:
Patients will receive compensation for the leukapheresis procedure,
$300/donation.

Principal Investigator's Assurance:
As Principal Investigator of this study, I assure the IRB that, as required by
federal regulations:

Proposed changes in approved studies will be presented to the IRB for
review and approval prior to initiation except where necessary to eliminate
apparent immediate hazards to the subjects.

The IRB, appropriate institutional officials, the Office for Protection from
Research Risks (OPRR) and the F D A , if applicable, will be promptly
informed of any unanticipated problems involving risks to subjects or others
and research related injuries.

The informed consent of the subject will be obtained by the investigator in
the manner and format approved by the IRB prior to the initiation of the
studies.

The study will be resubmitted to the IRB for continuing review at the
interval determined by the IRB to be appropriate to the risk, but not less
than once a year.

(Signature of Principal Investigator)

(Date)
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Conflict of Interest
D o you, your spouse or dependent children or any Professional Personnel* listed
on the application, have any Significant Financial Interest* (as defined by the
federal regulations):
(A)

that would reasonably appear to be affected by the research?

Yes
(B)

No
in any entities whose financial interest would reasonably appear to be
affected by the research?
Yes

No

(If you answered "Yes" for either (A) or (B), the Principal Investigator and/or
appropriate Professional Personnel must provide a confidential statement
describing the possible conflict of interest in the sealed envelope marked
"Confidential" and addressed to the IRB Chair).
Signed Date
Investigator
* NOTES:
Professional Personnel means any other person responsible for the design,
conduct, or reporting of this research.
Significant Financial Interest means anything of monetary value, including but
not limited to salary or other payment for services (e.g., consulting fees or
honoraria); equity interest (e.g., stock, stock options, or other ownership
interests); and intellectual property rights (e.g., patents, copyrights, and royalties
from such rights). This term does not include:
(i) Salary, royalties, or other remuneration from the institution;
(ii) A n y ownership interests in the institution, if the institution is the
applicant under the SBIR Program;
(iii) Income from seminars, lectures, or teaching engagements sponsored by
public or nonprofit entities;
(iv) Income from service on advisory committees or review panels for public
or nonprofit entities;
(v) A n equity interest which meets both of the following tests: does not
exceed $10,000 in value as determined through references to public prices
or other reasonable measures of fair market value w h e n aggregated for
the investigator and the investigator's spouse and dependent children;
and constitutes more than a 5 percent ownership interest in any single
entity w h e n aggregated in the same manner; or
(vi) Salary, royalties or other payments that are not reasonably expected to
exceed $10,000 per a n n u m from any single entity w h e n aggregated for the
investigator and the investigator's spouse and dependent children.
However, the exclusions in paragraphs (i), (v) and (vi) shall not apply if the
compensation or transfer of an equity interest is conditioned u p o n a particular
outcome in the PHS-funded research.
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